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Abstract
SYNTHESIS, SCREENING AND COCRYSTALLIZATION OF ADENOSINE BASED 
INHIBITORS WITH METHYLTRANSFERASES, ERMC' AND KSGA
By Matthew Ryan Baker, Ph.D.
A Dissertation submitted in partial fulfillment of the requirements for the degree of Doctor
of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2011
Major Director: Dr. Jason P. Rife
Associate Professor, Department of Physiology & Biophysics
 Antibiotic resistance threatens to throw mankind back into an era when infectious disease 
was the predominant cause of death. In an effort to mitigate this danger, we targeted ErmC’ and 
KsgA. Both methylate N6-adenosine of ribosomal RNA, though each serve different roles in their 
bacterial host. ErmC’ dimethylates A2058 on 23S rRNA, conferring resistance to MLSB 
antibiotics (macrolides, lincosamides, streptogramin B). KsgA aids in ribosome assembly, 
binding inactive 30S until dimethylating A1518/A1519 of 16S rRNA. Like most 
methyltransferases, ErmC’ and KsgA use cofactor S-adenosylmethionine (SAM) as their methyl 
source, which binds adjacent to their specific adenosine substrate. ErmC’ inhibitors could restore 
MLSB antibiotics against infections with this resistance mechanism. KsgA inhibitors could form 
novel antibiotics that stall 30S assembly.
! Previous studies reported a potent ErmC’ inhibitor, N6-cyclopentyl adenosine (1), binding 
to the substrate pocket with cyclopentyl bridging into the SAM pocket. We expanded this study 
by synthesizing 1 and 22 other N6-substituted analogs to explore more favorable interactions 
within the SAM pocket. When these compounds (1mM) were screened against ErmC’ and KsgA, 
some showed greater inhibition than 1. Two of these inhibitors that were crystallized with 
ErmC’, N6-8-octylamine adenosine (2.60Å) and N6-phenethyl adenosine (2.40Å), unexpectedly 
docked into the SAM pocket with their 5’-C pointing towards the substrate pocket.
  New compounds were made to exploit this orientation by adding substituents off the 5’-
C to probe the substrate pocket.  Through a five step synthesis, the 5’-OH of 1 was substituted 
with an amine linked to benzyl (30), phenethyl (31), propylphenyl (32) or butylphenyl (33). 
When 30-33 were screened using 20µM SAM, ErmC’ showed greater inhibition (relative to 1), 
while KsgA showed virtually none. However, when ErmC’ was tested using 0.5µM SAM, 
inhibition from 30-33 was nearly unchanged, whereas 1 became significantly more potent than 
30-33, suggesting 30-33 were not binding to the SAM  pocket. Preliminary data showed that 
raising 23S concentrations lowered inhibition from 32-33, while inhibition from 1, 30 and 31 
was nearly unchanged, suggesting that at least 32-33 bound within the substrate pocket.
xv
CHAPTER 1: Introduction
Antibiotic resistance 
 Since the discovery of penicillin in 1928 by Alexander Fleming et al., mankind has 
greatly benefited from the use of antibiotics.1 Prior to this period, infectious diseases like 
tuberculosis, typhoid, pneumonia and cholera were the predominant causes of death (contributed 
to 33% of the deaths in 1900).2  Yet, thanks largely to the introduction of antibiotics, as well as 
vaccination programs and improved sanitation during the mid-20th century, many of these 
diseases were near eradication by century’s end (<5% of deaths were from infectious diseases in 
1996).2   Antibiotics have also enabled dramatic rises in our food production through their use in 
animal husbandry and sterilization techniques. Also, the many advances in surgery that we enjoy 
today  would otherwise be unthinkable if not for antibiotics. Unfortunately, these popular drugs 
have been overused and misused, spawning new forms of resistant pathogens that have 
mushroomed throughout the globe. Antibiotic resistance has become so alarming in recent years 
that unless solutions are soon found, we risk being thrown back into this pre-antibiotic era.
 While the prolific use and improper dosing of antibiotics have been contributing factors, 
the other reason resistance has spread so quickly stems from the fact that many of these drugs 
were derived from the natural products of soil-dwelling bacteria or fungi. Most notable is the 
genus of bacteria Streptomyces, from which most of our antibiotics originate (ex.; streptomycin, 
1
tetracycline, and vancomycin) and the phylum of fungi Ascomycota, which has been the source 
of !-lactams like penicillin and cephalosporin.3 These organisms long ago evolved the means of 
releasing antimicrobials into their surroundings to gain an advantage over other microbes 
competing for the same food source. Microorganisms that were engaged in this biochemical 
warfare had also long ago evolved the means for self-defense. Genes responsible for these 
protective mechanisms are often found in plasmids, and are easily exchanged between a variety 
of different microbes. As a result, many of the bacterial pathogens that were once treatable by 
antibiotics soon acquired these resistance genes, which had been present in other microorganisms 
long before clinical antibiotics were ever used.
 There are many ways that a microorganism can develop  tolerance to an antibiotic. Those 
mechanisms of resistance that are acquired by pathogens (i.e., via gene transfer) have been 
categorized into three main groups.  One mechanism is by  modifying the antibiotic. For example, 
!-lactamases (ex: cephalosporinase and penicillinase) will hydrolyze the amide ring of !-
lactams, rendering them ineffective against the bacterium.4  A second mechanism is by 
modifying the binding site of the antibiotic. For example, some rRNA methyltransferases like 
ErmC and RmtA methylate key bases on the ribosome to block the binding of macrolides and 
aminoglycosides, respectively.  A third commonly acquired mechanism is to reduce the 
concentration of antibiotics through efflux pumps (ex: tetracycline efflux & TolC multi-drug 
efflux).5  It is also possible for an organism to use these mechanisms or other means (ex: reduced 
permeability  & alternate metabolic pathway) as an intrinsic source of antibiotic resistance (i.e., 
encoded on chromosomal DNA). The term, “superbug”, refers to a microbe that has gained 
multiple copies of these genes, allowing for resistance to multiple antibiotics.
2
 Resolving this threat of antibiotic resistance is by no means a simple task, since there are 
many kinds of antibiotics for which there are many types of resistance. One approach historically 
used to address this problem has been to develop novel antibiotics. Though the discovery rate of 
new antibiotics rose steadily  from the 1940’s to a peak in the 1970’s, this has  since dwindled to 
few new antibiotics reaching the market by 2000.6  An alternative approach would be to restore 
the effectiveness of existing antibiotics by  discovering ways to block the mechanisms of 
resistance that are currently the most threatening. Some success with this approach was achieved 
through !-lactamase inhibitors (ex. clavulanic acid, tazobactum and sulbactam), which when 
used as an adjunct therapy  with penicillins (ex: amoxicillin), restored the antibiotic’s potency 
against pathogens that  acquired this mechanism of resistance.7  However, bacterial strains 
producing !-lactamases that are resistant to such inhibitors have subsequently emerged.8  In this 
dissertation work, both of these approaches for combating antibiotic resistance were attempted 
by targeting two different, but structurally similar, rRNA methyltransferases: ErmC’ and KsgA. 
Inhibitors to ErmC’ were investigated with the ultimate goal of restoring the effectiveness of the 
large class of MLSB antibiotics (macrolides, lincosamides, and streptogramin B) when treating 
infections with this particular form of resistance. Additionally, inhibitors of KsgA were 
investigated as a potential source for a novel class of antibiotics that act by stalling ribosomal 
assembly.
3
Methyltransferases
  The large and diverse category of methyltransferases (MTases) occur in an equally  large 
number of biological systems.  By facilitating the addition of methyl groups to specific 
substrates, these enzymes effectively  change the biochemical properties of a wide variety  of 
different compounds. Examples of substrates that are modified by  MTases include: amino acids,9 
lipids,10 DNA, and RNA. Of particular interest  to medicine are MTases that epigenetically 
silence genes through the methylation of DNA.11  Another well known example are bacterial 
MTases, which methylate DNA for self-protection against the restriction enzymes that cleave 
foreign or viral DNA.12  MTases are usually  very substrate-specific, but nearly all must also bind 
the cofactor S-adenosyl methionine (SAM) for their methyl source. Examples of alternative 
methyl donors are betaine and N5-methyl-tetrahydrofolate, which are used by betaine-
homocysteine methyltransferase and methionine synthase (respectively) to convert homocysteine 
to methionine,13 and N-Methyl-L-glutamate synthase, which transfers the methyl from 
methylamine to glutamate.14
 ErmC’ and KsgA belong to the predominant class of MTases, which use SAM  as their 
methyl source.  Not surprisingly, SAM-dependent MTases share many of the same structural 
characteristics.  Figure 1 shows a schematic of the core fold that is typical of SAM-dependent 
MTases. This characteristic pattern of alternating !-strands and "-helices closely resembles the 
Rossman fold seen in other nucleotide-binding proteins. Also common to all SAM-dependent 
MTase are two closely adjoining pockets, one of which accepts the cofactor SAM  and the other 
of which binds the substrate to be methylated. This arrangement puts SAM in a position that 
allows for the methyl group to be directly transferred to a nucleophile on the substrate. Residues 
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that create the SAM-binding site are highly conserved among these MTases, while residues 
involved with substrate binding are more specific to the particular MTase substrate.  The 
conservation of the cofactor-binding region has been a challenge for medicinal chemists 
targeting a specific SAM-dependent MTase.  Inhibitors that act solely  on the SAM-binding site 
are liable to cause toxicity by  knocking out any  of the other SAM-dependent MTases vital in 
human physiology.  Therefore, the substrate-binding site has generally been the target for 
developing selective MTase inhibitors.15
Figure 1. Core fold typical of SAM-dependent MTases. Alternating !-strands (1-7) and "-helices 
(A, B, D, E & Z) are shown as red arrows and yellow cylinders, respectively. The gray cylinder 
(C) represents a less conserved region of SAM-dependent MTases. Chemical structures are of 
cofactor S-adenosyl methionine (SAM) and the by-product of methylation, S-adenosyl 
homocysteine (SAH). Information was adapted from the work of Martin et al.15
5
ErmC’
MLSB antibiotics
 MLSB antibiotics shown in Table 1 represent a large and important class of drugs used to 
treat both gram-positive and gram-negative infections, and have come under threat from ErmC’-
induced resistance. The first macrolide, erythromycin (a natural product of Saccharopolyspora 
erythraea), was introduced in 1952 and offered one of a few alternatives at that time to 
penicillin. However, resistance to erythromycin was soon found in clinical isolates from the US, 
Europe and Japan within one year of its being introduced. Later, semi-synthetic derivatives of 
erythromycin, such as roxithromycin (introduced in 1984), clarithromycin and azithromycin 
(both licensed in 1991), and dirithromycin (licensed in 1995) had improved absorption and acid-
stability with fewer side-effects, but still shared cross-resistance with their parent compound.16, 17  
 In response to the prevailing resistance to traditional macrolides, efforts were focused on 
a new sub-class of semi-synthetic derivatives of erythromycin known as Ketolides. These include 
telithromycin (approved 2001 in EU, 2004 in US), cethromycin (currently in FDA review) and 
solithromycin (now in phase II), which have been shown to be active against many of the 
macrolide-resistant strains.18  However, isolates of telithromycin-resistant bacteria have since 
been found in Taiwan, despite the fact that this drug had not yet been made available in Taiwan.19 
6
Table 1. Examples of MLSB-antibiotics. Structures were rendered in ChemDraw.
 Lincomycin (a natural product from Streptomyces lincolnensis) was introduced in 1963 as 
the first of two antibiotics in the class of lincosamides, yet was surpassed a few years later by its 
more effective, semi-synthetic derivative, clindamycin. This small class of compounds 
broadened the spectrum of MLSB antibiotics by  also being able to treat  fungus and protozoans 
(ex. malaria). Unfortunately, lincosamides have shared a similar fate of tolerance in several 
pathogens that were already resistant to existing macrolides, as well as eliciting resistance in 
newly indicated pathogens (in some cases of malaria).20 
7
  The last group of MLSB antibiotics is streptogramin B.  Streptogramins are a class of 
natural or semi-synthetic derivatives from certain Streptomyces. These bacteria simultaneously 
release two different types of streptogramins (A and B types), which are structurally distinct and 
act by  separate mechanisms, yet  have a powerful synergistic effect when dosed together. 
Streptogramin B utilizes the same mechanism of action as macrolides and lincosamides, and has 
similarly  become susceptible to many of the same forms of resistance.21 [Note: Streptogramin A 
binds near the B type and also interferes with tRNA binding (has a bacteriostatic effect by itself), 
but more importantly  the binding of the A-type induces a conformational change that  greatly 
improves the binding affinity of streptogramin B.]22
 Although structurally diverse, MLSB-antibiotics act  through a common mechanism of 
inhibiting protein synthesis by  binding to the large ribosomal subunit of bacteria (i.e., 50S). More 
specifically, these compounds bind at overlapping sites near the peptidyl transferase center on the 
23S rRNA portion of 50S, thereby  displacing the peptidyl-tRNA during elongation.16, 19, 23, 24 
The most widespread and medically concerning route of resistance to MLSB-antibiotics has been 
the modification of this binding site via Erm (Erythromycin resistance methylase),25 although 
other mechanisms may also be used by  some MLSB-antibiotic resistant pathogens (ex. efflux 
pumps and drug inactivation).26
Erm family of methyltransferases
 The Erm family includes over 60 different methyltransferases that have been found in a 
variety of bacterial species.16  All of these enzymes prevent  MLSB-antibiotics from binding to the 
ribosome by adding one or two methyl groups to the N6-position of a specific adenosine (A2058 
8
in Escherichia coli or A2085 in Bacillus subtilis), which is located in domain V of 23S rRNA 
(Figure 2).25  Research into the Erm family has largely focused on a couple of members in 
particular. ErmE, from the erythromycin-producing bacteria Saccharopolyspora erythraea, had 
been used in determining the recognition elements of 23S.27, 28  Another member that is of great 
medical interest is ErmC, from Staphylococcus aureus, whose gene has been found in many of 
the clinical isolates of MLSB-antibiotic resistant infections.29  A more stable and soluble 
substitute for ErmC that is typically used for experimental work is ErmC’ (from B. subtilis), 
which varies from ErmC by only 4 amino acids.25  ErmC’ has also been used to produced the 
only published X-ray  crystal structures for this family  of MTases, although one structure of 
ErmAM has been solved by solution NMR.30
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Figure 2. Secondary  structure of 23S rRNA substrate from E. coli.31  Magnified in the green box 
is the Erm methylation site on domain V (the red arrow indicates the target adenosine to be 
methylated, and highlighted nucleotides show key elements for recognition by Erm).25
Binding interactions of ErmC’
 For the reasons mentioned above, ErmC’ was chosen as the main subject  for the 
inhibition and crystallographic studies presented herein. This member of the Erm family is a 
monomer of 244 amino acids (28.9 kDa), and acts by dimethylating its rRNA substrate using two 
equivalents of SAM in a random bi-bi mechanism32 (Figure 3). The preferred and natural 
substrate of ErmC’ is 23S rRNA from B. subtilis, but ErmC’ will also methylate synthetic RNA 
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oligos as small as 32 nucleotides.33  ErmC’ has been found to also methylate the 23S rRNA from 
E. coli, although with about half of the same efficiency  in vitro. [Note: The primary structures of 
23S from B. subtilis and E. coli are 77% homologous.]34
Figure 3. Reaction scheme of ErmC’ dimethylating the target adenosine on 23S rRNA.
 Since one objective of our research was to find ways to block this reaction facilitated by 
ErmC’, previous crystal structures were studied to see how this enzyme might interact with the 
SAM cofactor and RNA substrate. As of yet, five crystal structures of ErmC’ have been 
deposited into the RCSB Protein Data Bank (PDB). Two of these exist in their apo form (2ERC 
at 3.03 Å, and 1QAM at 2.20 Å),35, 36 while the other three structures show ErmC’ with ligands 
in the SAM-binding pocket (SAM  in 1QAO at 3.03 Å, SAH in 1QAN at 2.40 Å, and sinefungin 
in 1QAQ at 2.80 Å).36  S-Adenosyl homocysteine (SAH) is a product of SAM-dependent 
methylation, and sinefungin is a natural product from Streptomyces incarnatus or S. griseolus.37 
Both of these structurally related compounds are often used experimentally as non-specific 
11
methyltransferase inhibitors.  Figure 4 shows these three co-structures of ErmC’ superimposed 
on one another to illustrate the similar binding modes of SAM  and the two inhibitors. In each 
case, the ligand binds into the SAM pocket with the adenosine moiety oriented in a similar 
manner. In fact, this orientation closely aligns with the adenine moiety  of SAM in complex with 
other MTases, and is likely conserved in all SAM-dependent methyltransferases.36, 38, 39 
Figure 4.  Superimposed co-structures of ErmC’ bound with SAM  (green), SAH (blue) and 
sinefungin (red).36  Chemical structures of each ligand are shown on the right side.
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 A closer look at the SAM-binding pocket in co-structure 1QAO reveals how ErmC’ 
interacts with its cofactor (Figure 5).  The purine ring of SAM  is held in place largely  through 
hydrophobic interactions with surrounding residues (Ile-60, Ile-85, Leu-86 and Ile-106). In 
addition, hydrogen bonds are donated from the N6 of SAM  to the carboxyl on Asp-84, and the N1 
on SAM  accepts a hydrogen bond from the backbone amide of Ile-85.  The ribose portion of 
SAM makes a critical contact with ErmC’ by donating a pair of hydrogen bonds from its 2’-OH 
and 3’-OH to the carboxylate of Glu-59 [Note: This interaction will become very relevant when 
evaluating activity of second-generation inhibitors 26-29 in Chapter 5].  The amino group on the 
methionine portion of SAM makes one H-bond with the backbone carbonyl of Gly-38. Two more 
H-bonds are accepted at the carboxyl end of SAM  from the amines of Asn-101 and backbone of 
Ile-13. The positive-charged sulfur on SAM forms ionic bonds with two carbonyl groups on the 
backbones of Asn-11 and Asn-101.36  While this co-structure has been very useful in explaining 
how ErmC’ binds to SAM, it  still leaves unanswered questions about the interaction with its 
RNA substrate.
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Figure 5.  Binding mode for SAM in the cofactor-pocket of ErmC’ (PDB 1QAO).36  H-bonds or 
ionic interactions are shown with dashed yellow-lines. Red atoms are oxygens, blue atoms are 
nitrogens, and the yellow atom is sulfur.
   Despite the attempts of several groups,36, 40 there are currently no structures of ErmC’ 
complexed with 23S or any  other substrates bound to the adenosine pocket. There is, however, a 
structure of a related methyltransferase, M.TaqI, which is complexed with its nucleic acid 
substrate (PDB 1G38).41  M.TaqI (from Thermus aquaticus) mono-methylates DNA at the N6-
position of adenine as part of the type II restriction-modification system that recognizes a 5’-
TCGA-3’ sequence.42  While having a slightly different function, the catalytic domain of M.TaqI 
is very similar to those in ErmC’ and KsgA, and thus, has been a useful comparison tool for our 
research.  Below is a sequence alignment for M.TaqI, ErmC’ and KsgA (Figure 6 ). 
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Figure 6. Structure-based sequence alignment of ErmC’ (PDB 1QAO),36 KsgA (PDB 1QYR)43 
and M.TaqI (PDB 1G38).41 This task was performed on a T-Coffee web server, version 8.99.44
 For the X-ray model of PDB 1G38, M.TaqI was co-crystallized with a 10-base pair 
duplex of DNA and a non-reactive SAM  analogue, 5'-[2-(amino)ethylthio]-5'-deoxyadenosine 
(AETA). This structure shows AETA positioned in the SAM pocket in a similar fashion as the 
endogenous cofactor (compared with co-structure of M.TaqI + SAM, PDB 2ADM).45 More 
importantly, this co-structure also shows the target adenine flipped out of the DNA-helix and 
binding into the substrate pocket of M.TaqI.  The target-adenine is held in close proximity to the 
would-be methyl donor through face-to-face #-stacking with Tyr-108, and edge-to-face #-
16
stacking with Phe-196. [Note: These residues are analogous to Tyr-104 and Phe-163 in ErmC’, 
respectively.]  Additionally, H-bonds from the backbone amide of Tyr-108 and the side-chain 
amide of Asn-105 (analogous to Asn-101 in ErmC’) are donated to N7 and N1 on the target 
adenine, respectively. Furthermore, the N6 of adenine donates H-bonds to the carbonyl oxygens 
on Asn-105 and backbone of Pro-106 (Ile-102 in ErmC’).  These interactions made by M.TaqI 
with its adenine substrate were extrapolated to make the predicted model of ErmC’ binding to its 
adenosine substrate (Figure 7).
Figure 7. Predicted binding mode of the target-adenine into the substrate pocket of ErmC’. 
Phe-163 and Tyr-104 of ErmC’ are predicted to form #-# stacking with the putative adenine 
substrate. Dashed yellow lines show H-bonds of this nucleotide with key residues of ErmC’.  In 
gray are the adenine substrate and “flipped” Tyr-108 from M.TaqI (PDB 1G38)41 that were 
modeled into ErmC’ with cofactor (PDB 1QAO)36.  Catalytic regions aligned in PyMOL with a 
root mean square (RMS) = 0.709 (70 to 70 atoms), aligning residues 11-13, 59-61, 63, 84, 98, 
101-105 and 163 of 1QAO with analogous residues of 21-23, 71-73, 75, 89, 91, 102, 105-109 
and 196 of 1G38.
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 Catalytic residues of ErmC’ and M.TaqI closely overlap in PyMol, and the adenine 
substrate of M.TaqI fits into the putative adenosine-binding pocket of ErmC’ to form nearly 
identical interactions. One important  distinction, however, is the rotation of the highly conserved 
tyrosine (Tyr-104 in ErmC’, Tyr-108 in M.TaqI).  In all published structures of ErmC’, the 
Tyr-104 points away from this pocket as shown in Figure 7.  It has been speculated that the 
binding of RNA substrate to ErmC’ involves this tyrosine flipping inwards to make favorable #-# 
stacking with the target adenosine,41, 46 which may  also aid in catalysis42 (discussed below in 
Predicted Mechanism for ErmC’ and KsgA Catalysis). 
 Another difference between these two MTases is an isoleucine in ErmC’ (Ile-102) rather 
than a proline at this same location in M.TaqI (Pro-106).  The reason for this discrepancy in an 
otherwise highly conserved region likely reflects the strict mono-methylating activity of 
M.TaqI.36  The C! and C" of Pro-106 would limit the space needed for an N6-monomethyl 
adenine to bind in the substrate pocket of M.TaqI, whereas Ile-102 in ErmC’ is far less confining 
and may provide favorable hydrophobic interactions with the N6 methyl when a monomethylated 
substrate binds.36
 Many of the interactions of ErmC’ with SAM or the putative adenosine substrate will be 
considered when designing inhibitors. This knowledge will also be valuable when evaluating the 
activity of inhibitors in vitro, as well as providing information used to interpret new co-structures 
presented in this dissertation.   
18
KsgA
KsgA/Dim1 family
 Also in the crosshairs of this inhibition study was a paralog of ErmC’, the rRNA 
methyltransferase KsgA (from E. coli). This enzyme belongs to a family that is uniquely 
conserved throughout the three domains of life. In bacteria, members of this family are named 
KsgA, whereas, in archaeal and eukaryotic organisms, these orthologs are called Dim1.47  
ErmC’ most likely  originated from the same ancestor in this family and, not surprisingly, shares a 
similar mechanism of action. With only a couple of exceptions,48, 49 the KsgA/Dim1 family 
dimethylates the N6 atom of two adjacent adenosine bases (A1518 and A1519 in E. coli) on helix 
45 of the small rRNA (16S rRNA in bacteria, Figure 8). The actions of KsgA/Dim1 are centrally 
involved with the ribosome assembly process.
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Secondary Structure: small subunit ribosomal RNA
Escherichia coli
November 1999 (cosmetic changes July 2001)
(J01695)
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Figure 8. Secondary structure of 16S rRNA from E. coli.31 KsgA methylation sites on helix 45 
are magnified in the green box (the red arrows indicate the target adenosine bases to be 
methylated, and the highlighted nucleotides are predicted to make interactions with KsgA.50 
(Personal communication, Drs. Jason Rife and Nenad Ban).
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KsgA from E. coli
  KsgA was first noticed when a strain of E. coli became resistant to the aminoglycoside 
kasugamycin (ksg) as the result of a mutation on the ksgA gene.51  Later it was found that KsgA 
modifies a pair of nucleotides at the end of a hair-pin loop on helix 45, which is near or indirectly 
associated with the binding area of kasugamycin on helixes 44, 28 and 25 (Figure 8).52 This 
antibiotic is believed to block protein synthesis by displacing the initiator tRNA from the P-site 
of the ribosome.52  Paradoxically, it  is the absence of KsgA (or rather, its methylation function) 
that causes resistance to kasugamycin. When bases A1518/1519 are unmethylated, the hairpin 
loop on helix 45 is thought to assume a slightly  different conformation that is enough to disrupt 
the adjacent binding sites of this antibiotic.53, 54  The lack of KsgA in this strain of kasugamycin 
resistant (ksgR) E. coli, however, comes with a consequence of reduced growth rate, translation 
errors, and sensitivity to stress.  While such a mutation has proven to be advantageous under the 
pressures of kasugamycin, this form of resistance has not been observed in the wild. [Note: ksgR 
E. coli arose from mutational experiments with nitrosoguanidine.51]
 In vivo, nucleotides A1518/1519 are not  methylated by  KsgA until 16S rRNA has been 
modified and assembled into a nearly complete, yet translationally inactive, small ribosomal 
subunit.55  The assembly of 16S into translationally active 30S involves incorporating a total of 
21 ribosomal proteins (S1-S21),56 which is aided by  and in concert with dozens of ribosome-
associated enzymes and biogenesis factors. These include: chaperones (ex. DnaK)57 and GTPases 
(ex. Era)58 that speed up  other binding and folding events; RNases trimming off the leading and 
tailing ends of pre-16S rRNA; isomerization of a uridine to a pseudouridine (U516 to pU516 by 
RsuA);59 and MTases (ex. KsgA and RsmB to RsmF)59 that modify  up to 10 rRNA bases.60  At 
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some point near the final stages of this maturation (maybe just  prior to the addition of the 
essential S21),61 KsgA completes its methylation. Afterwards, 30S forms a conformation that can 
bind 50S and begin translation.  Fortunately, for the sake of our experiments, certain salt 
conditions will trap 30S into a translationally inactive conformation that is a suitable substrate 
for KsgA methylation in vitro. Such conditions typically  consist of low divalent and intermediate 
monovalent ion concentrations (ex. 4 mM Mg++ and 40 mM NH3+).62 
 It has been proposed that KsgA’s role in ribosome biogenesis goes far beyond just 
methylating rRNA and that it  also functions as a biogenesis factor or gatekeeper during the final 
stages of 30S assembly.63  While methylated A1518/1519 do offer a slight improvement of 
reading accuracy during ribosome translation (in vivo),48 unmethylated 30S will still join with 
50S to form functional ribosomes, albeit at about half of the normal activity  (in vitro).64 
Therefore, if KsgA’s methylation is not essential (at least in E. coli) despite its ubiquitous 
conservation, it may have a secondary and possibly more important role than just adding four 
methyl groups to 16S rRNA.  Evidence for this claim can be found in recent experiments which 
showed that when the ksgA gene was deleted from a strain of E. coli ($ksgA), cell growth was 
significantly hindered by cold temperatures (20-25 °C) compared with wild-type E. coli. It was 
also observed that $ksgA cells had a greater ratio of subunits (30S and 50S) to fully formed 
ribosomes (70S) compared with wild type. Cold-sensitivity and the buildup of ribosomal 
subunits are also phenotypes in bacteria that have defective or deleted biogenesis factors, such as 
GTPases Era65 and YieQ.66  Therefore, the binding of KsgA to 30S may  similarly aid with 
subsequent or concurrent maturation steps that are separate from its catalytic function. 
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 This same study  also had very interesting results using a catalytically  inactive mutant of 
KsgA (E66A), inserted into a vector for inducible expression. When Glu-66 (analogous to 
Glu-59 in ErmC’) is mutated to an alanine, SAM  binding is blocked, but does not otherwise 
prevent KsgA from binding to the 30S substrate.  Expression of E66A KsgA in either $ksgA or 
wild-type E. coli showed significant inhibition of cell growth. Furthermore, cells expressing 
E66A had ratios of subunits:ribosomes that were shifted to nearly all 30S and 50S. It was 
concluded from this study that KsgA binding may also act as a checkpoint during ribosome 
assembly  by recognizing the proper conformation of the nearly complete 30S. Methylation by 
KsgA then triggers the release of 30S just before being allowed to join with 50S. The last 
maturation steps that make 30S translationally  active may happen while still bound to KsgA, or 
occur just following this release. Irrespective of this order, the nearly  complete 30S particle 
would be sequestered by KsgA until methylation is completed.63
 The greater implication of Connolly  et al.’s work is that KsgA is a viable target  for 
developing a novel class of antibiotics.63 Inhibitors that block the methylation by KsgA (but 
otherwise don’t block 30S from binding) could stall ribosomal assembly through the buildup of 
30S-KsgA complexes. Such an inhibitor could act as a biostatic antibiotic when given alone, or it 
could be combined with other antibiotics that might have a synergistic effect on an otherwise 
weakened cell. While many  current antibiotics directly  target the ribosome, KsgA inhibitors 
could be the first in a class of antibiotic that indirectly target the ribosome during biogenesis.
 Finally, it has been found that knocking out  KsgA can also hyper-sensitize E. coli to the 
antibiotic effects of the aminoglycoside gentamicin.67 This study showed that 30S unmethylated 
by KsgA was a less suitable substrate for ArmA (a methyltransferase conferring resistance to the 
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aminoglycosides). Therefore, KsgA inhibitors could also restore the effectiveness of certain 
aminoglycosides in bacteria that had acquired the ArmA mechanism of resistance.  
Likely Binding interactions of KsgA
 Designing inhibitors for KsgA requires an understanding of the binding interactions made 
with its substrates, and much of this can be gleaned from previous crystallographic work.  Our 
group has solved the only  crystal structure of KsgA from E. coli, which exists in the apo form 
(PDB entry 1QYR at 2.10 Å).43  While another group has obtained a crystal structure of KsgA 
from Aquifex aeolicus complexed with an RNA duplex and SAH (PDB entry 3FTF),68 some of 
their methodology and results remain speculative and was not fully  informative for our purposes. 
Fortunately, the similarities of KsgA with ErmC’ or M.TaqI permits the use of these co-structures 
to help  fill in the blanks (i.e., SAM  and target adenosine). These three MTases were 
superimposed together to illustrate how well the catalytic domains align (Figure 9). 
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Figure 9. Superimposed co-structures of KsgA (wheat), ErmC’+SAM (pink), and M.TaqI+AETA
+DNA (cyan) using the respective PDB entries 1QYR,43 1QAO36 and 1G38.41
 To illustrate how the cofactor likely binds into the SAM pocket of KsgA (Figure 10), the 
co-structure of ErmC’ + SAM  (1QAO)36 was aligned with the the apo structure of KsgA 
(1QYR).43  The SAM  molecule modeled into KsgA forms nearly  the same interactions that were 
observed with ErmC’ in Figure 5.  One difference was KsgA had slightly less space around the 
N6-position of SAM (discussed further in Chapter 3).
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Figure 10. Predicted binding mode for cofactor in the SAM-pocket of KsgA. Shown in gray is 
SAM from the co-structure of ErmC’ + SAM  (PDB entry 1QAO36), which was modeled into the 
apo form of KsgA (PDB entry 1QYR43).  Catalytic regions aligned in PyMOL with a root mean 
square (RMS) = 0.734 (95 to 95 atoms), aligning residues 18, 20, 45, 66, 91, 92, 111-120 and 
181 of 1QYR, and the analogous residues 11, 13, 38, 59, 84, 85, 99-109 and 163 of 1QAO.  
  
  Similarly, the co-structure of M.TaqI + DNA + AETA (PDB 1G3841) was aligned with 
the apo structure of KsgA to predict how the target-adenosine would likely interact with this 
substrate’s binding pocket.  When the target-adenine from the DNA of M.TaqI (PDB 1G3841), 
was modeled into the adenosine pocket of KsgA (Figure 11), interactions closely resemble those 
predicted for ErmC’ (Figure 7), though, this model of KsgA did not  show the full residue of 
Tyr-116 (possibly due to its dynamic nature).
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Figure 11. Predicted binding of target-adenine into the substrate-pocket of KsgA. In gray are the 
adenine substrate and Tyr-108 from M.TaqI (PDB 1G3841), and SAM from ErmC’ (PDB 
1QAO36), which were modeled into the apo form of KsgA (PDB entry 1QYR43).  Catalytic 
regions of KsgA and ErmC’ were aligned as in Figure 10, then M.TaqI was aligned with ErmC’ 
by the same  method described in Figure 7. 
Predicted Mechanism for ErmC’ and KsgA Catalysis
 Understanding the orientation of the target-adenosine relative to the cofactor and catalytic 
residues of ErmC’ or KsgA has allowed us to envision how a methyl group from SAM  is 
transferred to the N6-position of adenosine.  Previously, Goedecke et al. proposed a mechanism 
for M.TaqI catalysis based on his crystal structures,41 which has since been applied to ErmC’ and 
KsgA to give their predicted mechanism (Figure 12).  In short, the target adenosine becomes 
more labile for methylation after forming H-bonds with the asparagine residue and the adjacent 
peptide bond, and is then stabilized by #-interactions from a flipped tyrosine.
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Figure 12. Proposed mechanism for RNA methylation by ErmC’ and KsgA.
 The N6 atom on adenosine normally  exists in a more stable co-planar sp2 hybridization 
state. This is a result of the lone pair of electrons on N6 conjugating into the aromatic system of 
the connected purine ring. When the target adenosine binds to its respective pocket, hydrogens 
from the N6 atom should be pulled towards the carboxamide oxygens of both asparagine 
(Asn-101 in ErmC’, Asn-113 in KsgA) and the backbone of the neighboring amino acid (Ile-102 
in ErmC’, Leu-114 in KsgA), both of which lie slightly adjacent to the plane of the putative 
purine ring. This distortion should push the N6 atom into a more reactive sp3 hybridization as 
electrons are conjugated out of the purine ring and return to the lone orbital of N6.  As a result, 
the lone pair of electrons of N6 would point directly towards the methyl group on SAM, which 
lies on the opposite side of the plane from Asn-101/113 and Ile-102/Leu-114. The relative 
position of the methyl group would also be an ideal geometry for the nucleophilic N6 atom to 
perform an inline attack on SAM. The resulting charged intermediate (quaternary  N6+-adenosine) 
could then be stabilized though cation-# interactions with the electron rich tyrosine (Tyr-104 in 
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ErmC’, Tyr-116 in KsgA).42  The methylated adenosine should return to the co-planar sp2 
hybridization after the extra proton on N6 is carried off by another nucleophile, such as a 
hydroxyl ion (Figure 12). 
Research Aim
 There is clearly  an urgency to act upon the threat posed by antibiotic resistance.  In the 
past, scientists have responded to this danger by discovering new classes of antibiotics. 
However, most of these drugs were derived from soil-dwelling bacteria that are inherently prone 
to resistance.69  As an alternative, we suggest that the effectiveness of the large class of MLSB 
antibiotics can be restored by targeting one of the most widespread and threatening mechanisms 
of resistance, ErmC.  In addition, we will look for a potentially new class of antibiotics that stalls 
ribosome assembly by inhibiting the ubiquitously conserved KsgA.63 
 Conveniently, the similarities between ErmC’ and KsgA justifies using a common library 
of compounds to test against both of these methyltransferases.  After an efficient assay was 
developed for measuring RNA methylation (Chapter 2),70 compounds were synthesized for 
screening against  ErmC’ and KsgA in vitro (Chapter 3). Potential inhibitors were used with the 
adenosine scaffold with the objective of binding to the target-adenosine pockets of ErmC’ and 
KsgA.  Several alkyl, aromatic, or other functionalized substituents were added at the N6-
position of adenosine in the first-generation of compounds to probe for favorable interactions 
with the neighboring SAM  pocket.  Selected inhibitors were then co-crystallized with ErmC’, 
and the co-structure of two of these crystals were solved and shown to have an unexpected 
binding mode. 
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 The revelations of how two of these inhibitors bind to the SAM  pocket of ErmC’ 
redirected our focus to a second-generation of compounds (Chapter 4).  Here, we added phenyl 
groups with varying linker lengths to the 5’-position of our lead compound with the intent of 
bridging from the SAM  pocket  into the target-adenosine pocket. Initial screening showed that 
adding this second substituent provided a marked improvement in the inhibition of ErmC’ but 
not of KsgA.  However, when SAM concentration was lowered in IC50 studies with ErmC’, we 
saw an apparent loss of inhibition for some of the second-generation compounds relative to the 
first-generation lead compound (Chapter 5). These surprising results and other preliminary data 
led us to conclude that some of these second-generation compounds bind outside of the SAM 
pocket, possibly in the target-adenosine pocket. 
 While many questions remain unanswered and new questions created, this report should 
provide useful information about a new screening technique, structural data for two new ligands 
complexed with ErmC’ and synthesis procedures for several previously unreported compounds.
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CHAPTER 2: Scintillation Proximity Assay for 
Measurement of RNA methylation
Background
 As part of our study to investigate potential inhibitors for ErmC’ and KsgA, we needed an 
assay that would allow us to efficiently screen libraries of compounds for activity. At the time 
this method was developed, our research was also focused on another methyltransferase, RmtA. 
This protein is a member of the ArmA/RmtA family of rRNA methyltransferases, which confer 
resistance to aminoglycoside antibiotics.71 RmtA and related members monomethylate the N7-
position of G1405 (E. coli numbering) on 16S rRNA in the 30S ribosomal particle.72 Like 
ErmC’ and KsgA, RmtA also uses the S-adenosyl-methionine (SAM) cofactor as the methyl 
donor. While the work done with RmtA was very instrumental in the development of this 
screening assay, RmtA was not included in subsequent inhibitions studies and is limited to this 
chapter.
 In vitro characterization of RNA methyltransferases usually requires 3H-methyl-SAM 
(radiolabeled on the methyl group) to be reacted with the RNA substrate. The resulting 
radiolabeled RNA product can then be measured to determine the extent of methylation (i.e., 
how many  3H-methyl groups are added to substrate). This is commonly used for kinetically 
characterizing an enzyme and detecting inhibition for high throughput screening (HTS).   
 Typically, these assays also require radiolabeled RNA product to be separated from the 
31
unreacted 3H-methyl-SAM  before methylation activity  can be properly measured. This 
separation is usually  accomplished by filter binding73 or with a spin column.74  In either case, 
positively charged surfaces on the media allow RNA to adhere through their negatively  charged 
phosphate groups and allow residual SAM  to elute. While these methods are commonly  used, 
they  suffer from a variety of shortcomings, including empirical determination of wash 
conditions, variation in deposition efficiencies, large volumes of radioactive waste and the 
inability to scale up to a large number of parallel measurements as would be used in HTS.  One 
way to circumvent these deficiencies has been to use fluorescence-based assays that measure the 
S-(5’-adenosyl)-L-homocysteine (SAH) product rather than the methylated RNA. This type of 
assay has the advantages of being adaptable for HTS and not requiring radiolabeled reagents, but 
it does not directly  measure the methylated product and makes the assumption that RNA 
methylation will equal SAH production. One version of this assay uses SAH antibodies with 
conjugate tracers to measure activity,75 but high cross-reactivity  of the anti-SAH antibody  with 
SAM limits its use to low concentrations of SAM (i.e., 3 µM  or less).  Other indirect assays 
using coupled enzymes to convert SAH to detectable products76-78 are potentially  ambiguous, 
since test compounds (e.g., inhibitor screens) could inhibit  these enzymes but not the 
methyltransferase.  
 We have developed a scintillation proximity  assay  (SPA) for measuring RNA methylation 
using commercially available yttrium silicate (YSi) scintillant beads that capture DNA or RNA 
by non-specific electrostatic binding. In our application, radiolabeled methylated RNA product 
bound to the bead activates the scintillant whose emission can be measured and quantitated.  The 
intrinsic physical separation of the radiolabeled methylated RNA product from radiolabeled 
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SAM reactant permits the accurate direct  quantitation of methylated RNA product  without the 
need for a separation step.  This method should be generally  applicable to assay RNA-
methyltransferases and their products and adaptable for HTS.  
Optimization of SPA Assay Conditions
Bead concentration affects the signal to noise ratio
 To optimize the YSi bead concentration, we tested signal and background reactions with 
different amounts of YSi beads (Figure 13).  We found that for our assay conditions, 1 mg of YSi 
beads gave the highest signal:noise ratio with a signal greater than 6000 cpm.  These experiments 
also suggest that the apparent failure to reach saturation of the beads with bound, methylated 30S 
ribosomal particles is due to the non-proximity effect (NPE) as bead concentration increases 
(Figure 13).  The NPE arises from excitation of beads by radiolabeled substrate that is within the 
path length of the isotope’s !-particle (1.5 µm for 3H; GE Health Sciences), but is either free in 
solution or bound to other nearby beads. It  is recommended that bead concentrations be 
optimized for specific applications.
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Figure 13. Optimization of assay conditions. (A) Dilution of samples of 3H-methyl-SAM  with 
water: (%) beads mixed with 50 µL of sample (buffer R, 20 µM SAM 780 cpm/pmol) before 
adding water;  (&) beads mixed with 50 µL of sample (buffer R, 20 µM SAM  780 cpm/pmol, 10 
pmol 30S) before adding water; (') beads mixed with 50 µL of sample (buffer R, 20 µM SAM 
780 cpm/pmol) followed by addition of 3 mL of water; (() beads mixed with 50 µL of sample 
(buffer R, 20 µM SAM 780 cpm/pmol, 10 )mol 30S) after adding 3 mL of water. Data shown 
were from single samples. 
Minimizing background from 3H-methyl-SAM 
3H-methyl-SAM alone in reaction buffer produced surprisingly high counts (Figure 14.) 
that would raise background levels in the assay.  Addition of cold 30S (10 pmol) ribosomal 
particles to the incubation of 3H-methyl-SAM  with YSi beads lowered the counts, particularly 
for samples with smaller amounts of YSi beads, indicating that SAM and 30S ribosomal particles 
compete for sites on the YSi beads.  
    A significant diminution of background counts from 3H-methyl-SAM  binding to the 
beads was achieved by dilution of the sample with 3 mL of water (Figure 14). This indicated that 
the major contributor of 3H-methyl-SAM to the background counts is through the NPE and not 
through binding to the beads.  Dilution of the reaction solution with water to a volume of ~250 µl 
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(the well volume of a typical 96 well plate) in addition to the volume of the YSi beads almost 
entirely  eliminated this background. Attempts to lower background counts by dilution with 
solutes (adenosine, unlabeled SAM, spermine, HCl or MeOH) showed that only unlabeled SAM 
lowered background without lowering signal (data not shown).  We conclude that background 
contributions from the non-specific binding of 3H-methyl-SAM  to YSi beads is intrinsically 
optimized because the higher affinity 30S ribosomal particles in the sample and the cold SAM 
used in the quenching step reduce bound 3H-methyl-SAM to an inconsequential level.  
Figure 14. Optimizing bead concentration.  (&) beads mixed with quenching SAM and 50 µL of 
signal reaction (10 pmol RmtA, 10 )mol 30S, buffer R, 20 µM SAM  780 cpm/pmol, 37 ºC for 1 
hour) and diluted to 250 µL with water; (*) beads mixed with quenching SAM  and 50 µL of 
background reactions (10 pmol 30S, buffer R, 20 µM SAM 780 cpm/pmol, 37 ºC for 1 hour) and 
diluted to 250 µL with water. Assays were done in triplicate, plotting the average with error bars 
of +/- 1 standard deviation.
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Sample centrifugation increases the signal to noise ratio
 We found that centrifuging samples just prior to scintillation counting improved the 
signal:noise significantly (> 5:1).  Counts from signal reactions more than doubled, while those 
of background reactions increased only slightly  (Figure 15). This phenomenon may  be due to the 
NPE, arising in this case from more tightly packed radiolabeled 30S particle-bound beads 
exciting proximal YSi beads within the 1.5 µm path length of the tritium !-particles. 
Background counts did not increase significantly  on centrifugation, consistent with the low level 
of bound radiolabeled substrate. More importantly, centrifugation of the beads after product 
binding also reduced variability among replicate samples, possibly by detaching beads bound to 
the walls of the vial and packing them more uniformly.  A centrifugation step can be incorporated 
into HTS experiments by centrifuging 96-well plates in a special rotor as described in a similar 
SPA HTS assay.47
Figure 15. Centrifuging samples from time courses of RmtA + wild-type 30S.  (() signal 
reactions before centrifugation; (&) signal reactions after centrifugation; (+) background 
reactions before centrifugation; (*) background reactions after centrifugation. Assays were done 
in triplicate, plotting the average with error bars of +/- 1 standard deviation.
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Binding of methylated 30S ribosomal particles to YSi beads is instantaneous 
Incubation time for YSi beads with product mix was optimized to ensure maximum 
capture of 30S ribosomal particles. A large batch (70 pmol) of 30S rRNA particles was 
methylated by RmtA for 1 hour and separated into individual 10 pmol portions to test the effect 
of different  incubation times (0, 20, 40, 60, 80, 100 and 120 min).  YSi beads (density  = 4.1 g/
cm3) quickly settle in solution, so beads were thoroughly mixed with a pipette on addition of the 
reaction sample (time 0) and then mixed by  inversion every 20 min for the specified time. The 
signal from time 0 was approximately  the same as the other incubation times (data not shown), 
indicating that 30S binding occurs almost instantaneously and is complete with the first mixing. 
For convenience, all succeeding samples were incubated for 40 min (i.e., mixed by  pipette 
initially and again at 20 and 40 min before centrifugation). 
 With these optimized conditions, we attained minimum count levels of ~3000 cpm and 
signal:noise ratio of ~ 5:1, which are the recommended benchmarks for this bead-based assay 
(GE Health Sciences).  While these conditions are useful as a guide to implementing the assay, 
optimization should be done for applications to different assay systems.   
SPA vs. Filter-Binding Method in Measurement of Time Courses and Extent of Methylation 
Our standard filter-binding assay  for measurement of methyltransferase activity is based 
on an earlier method79 in which reaction solutions are pipetted onto cationic filter discs, washed 
twice with ~200 mL of 5% TCA and rinsed with ~3 mL ethanol.  After drying for an hour, filter 
discs are placed in 3 mL of scintillation fluid for counting.  
37
We compared this method of measuring RNA methylation with our SPA method in 
parallel time course experiments.  Using our standard optimized reaction conditions, we ran time 
courses of reaction for RmtA and KsgA, including separate background measurements (Figure 
16A). Identical time course experiments were also done using ErmC’ (Figure 16B).  For each 
time point, double the normal amount was removed from the reaction, quenched and divided so 
that equal amounts were measured by either the SPA method or the traditional filter binding 
technique. Both sets of experiments with RmtA and KsgA showed the expected exponential 
curve with an early linear phase extending up to about 5 min and an extended asymptotic plateau 
(Figure 16A) while, the time course for ErmC’ showed a linear phase extending up  to about 32 
min (Figure 16B). The more gradual rate of methylation by ErmC’ could be attributed to using 
23S from E. coli rather than the preferred substrate of 23S from B. subtilis. Although the SPA 
produced a higher background than the filter binding method, signals from the SPA were greater 
than for filter binding after backgrounds were subtracted. The consistent values of SPA 
background indicate that the high background does not compromise the results.  The SPA 
background increased slightly  over time in a linear fashion.  This could be due to degradation of 
3H-methyl SAM to a radiolabeled product with higher affinity for SPA beads; or substrate being 
methylated by contaminant MTases; or non-enzymatic reactions that transfer 3H-methyl to RNA 
or other products capable of binding to SPA beads. 
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(a)
(b)
Figure 16. Parallel time-course assays measured with SPA and filter binding methods. 
(a) Maroon are RmtA + wild-type 30S; orange are KsgA and ksgR 30S. (b) Black are ErmC’ + 
23S (from E. coli). Solid symbols indicate signal reactions (10 pmol 30S or 23S, 10 pmol 
enzyme, 20 µM SAM 780 cpm/pmol); empty symbols indicate background reactions (10 pmol 
30S or 23S, 20 µM SAM 780 cpm/pmol). Triangle symbols are measurements by YSi SPA 
beads; square (a) or diamond (b) symbols are the corresponding filter binding measurements. 
Assays were done in triplicate, plotting the average with error bars of +/- 1 Std Dev.
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The data from these parallel time courses allowed us to calculate the amount of 3H-
methyl transferred to RNA from the SPA measurements.  In the filter binding method, the extent 
of methylation can be easily determined from knowledge of the amount of RNA substrate in the 
assay and the measurable specific activity of the 3H-methyl-SAM used. However, in the SPA 
format, the amount of 3H-methyl-SAM used cannot  be directly  measured with a specific-activity 
test, because the different binding affinities of 3H-methyl SAM  and 3H-methylated RNA to the 
SPA beads will yield a different response for the same amount of 3H-methyl group. 
 This problem is circumvented by plotting the SPA and filter binding responses from the 
same samples and obtaining the linear equation that relates them (Figure 17).  SPA measurements 
can then be converted into “filter binding equivalent” values, from which RNA methylation is 
quantified (Figure 18) using the specific activity of 3H-methyl-SAM.  The number of methyl 
groups incorporated into RNA by  KsgA or RmtA determined from the SPA assay  is consistent 
with full methylation of the 10 pmol of 30S substrate by two of the enzymes: 10 pmol of methyl 
groups for RmtA and 40 pmol for KsgA.  As for ErmC’, around half of the expected 20 pmol of 
methyl groups were calculated to be incorporated into 23S, probably because this RNA substrate 
had been extracted from E. coli rather than the preferred source of B. subtilis. 
 Performing a parallel filter binding assay may be needed only when quantifying methyl 
group incorporation. In this case, once a correlation of SPA and filter binding measurements is 
established for a particular enzyme reaction, subsequent SPA measurements could be quantified 
by use of the previously obtained SPA to filter binding conversion factor and the measured 
specific activity of the 3H-methyl-SAM.
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(a)
(b)
Figure 17. Correlation of SPA and filter binding measurements. Net counts from time points in 
Figure 16 are plotted with SPA counts along the X-axis and filter binding counts along the Y-
axis. (a): Maroon are RmtA + wild-type 30S; orange are KsgA and ksgR + 30S. (b): Black are 
ErmC’ + 23S (from E. coli). Combined replicates were used to fit the least squares trend line. 
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(a)
(b)
Figure 18. Extent of methylation. Time courses measured by SPA in Figure 18 are expressed in 
number of methyl groups incorporated into RNA.  Formulas derived from Figure 17 were used to 
convert SPA measurements into “filter binding equivalent” values for quantitation of methyl 
group incorporation. (a): Maroon are RmtA + wild-type 30S; orange are KsgA + ksgR 30S. (b): 
Blue are ErmC’ + 23S (from E. coli).
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SPA Analysis of Extracted 3H-methyl RNA
 The experiments described above measure methylation of 30S subunit particles that bind 
intact to YSi beads.  We also tested the SPA assay format on methylated RNA extracted with 
phenol to remove proteins.  Phenol-extracted, methylated 16S rRNA from RmtA or KsgA 
catalyzed reactions was tested for binding to YSi beads in the SPA assay.  Signals for both 
reaction products increased linearly with amount of extracted 3H-methyl-RNA up to 10 pmol 
(Figure 19).  The counts measured for 10 pmol of extracted RNA were higher than those for the 
same amount of 30S particles, suggesting that free RNA has a higher affinity for YSi beads than 
RNA bound to protein in the 30S subunit, or that the NPE is larger for bound RNA in the absence 
of protein.  The background for the extracted RNA measurements was essentially nil, since all 
3H-methyl SAM is washed away in the extraction process.
Figure 19. Free 3H-methyl-RNA measured with YSi SPA beads. RNA extracted from 30S 
subunits following a 2 hr reaction with RmtA + wild-type 30S (maroon) or KsgA + ksgR 30S 
(orange), and incubated with different amounts of YSi beads. RNA concentration was determined 
by measuring the OD260 following extraction. 10 pmol of RNA extracted from reactions without 
enzyme were used as a negative control.  Data are for single samples.
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SPA Assay for Methylation of Free RNA Substrate
To verify that this SPA procedure can measure methylation of an RNA substrate alone, 
parallel time course experiments were performed as above using the ErmC’ enzyme and phenol-
extracted 23S rRNA from 50S ribosomal particles.  The kinetics of this reaction differ from those 
for KsgA and RmtA, but with 10 pmol of E. coli 23S rRNA substrate we measured ErmC’-
catalyzed incorporation of ~10 pmol of methyl group (Figure 18), in close agreement with the 
results of Denoya and Dubnau 81 for this reaction.  Furthermore, the correlation of SPA and filter 
binding values for the ErmC’-catalyzed reaction is closely similar to that obtained for the KsgA 
and RmtA assays.
 Use of a similar YSi SPA bead to monitor methylation of tRNA has been reported 82 for 
considerably different assay conditions, suggesting that this method can be applied widely to 
both methylated RNA and RNA-protein complexes.       
Dependence on Enzyme Concentration
 Based on the time course, we took early  samples (8 min for RmtA, 3.5 min for KsgA) of 
reactions carried out with varying amounts of RmtA or KsgA (Figure 20) to determine the 
dependence on enzyme concentration.  Under the reaction conditions used, the activity  measured 
from the SPA assay is linear for enzyme concentrations up to at least 200 nM (10 pmol enzyme 
in the reaction), validating the use of this assay for determining enzyme concentrations.
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Figure 20. Dependence on enzyme concentration. 10 pmol 30S ribosomal particles were 
incubated with RmtA (maroon) for 8 min and 10 pmol ksgR 30S ribosomal particles were 
incubated with KsgA (orange) for 3.5 min. Samples were done in triplicate and the average 
plotted with error bars of +/- 1 standard deviation.
Inhibitor Assays
 We tested the SPA assay for RmtA inhibition by  the known methyltransferase inhibitors 
sinefungin and SAH (Figure 21A).  Both compounds inhibited RmtA in a concentration-
dependent manner with calculated IC50 values of 19.95 ± 0.09 µM for sinefungin and 9.33 ± 0.07 
µM for SAH.  We also tested the effect of DMSO in the inhibition reactions, since this solvent is 
often used in HTS assays to dissolve test compounds (Figure 21B).  RmtA in the presence of 
DMSO appeared to be fully  active up to 15% (V/V), but the response from SPA beads dropped 
off at , 20% DMSO.  Whether the drop  in signal was from the effect of DMSO on enzyme 
activity or on the binding of methylated RNA product to the SPA beads was not determined.
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(b)
(a)
Figure 21. Inhibitors of methylation.  For each concentration of inhibitor, inhibitor/DMSO was 
added to 30 pmol RmtA + 30 pmol wild-type 30S ribosomal  particles + 20 µM  SAM 780 cpm/
pmol for an 8 min reaction.  One third of the reaction volume was added to each of the 3 vials of 
SPA beads and the average plotted with error bars of +/- 1 standard deviation. (a) reactions with 
sinefungin  (-) and with SAH (.). (b)  reactions with DMSO alone.
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CONCLUSIONS
 Yttrium silicate nucleic acid binding SPA beads are shown here to be a useful method for 
measuring methylation of rRNA and almost certainly  for other RNA and RNA-protein 
complexes.  This assay method gave signal:noise ratios > 5:1 under our optimized conditions and 
can be used to measure methylation of RNA alone or in a 30S ribosomal particle complex with 
protein.  While optimization of conditions for a specific assay and its products is advisable, all 
assays of RNA methylation will involve the common step of non-specific binding of the RNA 
product to the YSi beads.  Therefore the conditions described here are likely  to be a good starting 
point for any further optimization.  Through use of a standard reference curve relating SPA 
counts to counts from the traditional filter binding assay, the SPA assay can give reproducible 
and accurate measures of the stoichiometry of methyl group incorporation.  While the creation of 
this standard reference curve adds a step  to the assay when methylation stoichiometry  is to be 
determined, this would not be necessary for routine assays of relative activities or HTS 
applications, and may otherwise need only be done once.  This SPA method can be used in time 
course assays for kinetic measurements, for quantitation of methyltransferases and for assay of 
inhibitors in DMSO concentrations up  to 15% by volume.  It is easily adapted to HTS processes 
and for manual procedures offers the advantages over the filter binding assay of less time, 
materials, radioactive waste and lower overall cost.  
MATERIALS AND METHODS
Protein expression and purification
 KsgA was expressed and purified as described.73  RmtA and ErmC’ were expressed from 
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a cloned, synthetic gene inserted into pET15b plasmids, rmtA in Rosetta 2 (DE3) cells 
(Novagen) and ermC’ in BL21 (codon+ DE3-RIL) cells (Stratagene). All three enzymes were 
purified on a HiTrap Ni-chelating column (Amersham) to > 95% homogeneity on SDS gel. 
30S purification
 Wild type and ksgR strains of E. coli were provided by Dr. Heather O’Farrell (our lab) 
and 30S subunits were prepared according to a previously  described method.73 Concentration of 
30S was determined by multiplying OD260 by 6 pmol/mL.
30S Particle and 23S rRNA Methylation Reaction
 A standard 50 µL reaction contained 10 pmol enzyme (RmtA, KsgA or ErmC’), 10 pmol 
30S (wild type for RmtA, unmethylated ksgR for KsgA) or 23S (phenol extracted from E. coli 
50S for ErmC’), 0.02 mM 3H-methyl-SAM (780 cpm/pmol) (Perkin Elmer) and reaction buffer 
incubated at 37 °C for a specified time.  Prior to mixing the reactants, 30S particles were heated 
at 42 °C for 5 min to anneal subunits into a homogenous conformation (for reactions with RmtA 
and KsgA).  Reactants were mixed and the reaction initiated by addition of SAM.   Background 
reactions were performed in the same way without enzyme. In reactions with RmtA and for its 
background measurement, reaction buffer (buffer R) consisted of 40 mM Tris, pH 7.2, 40 mM 
NH4Cl, 8 mM  MgOAc, and 1 mM DTT.  Reaction buffer for KsgA and ErmC’ reactions and for 
its background measurement was 40 mM  Tris at pH 7.4, 40 mM NH4Cl, 4 mM  MgOAc, 6 mM 
2-mercaptoetanol.
At the end of the reaction time, the 50 µL reaction volume was removed and added to 
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clear 1.5 mL vials containing 180 µL deionized water, 10 µL (100 mg/mL) YSi binding beads 
(cat. RPNQ0013, GE Life Sciences) and 10 µL 100 mM unlabeled SAM (Sigma) and mixed 
thoroughly  by pipette. Vials were then incubated in the dark for 40 min with mixing by inversion 
at 20 and 40 min and then centrifuged at 13,000 rpm for 3 min, placed in the mouth of a 15 mL 
scintillation vial, and counted in a Packard 1500 Tri-Carb Liquid Scintillation Analyzer.  For 
experiments to optimize bead concentration (Figure 13) and water dilution (Figure 14), sample/
bead mixtures were pipetted into the bottom of the scintillation vial and allowed to settle for an 
additional 20 min in the dark without mixing before being counted.  Time course assays of 
samples before and after centrifugation (Figure 15) were done in one vial in volumes sufficient 
for 8 samples.  Samples of 50 µL were taken at each of the 8 designated time points and 
measured by  the standard SPA method with the additional step  of counting samples just prior to 
centrifugation.  Signal and background reactions were measured in triplicate at  1, 2, 4, 8, 16, 32, 
64 and 128 min.
 Parallel time course assays (Figure 16) were done as above except the reaction volume 
was sufficient for 16 samples for signal reactions and 6 samples for background reactions. 
Samples of 100 µL were removed at  each time point, quenched with 20 µL 100 mM  unlabeled 
SAM, and divided into two 60 µL aliquots for determination by the SPA and filter binding 
methods.  Signal reactions were measured at 1, 2, 4, 8, 16, 32, 64 and 128 min, while background 
reactions were measured at 1, 8, and 128 min, all in triplicate.  Excel was used to obtain a linear 
fit of data in Figures 17 and 21 and background data in Figure 16, and a logarithmic fit of signal 
data in Figures 16 and 18.
Inhibition studies were done using RmtA and wild type 30S in a triple volume reaction. 
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Inhibitor or solvent was added at a specified concentration prior to the addition of SAM  to 
initiate the reaction. Reactions were stopped after 8 min and dispensed in equal volumes into 3 
vials with YSi beads. Sinefungin (Sigma) was dissolved in deionized H2O, SAH (Sigma) was 
dissolved in DMSO (American Bioanalytical).  Data in Figures 21A and B were fitted with a 
sigmoidal dose-response curve provided in Sigma Plot 8.0; IC50 values were calculated as 
described.83
Extraction of 16S and 23S rRNA from 30S and 50S Particles.
Methylated 16S rRNA after reaction with KsgA or RmtA was extracted with buffer- 
saturated phenol (Invitrogen) and precipitated with ethanol before dilution and counting.  23S 
rRNA was similarly extracted from 50S particles with phenol prior to methylation by incubation 
with ErmC’ (this method is further detailed in Chapter 3).
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CHAPTER 3: First-Generation Compounds
Background
 In order for ErmC’ or KsgA inhibitors to be considered for drug development, 
compounds should demonstrate both potency and selectivity.  The former might be easy  if the 
latter were disregarded.  While many potent MTase inhibitors have been discovered, few have 
been developed into drugs. Catechol-O-methyltransferase (COMT) inhibitors like entacapone or 
tolcapone are rare exceptions.84  The biggest  hurdle has been selectively blocking the intended 
MTase without also affecting any of the many  vital MTases in humans, which could lead to 
toxicity.  Traditionally, this obstacle has been approached by aiming for the more unique 
substrate-binding pocket of MTases rather than the more common SAM-binding pocket. In the 
cases of our targets, ErmC’ and KsgA, this is particularly  difficult  since both pockets for the 
substrate and cofactor are binding molecules that contain the adenosine moiety.  There appeared 
to be a breakthrough for this challenge when Pfizer presented work on selective ErmC inhibitors, 
which allegedly did not  compete for the SAM binding site.85  This was followed up by a 
molecular modeling study from Feder et al. that showed one of these inhibitors (compound 1) 
binding to the adenosine-pocket of ErmC’ and not the SAM-binding pocket (Figure 22).40  The 
conclusions made from these two studies formed bases for much of our original research plan. 
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Flipped Tyrosine SAM
1
Figure 22. Representative model of lead compound 1, N6-cyclopentyl adenosine (on left), docked 
into the “M.TaqI-like” model of ErmC’ (aqua-blue, on right), based on the work of Feder et al.40 
Tyr-104 rotated to match Tyr-108 (yellow) of M.TaqI. Note: SAM (gray) was modeled in from 
(1QAO)36 for the sake of comparison, but was not present in this model used in in silico 
screening.
 In the first report,85 Clancy et al. performed high throughput screening of synthetic 
compounds on ErmC (from S. aureus), using COMT (from rat livers) and EcoRI methylase (from 
E. coli) to test for selectivity. Of the 160,000 compounds screened, seven of the inhibitors were 
selective towards ErmC, and were also structurally unrelated. One compound that had our 
interest (1) produced IC50 values of 63 µM  (ErmC), 390 µM (COMT) and >1 mM (EcoRI 
MTase). For comparison, the positive control (sinefungin), gave IC50 values of 5 µM (ErmC), 2 
µM (COMT) and 80 µM (EcoRI MTase). It was also reported that raising the concentration of 
SAM did not affect IC50 values, suggesting that 1 was not acting through the SAM-binding 
pocket, although supporting data for this conclusion was not shown.85
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 In the second report,40 Feder et al. screened in silico all compounds in the Maybridge 
collection using three different models of ErmC’s adenosine-binding pocket: 1) an “M.TaqI-like” 
model, where Tyr-104 was rotated to match the rotamer of Tyr-108 in M.TaqI. (PDB entry 
1G38),41  2) from the co-structure with SAM bound (1QAO),36 and  3) from the structure without 
SAM.  Those compounds that docked into the adenosine pocket had the greatest affinity in 
model 1, supporting the idea that Tyr-104 “flips-out” during binding of the target substrate 
(affinity scoring done by  Suflex software). Of the top 200 scoring compounds, 77 were visually 
selected for MIC studies with an ErmC’-expressing clone of E. coli. Seventeen of these 
compounds were shown to restore the potency of erythromycin in vivo. When these 17 were 
tested against ErmC’ in vitro, 8 compounds had IC50 values between 180 to 500 µM.  Compound 
1 was also tested by this group for comparison, and was found to be more potent than the other 
test compounds, with an IC50 = 80 µM. [Note: IC50 assays used 0.13 µM  SAM, 0.2 µM ErmC’, 1 
µM synthetic RNA of 32 nucleotides.] 
  More interestingly, when 1 was docked into the “M.TaqI-like” model of ErmC’ (Figure 
22), the adenosine moiety of this inhibitor oriented against the “flipped” tyrosine in a similar 
manner as the putative target-adenosine (Figure 7, Chapter 1). Furthermore, the cyclopentyl 
substituent on the N6 atom could be seen branching into the SAM pocket, reaching about as far 
as the sulfur atom of the modeled SAM ligand (Figure 22).  Feder et al. predicted that this 
substituent improved potency  by extending it into the SAM pocket  to make favorable 
interactions.40  [Note: Feder et al.40 briefly  stated 1 was competitive with SAM when tested 
between 0.05 - 0.5 µM (SAM), contrary to their docking model and the claim by Clancy et al.85] 
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Rationale
  The assumption was made that the lead compound (1) bound to the target-adenosine 
pocket to form many of the same interactions as the putative substrate, namely  #-stacking with 
Tyr-104 and Phe-163, and H-bonding with Asn-101 and Ile-102.  It was reasoned that if the 
cyclopentyl substituent branched into the SAM-binding pocket of ErmC’, then other substituents 
may also be added to this position in order to explore more favorable interactions. We anticipated 
that 1 (or related analogs) might also inhibit KsgA because of the similarities with ErmC’. 
Therefore, a small library of N6-substituted adenosine analogs was designed for a preliminary 
survey of potential interactions in ErmC’ and KsgA. Any  analog that showed particular promise 
as a good inhibitor could later be expanded upon in subsequent libraries to further improve these 
interactions. Such a strategy would be similar to the Topliss scheme often used to optimize 
inhibitors during drug design.86
 For the first library, 23 substituents were selected from a general array of chemical 
groups that  could be placed in the N6-position of adenosine. These included aliphatic single 
chains ranging from one to eight carbons (as on 2-7, see Table 2), which were designed to probe 
for hydrophobic interactions at various lengths. Two of these chains had a terminal amine (as on 
6 & 7) able to form ionic bonds with acidic residues.  Also selected were small branched alkyl 
groups (as on 8 & 9), which could probe for steric hindrance near the N6 region of the adenosine 
analog.  Several aromatic rings were also picked to explore #-stacking, hydrophobic or other 
interactions. For example, the benzyl groups on 10 - 12 were attached by linkers varying from 0 - 
2 carbon bonds, which might also tell us about a preferential linker length. Three aromatic rings 
with para-substitutions (as on 13-15) could explore additional steric and electronic effects. 
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Another two substituents were heterocyclic (as on 16 & 17), which could form H-bonds.  Non-
aromatic rings were also selected (as on 1, 18-21), which could explore hydrophobic interactions 
with slightly more flexibility  than the aromatic substituents, but with more spatial constraints 
than the aliphatic chains.  Lastly, two short, unsaturated chains (as on 22 & 23) could test  for #-
interactions close to the N6-position. 
 We hypothesized that these new adenosine analogs would bind to the substrate pockets of 
ErmC’ or KsgA with substituents branching into the adjacent SAM pocket, similarly to how 1 
was proposed to dock into the ErmC’ model.40  Compounds 1-23 should offer us an initial 
assessment about preferred binding interactions when tested against ErmC’ and KsgA in vitro. 
The lead compound (1) will be used as a reference inhibitor, and a benchmark we aim to surpass. 
Synthesis
  Compounds 1, 3 - 23 were made by following the general reaction shown atop Table 2. 
[Note: Compound 2 (N6-methyladenosine) was also part of the original synthesis plan, but had 
been previously purchased from Sigma.]  Those substituents that we chose to add at the N6-
position of adenosine were purchased in the form of a primary amine attached to the desired 
substituent.  This substituted amine was then reacted with 6-chloropurine riboside under the 
presence of a base, triethylamine (Et3N), and heat (60-110 °C). [Note: K2CO3 was initially used 
as the base, but gave poor yields.]  In this reaction, the primary amine performs a nucleophilic 
attack on the C6 of 6-chloropurine riboside, thereby replacing the Cl6 with the desired N6-
substituent. Structures of these products and their respective yields are summarized below (Table 
2).  Further details of each reaction can be found at the end of the experimental section.
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Table 2. Synthesis of first-generation compounds.
          substituted          6-chloropurine                                      1, 3 - 23
             amine                   riboside
product        -R               (name) yield product        -R                 (name) yield
1
              cyclopentyl 82%
13
   4-methylbenzyl 62%
2                         methyl (Sigma) 14  4-chlorobenzyl 72%
3                        ethyl 75%
15
                      4-methoxybenzyl
60%
4                n-butyl 8%
5   octyl 22% 16    4-methylpyridine
97%, 
crude
6        ethylamine 23%
17
                 tetrazole
34%, 
crude
7  
octylamine
64%
18
             cyclohexyl 31%
8
                   isopropyl 73%
19
         tetrahydropyran 41%
9
                    tert-butyl 84%
20
             piperidine 75%
10
                  phenyl
44% 21    methylcyclopropyl 82%
11
               benzyl 54%
22                  propargyl 44%
12
           phenethyl 67%
23                        allyl 42%
Structures of the N6-substituents and yields for each compound are shown above.
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 Following each reaction, product was purified by normal phase or reverse phase 
chromatography, and analyzed by proton (1H) and carbon (13C) NMR. In addition, two-
dimensional NMR experiments, Correlation Spectroscopy (COSY) and Heteronuclear Single 
Quantum Coherence (HSQC) were performed on each product to help in the assignment of 
proton and carbon peaks.  COSY is typically used to show which protons are within two to three 
bond lengths of a particular proton. Similarly, HSQC can indicate which protons are directly 
attached to a particular carbon.  The resulting spectra from these NMR experiments corroborate 
the formation of the desired products 1, 3 - 23 (see appendix A). The assignment of NMR peaks 
(1H and 13C) to their respective atoms are listed for each product in the experimental section. 
[Note: Compound 4 was the one exception, which did not have enough material to produce a 
quality 13C NMR spectra, though other NMR data supported the formation of this product.] 
Some of these products were also analyzed by mass spectrometry, which are reported in the 
experimental section.
Inhibition Assays
 First-generation compounds were tested in vitro for inhibition against ErmC’ and KsgA 
using methods similar to those described in Chapter 2. In short, compounds (1-23) and positive 
control (sinefungin) were tested at 1 mM in 10% DMSO with 20 µM SAM, incubated at 37 °C 
for 32 min (ErmC’, Figures 23) or 5 min (KsgA, Figures 24), and activity measured by SPA. 
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(a)
N6-substituent on adenosine analog
(b)
Figure 23. Results of screening first-generation compounds with ErmC’.  a) Methylation activity 
was measured by  SPA.  b) Percent inhibition was calculated by  relating activity from test-
compound with DMSO control, after subtracting the background.  The blue bars show the 
average of three replicate reactions, and error bars of +/- 1 std dev. 
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(a)
N6-substituent on adenosine analog
(b)
Figure 24. Results of screening first-generation compounds with KsgA.  a) Methylation activity 
was measured by  SPA.  b) Percent inhibition was calculated by  relating activity from test-
compound with DMSO control, after subtracting the background. The blue bars show the 
average of three replicate reactions, and error bars of +/- 1 std dev. 
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  To our delight, the results from ErmC’ reactions showed that at  least one of our 
compounds (7, and maybe 18) was more inhibitory than the lead compound 1, and a few others 
(4, 12 and 19) were not far behind in activity  (Figure 23). Likewise, we were pleased to see that 
for the first time 1 had also inhibited KsgA (albeit, to a lesser extent than with ErmC’), and that a 
few other analogs were as inhibitory (7 and 18) or more inhibitory (5) towards KsgA than was 1 
(Figure 24). Compound 6 was uniquely inhibitive to KsgA in our tests, while inhibitors 4, 12 and 
19 were active only against ErmC’.  Overall, the inhibitors from the first-generation compounds 
showed slightly  more of an effect against ErmC’ than with KsgA.  While these results may 
suggest partial selectivity towards ErmC’, some inhibitors (1, 7 and 18) were still active against 
both MTases.
 It was difficult  to decipher a governing trend of inhibition for the different substituents 
we had added. Generally, groups that were more aliphatic and less spatially constrained seemed 
to be preferred. The octylamine substituent (as on 7) was particularly inhibitory for both ErmC’ 
and KsgA, though its shorter equivalent, ethylamine (as on 6) was not inhibitory  for either 
MTases. The only aromatic substituent that showed inhibition greater than 15% was the 
phenethyl (as on 12), which only affected ErmC’.  In order to better understand the binding 
interactions of first-generation compounds, we attempted to crystallize ErmC’ and KsgA 
complexed with some of these inhibitors. 
 
Co-crystal Structures of ErmC’ and Selected Inhibitors
Crystallization
 A few of the more potent inhibitors (1, 7, 12, and 21) were selected for co-crystallization 
with either ErmC’ or KsgA.  In short, protein was expressed, purified, and concentrated (8-13 
60
mg/mL), then inhibitor (at 1-20x protein conc.) was added immediately before crystallization. 
ErmC’ was crystallized by hanging drop vapor diffusion, equilibrated against a range of reservoir 
buffers (0.1 M  Tris pH 8, 50-300 mM Li2SO4, 20-35% PEG 3350).  ErmC’ usually  formed large 
and diffraction-quality crystals (Figure 25) after just  1-2 days, although the protein was often lost 
during the preceding dialysis or concentration steps (as discussed in experimental section). Of 
those crystals that did grow to a reasonable size and quality, two were successfully  diffracted by 
X-rays (co-crystals of ErmC’ with 7 or 12), while co-crystals of ErmC’ with 1 or 21 were lost 
during the mounting procedures. The apo form of ErmC’ was also crystallized under these 
conditions, but was not used for soaking in any of the first-generation inhibitors as was originally 
intended.
   
Figure 25. Photos of ErmC’ co-crystals complexed with inhibitors 7 (left) and 12 (right). 
Dimensions of crystals were approximated at 520 x 260 x 90 µm and 230 x 140 x 60 µm, 
respectively.   
 KsgA was similarly  crystallized with inhibitor 7, using a reservoir buffer of 1.4 M 
MgSO4 and 0.1 M  1 MES pH 6.5.  However, this crystal did not diffract to a resolution greater 
than 10 Å. Other attempts with KsgA produced crystals that were too small for analysis. 
Interestingly, KsgA seemed to only crystallize when inhibitor was present, as attempts to 
crystallize the apo form were not successful. This may suggest that  the bound ligand pushes 
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KsgA into a more stable or rigid conformation than its apo form, allowing for a more orderly 
aggregation of protein during crystallization.  The work done on co-crystallizing KsgA was 
rather limited. Instead, efforts were focused more on crystallizing ErmC’ with inhibitors. 
Nevertheless, there is certainly potential for successfully co-crystallizing KsgA if these 
experiments were revisited in the future. 
Structure Refinement
 The structures of ErmC’ complexed with either N6-8-octylamine-adenosine (7) or N6-
phenethyl-adenosine (12) were solved by X-ray diffraction to resolutions of 2.60 Å and 2.40 Å, 
respectively.  Initial phasing of the diffraction data used molecular replacement from the apo 
form of ErmC’ (1QAM)36 to generate electron density maps.  Both of our structures, like 1QAM, 
were solved from crystals with the space group P43212.  After refinement, the models that were 
created showed reasonable R and Rfree values of 23.7% and 28.3% for ErmC’ complexed with 7, 
and 23.8% and 26.9% for ErmC’ complexed with 12, respectively (see Table 3). Both models 
consisted of residues 9 - 244 out of the total 244 amino acids in ErmC’.  Residues 1 - 8 were 
omitted owing to the lack of electron density at the  N-terminus. 
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Table 3.  Refinement statistics of ErmC’ co-crystallized with inhibitors 7 and 12
8-amino octyl (7) Phenethyl (12)
Data Collection
Space group P43212 (No. 96) P43212 (No. 96)
Unit-Cell parameters a = 81.34 Å, b = 81.34 Å, 
c = 122.07 Å, ! = 90.00º
a = 81.62 Å, b = 81.62 Å, 
c = 122.68 Å, ! = 90.00º
Resolution (Å) 24.78 - 2.60 (2.69 - 2.60) 33.37 - 2.40 (2.49 - 2.40)
Total Number of Reflections 59,438 159,517
Number of Unique Reflections 13,112 16,788
Average redundancy 4.53 (4.58) 9.50 (9.23)
Completeness (%)d 99.6 (99.8) 99.8 (100.0)
Rmerge 0.049 (0.319) 0.047 (0.384)
Reduced ChiSquared   0.84 (0.94)    0.90 (1.04)
I//(I)d 17.6 (4.3) 25.9 (5.7)
Reduced ChiSquared           0.84 (0.94)  0.90 (1.04)
Refinement
Resolution (Å) 2.60 - 24.00 (2.600 - 
2.667)
2.40 - 33.00 (2.400 - 2.462)
Reflections: working/free 11,799/1,311 14,954/1,661
Protein Atoms 1978 1978
Ligand Atoms 28 27
Water Atoms 36 0
Residues not Modeled 1 - 9 1 - 9
Rwork 0.237 (0.302) 0.238 (0.318)
Rfree 0.283 (0.346) 0.269 (0.340)
Roverall 0.242 0.241
Mean B value (Å2) 56.857 38.523
Estimated Maximum Coordinate 
Error (Å) 0.247 0.177
RMSD Bond Lengths (Å) 0.009 0.010
RMSD Bond Angles 1.190º 1.147º
Note: Values in () are for the last resolution shell.
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Unexpected binding mode
 Surprisingly, these refined crystal structures of ErmC’ revealed that both 7 and 12 bound 
to the SAM pocket rather than the intended adenosine pocket. In fact, ligands in these new co-
structures aligned nearly identically with the cofactor from the previous co-structure of ErmC’ + 
SAM (1QAO).36  Figure 26 shows how well the adenosine moiety of these three ligands overlap 
when co-structures are superimposed. This was in stark contrast to the binding mode predicted 
by Feder et al. for the similar analog 1.40  
 
Figure 26. Superimposed structures of ErmC’ complexed with their respective ligand: SAM (red) 
from PDB no. 1QAO,36 compound 7 (blue), compound 12 (green).
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  A closer look at the SAM-binding pocket of our co-structures shows that inhibitors 7 and 
12 form many of the same interactions with ErmC’ as seen with the cofactor in the previously 
solved structure of ErmC + SAM  (1QAO).36  With our ligands, however, an additional hydrogen 
bond is made through the 5’-OH to the peptide-backbone of Asn-101 (Figure 27). This figure 
also shows the electron density around the N6-substituents to be sparse, suggesting that these 
groups remained dynamic during binding. We also observed how these inhibitors oriented with 
the 5’-carbon pointed towards the adenosine pocket. This unexpected binding mode would later 
be exploited to make a second library of test compounds (discussed in Chapters 4 & 5).  
Figure 27. A close view of inhibitors 7 (left) and 12 (right) bound to SAM pockets of ErmC’. 
Electron density of ligands is shown as a gray mesh, and H-bonds as yellow dotted lines.
Discussion
 As mentioned before, the trend among first-generation inhibitors appeared to be that 
aliphatic substituents that  were less spatially constrained made better inhibitors. For ErmC’, 
those substituents on compounds that showed an inhibition greater than 15% were n-butyl (4 at 
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24.8%), 8-octylamine (7 at 51.1%), cyclopentyl (1 at 32.2%), cyclohexyl (18 at 32.2%), 
tetrahydropyran (19 at 20.3%), and phenethyl (12 at 18.5%) (Table 4).  Now that we have co-
structures for two of these inhibitors in complex with ErmC’, we can better explain why certain 
substituents may  have been preferred over other groups, and why KsgA was overall less affected 
by these inhibitors than was ErmC’.
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Table 4.  Summary of Inhibition for ErmC’ and KsgA with 1 mM of first-generation compounds.
Test Compound ErmC' Inhibition KsgA Inhibition
# Chemical Name Average SD Average SD
1 N6-cyclopentyl-adenosine 32.2% 7.4 16.2% 9.4
2 N6-methyl-adenosine 1.5% 10.2 5.9% 14.3
3 N6-ethyl-adenosine 7.1% 6.6 7.0% 10.0
4 N6-n-butyl-adenosine 24.8% 10.4 5.5% 12.2
5 N6-octyl-adenosine 10.7% 11.0 38.9% 8.6
6 N6-ethylamine-adenosine -8.5% 6.7 -4.1% 3.3
7 N6-octylamine-adenosine 51.1% 10.7 25.5% 14.0
8 N6-isopropyl-adenosine 13.1% 12.5 6.1% 13.9
9 N6-t-butyl-adenosine -6.7% 16.2 7.3% 16.8
10 N6-phenyl-adenosine -0.3% 12.7 3.4% 6.6
11 N6-benzyl-adenosine -1.5% 8.8 12.8% 17.8
12 N6-phenethyl-adenosine 18.5% 10.3 -1.1% 5.8
13 N6-4-methylbenzyl-adenosine 2.8% 0.2 6.5% 14.6
14 N6-4-chlorobenzyl-adenosine 10.9% 2.0 6.5% 3.6
15 N6-4-methoxybenzyl-adenosine 3.3% 3.0 1.9% 18.2
16 N6-4-pyridinemethyl-adenosine -0.7% 12.7 2.4% 11.4
17 N6-tetrazole-adenosine -10.6% 3.9 4.6% 9.5
18 N6-cyclohexyl-adenosine 32.2% 11.9 19.2% 23.1
19 N6-tetrahydropyran-adenosine 20.3% 11.5 7.4% 15.5
20 N6-piperidine-adenosine -10.9% 14.5 8.1% 20.9
21 N6-methylcyclopropyl-adenosine 10.2% 9.6 -2.1% 10.7
22 N6-propargyl-adenosine -1.3% 12.7 2.4% 9.7
23 N6-allyl-adenosine -4.2% 7.6 -1.5% 8.7
C+ sinefungin 97.7% 2.1 97.2% 0.3
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 Using our co-structure of ErmC’ + 12 as an example (Figure 28), we see that  there is little 
space immediately in front of the N6 atom of this ligand bound into the SAM  pocket. The phenyl 
group on 12 branches off the N6-position by  three bond lengths, which is just long enough to 
clear the narrowing at the distal end of the SAM pocket.  In contrast, the phenyl substituents on 
10 and 11, which did not cause inhibition, are linked to the N6 atom by only one and two bond 
lengths, respectively. The discrepancy  of how 10 and 11 did not cause inhibition, while the 
similar compound 12 did inhibit ErmC’, may be explained by the spatial constraints associated 
with the shorter linkers of 10 and 11. 
Figure 28. Spatial constraints of the SAM pocket for ErmC’ around the N6-substituent of 12. 
Distances between residues are shown as yellow dotted lines and were measured in Å using 
MacPyMOL.87 The red dotted lines represent polar contacts between 12 and residues of ErmC’.
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 In contrast, compounds 1, 18 and 19 showed inhibition with ErmC’ despite having only 
one bond length between their cyclic substituent and the N6 atom.  This could be the result  of 
these substituents adopting conformations that are more easily  accommodated within this 
narrowing of the SAM pocket than an aromatic ring with the same linker-length (as on 10 & 17). 
For all of these first-generation inhibitors, the N6-substituents could have formed hydrophobic 
interactions with the surrounding residues of ErmC’ (i.e., Ile-60, Ile-84, Leu-86, or Ile-106).
 In regard to KsgA, those substituents on compounds that showed an inhibition greater 
than 15% were octyl (5 at 38.9%), 8-octylamine (7 at 25.5%), cyclopentyl (1 at 16.2%), and 
cyclohexyl (18 at 19.2%).  For the sake of this discussion, it will be assumed that these inhibitors 
bound to the SAM  pocket of KsgA in the classical mode seen with adenosine analogs complexed 
with other MTases. In that case, substituents branching off the N6-position likely benefited from 
hydrophobic interactions with nearby residues of Leu-67, Leu-122, Ile-118, or Ile-114 (Figure 
29), similar to what has been proposed for ErmC’.
 Those inhibitors that were active against both ErmC’ and KsgA, were still less inhibitory 
towards KsgA. This could be the result  of KsgA having an even narrower opening in the SAM 
pocket than that of ErmC’. The distances between three atoms that triangulate around the N6-
position of 12 were measured from the SAM pocket of ErmC’ and compared with the analogous 
atoms on KsgA.  It was found that this opening at the distal end of the SAM  pocket was about 
1.5 Å narrower in KsgA. For ErmC’, these measurements were as follows: Ile-106 C!2 was 7.7 Å 
to Asp-84 O"2, which was 4.5 Å to Ile-60 C"1, which was 9.1 Å to Ile-106 C!2 (Figure 28). The 
analogous positions in KsgA were measured as follows: Ile-118 C!2 was 5.9Å to Asp-91 O"1, 
which was 4.8 Å to Leu-67 C"1, which was 7.6 Å to Ile-118 C!2 (Figure 29).
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Figure 29. Spatial constraints of KsgA around the supposed N6-substituent of first-generation 
inhibitors.  Distances between residues are shown as yellow dotted lines and were measured in Å 
using MacPyMOL87 and the apo structure of KsgA (1QYR).43
Trans-cis isomerization of X-Proline in co-structure of ErmC’ with inhibitor 8.
 The model for ErmC’ in complex with 7 originally showed two conformations for 
Pro-103, one a cis isomer and the other a trans isomer (Figure 30). In all reported ErmC’ 
structures (including ErmC’ + 12), this peptide bond has a trans configuration. In the trans 
configuration, the C# of Pro-103 is trans to the C# of Ile-102. [Note: amides have partial double-
bond character due to resonance between the lone pair of electrons from nitrogen and the 
carbonyl group.  Loss of this double bond character can lead to rotation about the –C – N- bond 
resulting in  isomerization.]  However, at the very  end of this project our model (ErmC’ + 7) was 
refined again to reveal that the peptide bond of Ile-102 - Pro-103 is entirely in the cis isomer. 
This atypical configuration shows the side chain of Ile-102 pointing into the adenosine-binding 
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pocket of ErmC’. Such a rotation might preclude binding of the target adenosine, and may 
explain why 7 was such a good inhibitor in our tests. 
Figure 30. Alternate conformations of ErmC’ in complex with 7.  Residues Ile-102 and Pro-103 
were initially  found to be in both the atypical cis configuration (shown in hot-pink) as well as the 
typical trans configuration (shown in green). Later refinements revealed said residues to be all in 
the cis configuration.
 While our research into this phenomenon is just in its infancy, the implications of this 
trans to cis isomerization may actually be quite profound. From this early observation, it appears 
inhibitor 7 may be catalyzing the conversion of the Ile102 - Pro103 peptide bond from a trans 
isomer to the cis isomer. Normally, the interconversion of an X-Pro in native proteins is limited 
due to a high energy barrier (~20 kcal/mol).88  However, it has been found that certain proteins 
(ex. peptidylprolyl isomerases)89, 90 or strong acids91 can facilitate a similar cis to trans 
isomerization of X-Pro. This probably occurs through a mechanism where the partial double-
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bond character of the peptide bond is reversed by protonation of the amide, thus allowing the two 
C#’s to rotate about the adjoining C-N bond to form a more energetically favored arrangement 
overall.88  It  is conceivable that the protonated terminal amine on 7 could also disrupt  the partial 
double-bond character between Ile102 - Pro103 and catalyze a trans to cis isomerization in 
ErmC’.  Further experimentation will be needed to confirm this.
Acknowledgements 
 We would like to thank Dr. Keith C. Ellis of Virginia Commonwealth University (VCU) 
for his contributions made with designing the library  of test compounds 1-23 and the reaction 
scheme used to synthesize compounds 1, 3-23.  We also thank Dr. Neil Scarsdale of VCU for 
refining and building molecular models of ErmC’ co-structures. Additionally  we thank Dr. Faik 
N. Musayev of VCU for suggesting conditions used to crystallize ErmC’ and KsgA.
Experimental Section
Buffers
The following two buffers were used for pelleting 70S particles.
Buffer I: 50 mM Tris pH 7.4, 10 mM MgOAc, 0.5 mM EDTA, 6 mM DTT, and  100 mM NH4Cl.
Buffer II: Same as Buffer I except for the addition of 1.1 M sucrose, and NH4Cl was at 1 M.
ErmC’ Lysis Buffer. The following was used to resuspend cells prior to breaking and loading 
onto Ni-NTA column: 50 mM  NaPO4 (pH 8), 300 mM NaCl, 5 mM imidazole, 10% glycerol, 1 
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mM phenylmethylsulfonyl fluoride (PMSF) dissolved in EtOH (17.4 mg/mL), 2 mM !-
mercaptoethanol (BME), and 0.2% triton X-100.
ErmC’ Washes and Elution Buffers. These were the same as ErmC’ Lysis Buffer except no triton 
X-100, and increasing concentrations of imidazole (5, 15, 30, to 75 mM) were used for each 
washing step (15-20 mL each). Protein was eluted from the Ni-NTA column with buffer 
containing 175 mM imidazole.  
ErmC’ Storage Buffer. Purified protein for activity  assays or crystallization was kept in 50 mM 
Tris pH of 7.4, 100 mM NaCl, 10% glycerol, and 2 mM dithiothreitol (DTT). ErmC’ elution (175 
mM imidazole) was first  dialyzed against  storage buffers containing 100 mM imidazole, then the 
same with 50 mM imidazole, and finally storage buffer with no imidazole.  
Buffer K. The following was used for enzymatic reaction with KsgA and ErmC’: 40 mM  Tris at 
pH 7.4, 40 mM NH4Cl, 4 mM MgOAc, and 6 mM 2-mercaptoetanol.
Protein expression and purification.
ErmC’.  The ermC’ gene was inserted into the pET15b plasmid to have a 6x-polyhistidine tag at 
the C-terminus. This plasmid was then transfected into E. coli BL21 (codon+ DE3-RIL) cells 
(Stratagene). Cells were cultured in 1 L of LB media at 37 ºC to an OD600 of 0.6, at which time 
expression of protein was induced with 1 mM IPTG and incubated at 25 ºC for 5 more hours. 
Cells were grown in the presence of Ampicillin (50 µg/mL) and Chloramphenicol  (30 µg/mL) to 
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preserve the plasmid and cell line, respectively. Cells were harvested by centrifugation and 
divided into two equal halves for storage at -20 ºC. Cell pellet (equal to 500 mL of growth) was 
resuspended in ~25 mL of ErmC’ Lysis Buffer, passed twice through Emulsiflex cell breaker 
(Avestin) at ~15,000 psi, and centrifuged twice (20 min at 11,000 rpm, then 45 min at 15,000 
rpm), discarding cell debris after each time. Lysate was passed through a column with 5 mL 
HiTrap Ni-chelating column (Amersham), then rinsed with ErmC’ Washing Buffers (5, 10, 30 
and 75 mM imidazole; 20 mL of each) and eluted with 20 mL of same buffer with 175 mM 
imidazole. Purity of collected fractions was later checked by  gel-electrophoresis and found to be 
greater than 95%. Fractions 2 - 12 (~1 mL each) were usually selected as the most pure, and 
dialyzed in ErmC’ Storage Buffers with gradually decreasing concentrations of imidazole, then 
concentrated using Centricon YM-10 tubes (Millipore).
Expression and purification of KsgA. “see Chapter 2”
Preparation of 23S
Bacilus subtilis (BD170) was purchased from ATCC.
 One liter of BHI (brain heart infusion) broth was inoculated with an overnight growth of 
B. subtilis, and grown at 34 °C for 4 hours until OD600 = 1.0. Then, cells were pelleted, washed 
with lysis buffer and stored in 2 aliquots at -20 °C. One aliquot of cells was resuspended in 30 
mL Buffer I, and lysed at 10,000 psi (French press). Cell debris was pelleted and discarded by 
centrifugation at  11,000 RPM for 20 min, and again at  14,500 RPM for 60 min. In order to 
collect the 70S pellets, cell lysate was layered onto a sucrose cushion (Buffer II) in 4 x 40 mL 
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tubes, and centrifuged at 35,000 RPM for 22 hours. The glassy 70S pellets (from 2 of the 4 
tubes) were slowly resuspended in 1 mL of low [Mg] buffer, twice dialyzed in 500 mL for 1 hr in 
same buffer, before layering onto 10-40% sucrose gradient in 6 x 30 mL tubes, and centrifuged 
for 17 hours at 19,000 rpm. Ribosomal subunits (50S and 30S) were separated from sucrose 
gradient with a fraction collector, discarding the 30S portion. After dialyzing the 50S fractions 
(~37 mL) in low [Mg] buffer (3 x ~420 mL for 1 hr each), subunits were concentrated with 
100,000 MWCO spin column until OD260 x 44 µg/mL = 2.5 µg/µL (concentrate divided into 6 x 
0.5 mL aliquots and stored at -80 °C). 
 Extraction of 23S rRNA from 50S subunits followed an earlier procedure.110 In short, 600 
0L of phenol:chloroform:isoamyl alcohol (25:24:1) was mixed with each aliquot of 50S (6 x 0.5 
mL of 2.5 µg/µL), and centrifuged at  14,000 rpm for 5 min.  The top 90% of the aqueous layer 
was pipetted out and used in the same extraction process twice more. Then, 15 0L of 5 M NaCl 
were added to each vial of ~400 0L of aqueous portion, followed by 1 mL of ice cold EtOH 
(100%) and mixed by hand. After vials sat on dry-ice for 30 min, precipitated RNA was spun 
down at 14,000 RPM for 20 min (in the cold room). Pellets were rinsed with 0.5 mL of EtOH 
(70%), centrifuged, decanted, and air-dried for ~3 hrs (taped upside down in the ventilation-
hood). Dried RNA pellets were each dissolved in 200 0L of H2O for a final concentration of 4.8 
µg/µL (OD260 x 44 µg/mL). The amount of 23S was determined to be 5 pmol/µL based on the 
assumption that 96% of the RNA was 23S and 4% was 5S rRNA (23S has 2923 bases, 5S has 
122 bases), and that 23S has a MW of 1 x 106 g/mol.
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Inhibition Assays
 First-Generation compounds were tested in vitro for inhibition against ErmC’ and KsgA 
using methods similar to those described in Chapter 2. In short, compounds (1-23) and positive 
control (sinefungin) were tested at a final concentration of 1 mM dissolved in 10% DMSO.  Also 
in this reaction (final vol = 50 µL) was 0.2 µM  MTase (ErmC’ or KsgA), 0.2 µM rRNA (23S for 
ErmC’ or unmethylated ksgR  30S for KsgA) and buffer K. Reactions where initiated with the 
addition of 20 µM 3H-methyl-SAM (780 cpm/pmol), and incubated at 37 °C for a set  duration 
(32 min for ErmC’, 5 min for KsgA), at which point reactions were quenched by  the addition of 
10 µL of 100 mM  cold SAM.  Activity of ErmC’ and KsgA methylation was measured by RNA 
binding SPA beads (1 mg YSi per reaction) as described in Chapter 2. 
 For the negative control, the same reaction was performed in 10% DMSO, but without 
inhibitor. Likewise, background reactions (i.e., “no enzyme”) were also done in 10% DMSO 
without inhibitor and without MTase present. All reactions were done in triplicate. Figures 23a 
(ErmC’) and 24a (KsgA) show the resulting activity  from these reactions, measured in counts per 
minute (cpm). To calculate the percent inhibition shown in Figures 23b and 24b, the background 
signal was first  subtracted from all of the other signals. Then, it was determined how much lower 
(in percentage) each of the test signals were compared to the signal from the negative control 
(i.e., “no inhibitor”). The following formula simplifies this calculation: % inhibition = [1-(test 
compound - “no enzyme”)/(“no inhibitor” - “no enzyme”)] x 100% .
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ErmC’ crystallization
 Protein was obtained in the same manner as above then concentrated to 13.1 mg/mL 
(0.45 mM) and co-crystallized with either 5x or 20x concentration of inhibitor 7 by hanging drop 
vapor diffusion.  Each drop contained 3 µL of protein/inhibitor in storage buffer plus 3 µL of 
reservoir buffer (0.1 M Tris pH 8, 50-300 mM  Li2SO4, 20-35% PEG 3350).  Crystals were seen 
after 15 hours and were allowed to grow for ~2 weeks before attempting to diffract by X-rays. 
The selected crystal was cryoprotected by soaking in reservoir solutions with increasing glycerol 
concentrations, as follows: 1 min soak in 10% glycerol, then a quick dip  in 15% glycerol. With a 
nylon loop, the crystal was fished from solutions and mounted immediately on the goniometer to 
be frozen in a stream of N2 gas (98 K). Note that inhibitor 7 had been inadvertently  omitted from 
cryoprotectant solutions, nonetheless data collected from this crystal was still of good quality  and 
the ligand was present.  
 On a later occasion, ErmC’ was co-crystallized with compounds 1, 12, or 21. The 
previous procedure was followed with the exception of ErmC’ concentrated to 9.8 mg/mL and 
co-crystallized with either 1x, 5x or 10x inhibitor concentration using reservoir buffers of (0.1 M 
Tris pH 8, 200-300 mM  Li2SO4, 25-30% PEG 3350). Co-crystals of 1 and 21 were both lost 
during the mounting procedures.  Co-crystals of 12 (from 200 mM Li2SO4, 30% PEG 3350 and 
1x inhibitor conc.) was successfully  mounted for X-ray diffraction from cryoprotectant solution 
containing ligand. 
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Synthesis
Chemicals and Solvents.  6-Chloropurine riboside, triethylamine, N6-methyladenosine (2), 
ethylamine, isopropylamine, tert-butylamine, octylamine, 4-(aminomethyl)pyridine, 5-
aminotetrazole, and deuterated dimethoxy  sulfide (DMSO-d6) were purchased from Sigma-
Aldrich (USA). n-Butylamine, ethylenediamine, 1,8-diaminooctane, cyclopentylamine, 
cyclohexylamine, aminomethylcyclopropane, aniline, benzylamine, 4-methylbenzylamine, 4-
methoxybenzylamine,  propargylamine, and allylamine were purchased from Acr1s Organics 
(Belgium). 4-Aminotetrahydropyran was purchased through Maybridge (England). 4-
Aminopiperidine, 4-chlorobenzylamine, and 2-phenethylamine were bought from Alfa Aesar 
(England). Methanol (MeOH), dichlromethane (DCM), acetonirile (AcN), isopropanol (IPA), 
tetrahydrofuran (THF), hexanes, and formic acid were purchased through Fisher Scientific 
(USA).  
Chromatography. Thin-layer chromatography (TLC) was performed on silica plates purchased 
from Analtech (USA). Preparative chromatography was done with RediSep®Rf  columns 
containing silica, C18 or amine-functionalized silica, and a Combiflash®Rf  instrument, all 
purchased through Teledyne Isco, Inc (USA). 
Instruments and Analyses.  1H and 13C NMR spectra were obtained using a 400 MHz Bruker 
spectrometer with Bruker Topspin 2.1 software. Chemical shifts are reported as ppm (2) using 
solvent peaks or tetramethylsilane (TMS) as the internal standard. Mass spectra (MS) were 
performed at the Department of Pharmacology and Toxicology, Virginia Commonwealth 
University. 
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General procedure for N6 substitution/amination of 6-chloropurine riboside into 
compounds 1 and 3 through 23.92  To a suspension of 6-chloropurine riboside (57.3 mg, 0.2 
mmol) in MeoH (2.86 mL), 3.6 eq. of triethylamine (0.1 mL, 0.72 mmol) was added. Then one 
of 21 different alkylamines was added and allowed to reflux at 60 oC for 18 hr to yield 
compounds 1,  3- 23.  
N6-cyclopentyl-adenosine (1). To a suspension of 6-chloropurine riboside (2.0 g, 7.0 mmol) in 
50 mL of dry methanol, 3.6 eq of cyclopentylamine (2.5 mL, 25.3 mmol) and 4.9 eq of dry 
triethylamine (4.75 mL, 34.1 mmol) were added then stirred at 60 oC for 20 hours. Reaction was 
concentrated in vacuo and separated by reverse phase chromatography (130 g C18 RediSep 
Column, 5-100% THF in DI H2O over 23.4 min with flow rate of 85 mL/min). Product was co-
evaporated with hexanes to yield 1.9 g of white powder (5.7 mmol, 82%).  Rf 0.37 (MeOH:DCM 
= 1:9); 1H NMR (DMSO-d6) 2 8.34 (s, 1H, 8-H), 8.20 (bs, 1H, 2-H), 7.73 (bd, 1H, N6-H, J = 
7.52 Hz), 5.90 (d, 1H, 1’-H, J = 6.20 Hz), 5.45-5.38 (m, 2H, 5’-OH + 2’-OH), 5.16 (d, 1H, 3’-
OH, J = 4.64), 4.62 (dd, 1H, 2’-H, J = 6.12, 11.24 Hz), 4.55 (bs, 1H, 1”-H, cyclopentyl), 4.19 - 
4.13 (m, 1H, 3’-H), 3.98 (dd, 1H, 4’-H, J = 3.4, 6.5 Hz), 3.74 - 3.65 (m, 1H, 5’-Ha), 3.64 - 3.52 
(m, 1H, 5’-Hb), 2.04 - 1.88 (m, 2H, 2’’-Ha + 5’’-Ha, cyclopentyl), 1.79 - 1.67 (m, 2H, 3’’-Ha + 
4’’-Ha, cyclopentyl),  1.67 - 1.47 (m, 4H, 2’’-Hb, 5’’-Hb, 3’’-Hb + 4’’-Hb cyclopentyl); 13C NMR 
(DMSO-d6) 2 154.38 (C-6), 152.24 (C-2), 148.38 (C-4), 139.51 (C-8), 119.56 (C-5), 87.94 
(C-1’), 85.87 (C-4’), 73.45 (C-2’), 70.63 (C-3’), 61.66 (C-5’), 51.46 (C-1’’, cyclopentyl), 32.07 
(C-2’’+ C-5’’, cyclopentyl), 23.45 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 336.1689, expected 
336.1672 (M + H)+. 
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N6-ethyl-adenosine (3). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 2.8 
mL of MeOH, 2 eq of ethylamine (26 µL, 0.4 mmol) and 3.6 eq of dry triethylamine (100 µL, 
0.72 mmol) were added and stirred for 18 hr at 60 oC, concentrated in vacuo and purified by 
normal phase chromatography  (4 g silica RediSep Column, 0-15% MeOH in DCM over 45 cv) 
to yield 44 mg (0.15 mmol, 75%) as a white powder. Rf 0.58 (MeOH:DCM = 1:9); 1H NMR 
(DMSO-d6) 2 8.34 (s, 1H, 8-H), 8.21 (bs, 1H, 2-H), 7.73 (bs, 1H, N6-H), 5.89 (d, 1H, 1’-H, J = 
6.16 Hz), 5.45-5.37 (m, 2H, 5’-OH & 2’-OH), 5.17 (d, 1H, 3’-OH, J = 4.60), 4.62 (dd, 1H, C2’-
H, J = 6.12, 11.24 Hz),  4.15 (m, 1H, 3’-H), 3.97 (dd, 1H, 4’-H, J= 3.4, 6.6), 3.74 - 3.63 (m, 4H, 
5’-H2 & 1”-H2, ethyl), 1.18 (t, 3H, 2’’-H3, J = 7.12 Hz, ethyl); 13C NMR (DMSO-d6) 2 154.50 
(C-6), 152.33 (C-2), 148.21 (C-4), 139.60 (C-8), 119.71 (C-5), 87.92 (C-1’), 85.88 (C-4’), 73.44 
(C-2’), 70.63 (C-3’), 61.66 (C-5’), 34.50 (C-1’’, ethyl), 14.78 (C-2’’, ethyl); MS m/z 296.3, 
expected 296.1 (M + H)+.
N6-n-butyl-adenosine (4). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 2.8 
mL of MeOH, 2 eq of n-butylamine (40 µL, 0.4 mmol) and 3.6 eq of dry triethylamine (100 µL, 
0.71 mmol) were added then stirred overnight at 60 oC. Reaction was concentrated in vacuo and 
crystallized in ~2 mL MeOH. This solid was captured on filter connected to a vacuum manifold 
and rinsed with a small amount of MeOH to yield 5 mg of white powder (0.02 mmol, 8%). Rf 
0.66 (MeOH:DCM = 3:17); 1H NMR (DMSO-d6) 2 8.33 (s, 1H, 8-H), 8.20 (bs, 1H, 2-H), 7.85 
(bs, 1H, N6-H), 5.88 (d, 1H, 1’-H, J = 6.20 Hz), 5.45-5.36 (m, 2H, 2’-OH, & 5’-OH), 5.16 (d, 
1H, 3’-OH, J = 4.60 Hz), 4.61 (dd, 1H, 2’-H, J = 6.0, 11.2 Hz), 4.17-4.12 (m, 1H, 3’-H), 3.97 
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(dd, 1H, 4’-H, J= 3.4, 6.6 Hz), 3.72 - 3.64 (m, 1H, 5’-Ha), 3.60 - 3.52 (m, 1H, 5’-Hb) 3.52 - 3.42 
(m, 2H, 1’’-H2, n-butyl), 1.63 - 1.52 (m, 2H, 2’’-H2, n-butyl), 1.40-1.28 (m, 2H, 3’’-H2, n-butyl), 
0.90 (t, 3H, 4’’-H3 , n-butyl, J= 7.3 Hz). 
N6-octyl-adenosine (5). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 2.8 
mL of MeOH, 2 eq of octylamine (66 µL, 0.4 mmol) and 3.6 eq of dry triethylamine (100 µL, 
0.71 mmol) were added then stirred overnight at 60 oC. Reaction was concentrated in vacuo and 
crystallized in ~2 mL MeOH. This solid was captured on filter connected to a vacuum manifold 
and rinsed with a small amount of MeOH to yield 17 mg (0.04 mmol, 22%) of white powder. Rf 
0.60 (MeOH:DCM = 3:17); 1H NMR (DMSO-d6) 2 8.33 (s, 1H, 8-H), 8.20 (bs, 1H, 2-H), 7.85 
(bs, 1H, N6-H), 5.88 (d, 1H, 1’-H, J = 6.20 Hz), 5.45-5.37 (m, 2H, 2’-OH, & 5’-OH), 5.16 (d, 
1H, 3’-OH, J = 4.64 Hz), 4.62 (dd, 1H, 2’-H, J = 6.1, 11.3 Hz), 4.18-4.12 (m, 1H, 3’-H), 3.97 
(dd, 1H, 4’-H, J= 3.40, 6.56 Hz), 3.73 - 3.63 (m, 1H, 5’-Ha), 3.60 - 3.52 (m, 1H, 5’-Hb), 3.47 (bs, 
2H, 1’’-H2, octyl), 1.59 (p, 2H, 2’’-H2, octyl, J = 7.0 Hz), 1.39-1.52 (m, 10H, 3’’-H2, 4’’-H2, 5’’-
H2, 6’’-H2, 7’’-H2, octyl), 0.85 (t, 3H, 8’’-H3 , octyl, J= 7.88 Hz); 13C NMR (DMSO-d6) 2 154.67 
(C-6), 152.32 (C-2), 148.27 (C-4), 139.55 (C-8), 119.89 (C-5), 87.94 (C-1’), 85.87 (C-4’), 73.43 
(C-2’), 70.64 (C-3’), 61.66 (C-5’), 40.1 (C-1’’, octyl), 31.19 (C-4’’, octyl), 29.00 (C-2’’, octyl), 
28.73 (C-3’’, octyl), 28.64 (C-5’’, octyl), 26.37 (C-6’’, octyl), 22.03 (C-7’’, octyl), 13.89 (C-8’’, 
octyl). 
N6-ethylamine-adenosine (6). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) 
in 2.8 mL of MeOH, 2 eq of ethylenediamine (27 µL, 0.4 mmol) and 3.6 eq of dry  triethylamine 
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(100 µL, 0.71 mmol) were added then stirred overnight at 60 oC. Reaction was concentrated in 
vacuo and loaded on ~2 g silica in an attempt to purified by  normal phase chromatography. 
However, product failed to elute after 100 column volumes of 20% MeOH, but was instead, 
sticking to the column as a yellow band. Product was recovered by flushing column with 100% 
MeOH and found to be free of starting material by  TLC. MeOH flush was concentrated in vacuo 
to yield 14 mg of thick, yellowish gel (0.05 mmol, 23%).  Rf 0.55 (MeOH:DCM  = 1:4); 1H NMR 
(DMSO-d6) 2 8.42 (s, 1H, 8-H), 8.27 (s, 1H, 2-H), 7.97 (bs, 1H, N6-H), 5.91 (d, 1H, 1’-H, J = 
6.08 Hz), 5.84-4.84 (m, 3H, 2’-OH, 3’-OH & 5’-OH), 4.60 (dd, 1H, 2’-H, J = 5.20, 5.84 Hz), 
4.16 (dd, 1H, 3’-H, J = 3.20, 4.88 Hz), 3.97 (dd, 1H, 4’-H, J= 3.48, 6.80 Hz), 3.76 (bs, 2H, 1’’-
H2, ethylamine), 3.71 - 3.64 (m, 1H, 5’-Ha), 3.60 - 3.52 (m, 1H, 5’-Hb), 3.10 - 2.99 (m, 2H, 2’’-
H2, ethylamine).13C NMR (DMSO-d6) 2 154.55 (C-6), 152.16 (C-2), 148.60 (C-4), 140.05 (C-8), 
119.97 (C-5), 87.82 (C-1’), 85.81 (C-4’), 73.59 (C-2’), 70.54 (C-3’), 61.54 (C-5’), 38.47 (C-2’’, 
ethylamine), 37.64 (C-1’’, ethylamine). 
N6-octylamine-adenosine (7). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 
10 mL of MeOH, 3 eq of 1,8-Diaminooctane (86.6 mg, 0.6 mmol) and 3.6 eq of dry 
triethylamine (100 µL, 0.71 mmol) were added and stirred overnight at  60 oC. Reaction was 
separated by  normal phase chromatography (4 g silica RediSep Column, 0-50% MeOH in DCM, 
over 55 cv) to yield 50.2 mg (0.13 mmol, 64%) as a white powder. Rf 0.15 (MeOH:DCM = 1:3); 
1H NMR (DMSO-d6) 2 8.34 (s, 1H, 8-H), 8.20 (bs, 1H, 2-H), 8.05 (bs, 2H, N8’’-H2, octylamine), 
7.85 (bs, 1H, N6-H), 5.89 (d, 1H, 1’-H, J = 6.20 Hz), 5.46 (bs, 2H, 2’-OH & 5’-OH), 5.23 (bs, 
1H, 3’-OH), 4.61 (dd, 1H, 2’-H, J = 5.56, 5.52 Hz), 4.16 (dd, 1H, 3’-H, J = 3.04, 4.80 Hz), 3.97 
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(dd, 1H, 4’-H, J= 3.44, 6.60 Hz), 3.72 - 3.62 (m, 1H, 5’-Ha), 3.60 - 3.51 (m, 1H, 5’-Hb), 3.46 (bs, 
2H, 1’’-H2, octylamine), 2.72 (dd, 2H, 8’’-H2, octylamine, J = 7.48, 7.68 Hz), 1.65 - 1.49 (m, 4H, 
2’’-H2 & 7’’-H2, octylamine), 1.27 (bs, 8H, 3’’-H2, 4’’-H2, 5’’-H2 & 6’’-H2, octylamine).13C 
NMR (DMSO-d6) 2 154.65 (C-6), 152.32 (C-2), 148.33 (C-4), 139.52 (C-8), 119.68 (C-5), 87.87 
(C-1’), 85.85 (C-4’), 73.50 (C-2’), 70.62 (C-3’), 61.62 (C-5’), 39.91 (C-1’’, octylamine), 38.94 
(C-8’’, octylamine), 28.97 (C-2’’, octylamine), 28.54 (C-3’’, octylamine), 28.45 (C-4’’, 
octylamine), 26.86 (C-7’’, octylamine), 26.23 (C-5’’, octylamine), 25.78 (C-6’’, octylamine).
N6-isopropyl-adenosine (8). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 
2.8 mL of MeOH, 2 eq of isopropylamine (33 µL, 0.4 mmol) and 3.6 eq of dry  triethylamine 
(100 µL, 0.72 mmol) were added and stirred for 18 hr at 60 oC, concentrated in vacuo and 
purified by  normal phase chromatography (4 g silica RediSep Column, 0-20% MeOH in DCM 
over 35 cv) to yield 45 mg (0.15 mmol, 73%) as a white powder. Rf 0.67 (MeOH:DCM = 1:9); 
1H NMR (DMSO-d6) 2 8.34 (s, 1H, 8-H), 8.21 (bs, 1H, 2-H), 7.73 (bs, 1H, N6-H), 5.89 (d, 1H, 
1’-H, J = 6.20 Hz), 5.45-5.40 (m, 2H, 5’-OH & 2’-OH), 5.17 (d, 1H, 3’-OH, J = 4.64), 4.62 (dd, 
1H, 2’-H, J = 6.08, 11.2 Hz), 4.46 (bs, 1H, 1’’-H, i-propyl),  4.18-4.13 (m, 1H, 3’-H), 3.97 (dd, 
1H, 4’-H, J= 3.4, 6.6), 3.73 - 3.64 (m, 1H, 5’-Ha), 3.61 - 3.51(m, 1H, 5’-Hb),1.18 (d, 6H, 2’’-H3 
& 3’’-H3 , J = 7.12 Hz, i-propyl). 13C NMR (DMSO-d6) 2 153.96 (C-6), 152.30 (C-2), 148.34 
(C-4), 139.53 (C-8), 119.58 (C-5), 87.91 (C-1’), 85.88 (C-4’), 73.43 (C-2’), 70.63 (C-3’), 61.66 
(C-5’), 41.34 (C-1’’, i-propyl), 28.83 (C-2’’ + C-3’’, i-propyl); MS m/z 310.3, expected 310.2 (M 
+ H)+.
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N6-t-butyl-adenosine (9). To a suspenion of 6-chloropurine riboside (57 mg, 0.20 mmol) in 10 
mL of IPA, 10 eq of tert-butylamine (504 µL, 2.0 mmol) and 7.2 eq of dry triethylamine (200 µL, 
1.43 mmol) were added then stirred in a sealed tube at  110 oC for 48 hours. Reaction was 
separated by  reverse phase chromatography (4.3 g C18 RediSep  Column, 0-30% AcN in DI H2O 
with 0.1% formic acid, over 70 cv). Product dried in vacuo to yield 54.3 mg of white powder 
(0.17 mmol, 84%).  Rf 0.43 (MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 8.35 (s, 1H, 8-H), 8.24 
(s, 1H, 2-H), 6.81 (s, 1H, N6-H), 5.88 (d, 1H, 1’-H, J = 6.12 Hz), 5.81 - 4.91 (bs, 3H, 2’-OH, 3’-
OH & 5’-OH), 4.62 (dd, 1H, 2’-H, J = 5.2, 5.8 Hz), 4.16 (dd, 1H, 3’-H, J= 4.8, 3.1 Hz), 3.97 
(dd, 1H, 4’-H, J= 3.48, 6.72 Hz), 3.72 - 3.64 (m, 1H, 5’-Ha), 3.60 - 3.51(m, 1H, 5’-Hb), 1.52 (s, 
9H, 2’’-H3, 3’’-H3 & 4’’-H3 , t-butyl); 13C NMR (DMSO-d6) 2 154.52 (C-6), 151.67 (C-2), 148.12 
(C-4), 139.56 (C-8), 120.20 (C-5), 87.96 (C-1’), 85.83 (C-4’), 73.43 (C-2’), 70.58 (C-3’), 61.62 
(C-5’), 51.58 (C-1’’, t-butyl), 28.83 (C-2’’, C-3’’+ C-4’’, t-butyl).
N6-phenyl-adenosine (10). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 10 
mL of MeOH, 10 eq of aniline (182 µL, 2.0 mmol) and 7.2 eq of dry  triethylamine (200 µL, 1.43 
mmol) were added and stirred at 60 oC for 24 hours. Reaction was separated first by normal 
phase chromatography (4 g silica RediSep Column, 0-20% MeOH in DCM, over 55 cv) and later 
by reverse phase chromatography (4.3 g C18 RediSep Column, 0-30% AcN in DI H2O with 
0.1% formic acid, over 70 cv) to yield 30.3 mg (0.09 mmol, 44%) as a white powder. Rf 0.63 
(MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 9.93 (s, 1H, N6-H), 8.55 (s, 1H, 8-H), 8.41 (s, 1H, 
2-H), 7.95 (dd, 2H, 2’’-H + 6’’-H, phenyl, J = 8.50, 0.85 Hz), 7.37 -7.30 (m, 2H, 3’’-H + 5’’-H, 
phenyl), 7.05 (t, 1H, 4’’-H, phenyl, J = 7.35 Hz), 5.97 (d, 1H, 1’-H, J = 6.04 Hz), 5.50 (d, 1H, 
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2’-OH, J = 6.18 Hz), 5.29 (dd, 1H, 5’-OH, J = 6.28, 11.31 Hz), 5.23 (d, 1H, 3’-OH, J = 4.68 
Hz), 4.65 (dd, 1H, 2’-H, J = 5.8, 11.1 Hz), 4.19 (dd, 1H, 3’-H, J = 4.5, 7.9 Hz), 4.03 - 3.97 (m, 
1H, 4’-H), 3.76 - 3.66 (m, 1H, 5’-Ha), 3.64 - 3.53 (m, 1H, 5’-Hb). 13C NMR (DMSO-d6) 2 152.14 
(C-6), 151.89 (C-2), 149.33 (C-4), 140.64 (C-8), 139.50 (C-1’’, phenyl), 128.35 (C-3’’ + C-5’’, 
phenyl), 122.69 (C-4’’, phenyl), 120.88 (C-2’’ + C-6’’, phenyl), 120.33 (C-5), 87.83 (C-1’), 
85.82 (C-4’), 73.61 (C-2’), 70.52 (C-3’), 61.52 (C-5’).
N6-benzyl-adenosine (11). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 10 
mL of MeOH, 3 eq of benzylamine (66 µL, 0.6 mmol) and 3.6 eq of dry triethylamine (100 µL, 
0.71 mmol) were added and stirred overnight at 60 oC. Reaction was separated first by normal 
phase chromatography (4 g silica RediSep Column, 0-20% MeOH in DCM, over 55 cv) and 
again by reverse  phase chromatography (4.3 g C18 RediSep  Column, 0-30% AcN in DI H2O 
with 0.1% formic acid, over 70 cv) to yield 38.6 mg (0.11 mmol, 54%) as a white powder. Rf 
0.72 (MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 8.44 (bs, 1H, N6-H), 8.38 (s, 1H, 8-H), 8.21 
(bs, 1H, 2-H), 7.37 - 7.25 (m, 4H, 3’’-H, 4’’-H, 6’’-H + 7’’-H, benzyl), 7.24 -7.17 (m, 1H, 5’’-H, 
benzyl), 5.90 (d, 1H, 1’-H, J = 6.16 Hz), 5.40 (bs, 3H, 2’-OH, 3’-OH + 5’-OH), 4.72 (bs, 2H, 
1’’-H2, benzyl), 4.63 (t, 1H, 2’-H, J = 5.5 Hz), 4.16 (dd, 1H, 3’-H, J = 3.1, 4.8 Hz), 4.01 - 3.95 
(m, 1H, 4’-H), 3.68 (dd, 1H, 5’-Ha, J = 3.6, 12.1 Hz), 3.56 (dd, 1H, 5’-Hb, J = 3.6, 12.1 Hz). 13C 
NMR (DMSO-d6) 2 154.51 (C-6), 152.30 (C-2), 148.01 (C-4), 139.98 (C-2’’, benzyl), 139.87 
(C-8), 128.16 (C-4’’ + C-6’’, benzyl), 127.07 (C-3’’ + C-7’’, benzyl), 126.57 (C-5’’, benzyl), 
119.73 (C-5), 87.92 (C-1’), 85.86 (C-4’), 73.47 (C-2’), 70.61 (C-3’), 61.62 (C-5’), 42.86 (C-1’’, 
benzyl). 
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 N6-phenethyl-adenosine (12). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) 
in 10 mL of MeOH, 3 eq of 2-phenethylamine (76 µL, 0.6 mmol) and 3.6 eq of dry triethylamine 
(100 µL, 0.71 mmol) were added and stirred overnight at 60 oC. Reaction was separated by 
normal phase chromatography (4 g silica RediSep  Column, 0-20% MeOH in DCM, over 55 cv) 
to yield 50.1 mg of product as a white powder (0.13 mmol, 67%). Rf 0.79 (MeOH:DCM = 1:9); 
1H NMR (DMSO-d6) 2 8.36 (bs, 1H, 8-H), 8.25 (bs, 1H, 2-H), 7.92 (bs, 1H, N6-H), 7.34 - 7.23 
(m, 4H, 4’’-H, 5’’-H, 7’’-H + 8’’-H), 7.22 - 7.16 (m, 1H, 6’’-H, phenethyl), 5.90 (d, 1H, 1’-H, J = 
6.12 Hz), 5.46 -5.37 (m, 2H, 2’-OH + 5’-OH), 5.18 (d, 1H, 3’-OH), 4.62 (dd, 1H, 2’-H, J = 6.12, 
11.25 Hz), 4.19 - 4.13 (m, 1H, 3’-H), 3.98 (dd, 1H, 4’-H, J = 3.4, 6.6 Hz), 3.80 - 3.64 (m, 3H, 
1’’-H2, phenethyl, & 5’-Ha), 3.62 - 3.57 (m, 1H, 5’-Hb), 2.93 (dd, 2H, 2’’-H2, phenethyl, J = 7.83, 
15.00 Hz). 13C NMR (DMSO-d6) 2 154.53 (C-6), 152.37 (C-2), 148.26 (C-4), 139.71 (C-8), 
139.48 (C-3’’, phenethyl), 128.64 (C-5’’ + C-7’’, phenethyl), 128.28 (C-4’’ + C-8’’, phenethyl), 
126.01 (C-6’’, phenethyl), 119.75 (C-5), 87.90 (C-1’), 85.87 (C-4’), 73.46 (C-2’), 70.62 (C-3’), 
61.64 (C-5’), 41.25 (C-1’’, phenethyl), 34.95 (C-2’’, phenethyl).
N6-4-methylbenzyl-adenosine (13). To a suspension of 6-chloropurine riboside (57 mg, 0.20 
mmol) in 10 mL of MeOH, 3 eq of 4-methylbenzylamine (76 µL, 0.6 mmol) and 3.6 eq of dry 
triethylamine (100 µL, 0.71 mmol) were added and stirred overnight at  60 oC. Reaction was 
separated first by normal phase chromatography (4 g silica RediSep Column, 0-20% MeOH in 
DCM, over 55 cv) and again by reverse  phase chromatography (4.3 g C18 RediSep Column, 
0-30% AcN in DI H2O with 0.1% formic acid, over 70 cv) to yield 46.4 mg of product as a white 
granular powder (0.12 mmol, 62%). Rf 0.59 (MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 8.39 
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(bs, 1H, N6-H), 8.37 (s, 1H, 8-H), 8.20 (bs, 1H, 2-H), 7.23 (d, 2H, 3’’-H + 7’’-H, methylbenzyl, J 
= 7.97 Hz), 7.09 (d, 2H, 4’’-H + 6’’-H, methylbenzyl, J = 7.84 Hz), 5.90 (d, 1H, 1’-H, J = 6.16 
Hz), 5.43 (d, 1H, 2’-OH, J = 6.24 Hz), 5.38 (dd, 1H, 5’-OH, J = 4.64, 6.28 Hz), 5.17 (d, 1H, 3’-
OH, J = 4.60 Hz), 4.67 (bs, 2H, 1’’-H2, methylbenzyl), 4.63 (dd, 1H, 2’-H, J = 6.0, 11.3 Hz), 
4.19 - 4.13 (m, 1H, 3’-H), 3.98 (dd, 1H, 4’-H, J = 3.44, 6.64 Hz), 3.74 - 3.64 (m, 1H, 5’-Ha), 
3.61 - 3.51 (m, 1H, 5’-Hb). 13C NMR (DMSO-d6) 2 154.49 (C-6), 152.29 (C-2), 148.43 (C-4), 
139.82 (C-8), 136.91 (C-2’’, methylbenzyl), 135.57 (C-5’’, methylbenzyl), 128.70 (C-4’’ + C-6’’, 
methylbenzyl), 127.08 (C-3’’ + C-7’’, methylbenzyl), 119.72 (C-5), 87.92 (C-1’), 85.87 (C-4’), 
73.45 (C-2’), 70.62 (C-3’), 61.63 (C-5’), 42.60 (C-1’’, methylbenzyl).
N6-4-chlorobenzyl-adenosine (14). To a suspension of 6-chloropurine riboside (57 mg, 0.20 
mmol) in 10 mL of MeOH, 3 eq of 4-chlorobenzylamine (73 µL, 0.6 mmol) and 3.6 eq of dry 
triethylamine (100 µL, 0.71 mmol) were added and stirred overnight at  60 oC. Reaction was 
separated first by normal phase chromatography (4 g silica RediSep Column, 0-20% MeOH in 
DCM, over 55 cv) and again by reverse phase chromatography (4.3 g C18 RediSep  Column, 
0-30% AcN in DI H2O with 0.1% formic acid, over 70 cv) to yield 56.7 mg (0.14 mmol, 72%) as 
light amber crystals. Rf 0.60 (MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 8.48 (bs, 1H, N6-H), 
8.40 (s, 1H, 8-H), 8.21 (bs, 1H, 2-H), 7.35 (s, 4H, 3’’-H, 4’’-H, 6’’-H + 7’’-H, chlorobenzyl), 
5.91 (d, 1H, 1’-H, J = 6.12 Hz), 5.40 (bs, 3H, 2’-OH, 3’-OH + 5’-OH), 4.70 (bs, 2H, 1’’-H2, 
chlorobenzyl), 4.62 (dd, 1H, 2’-H, J = 5.6, 11.0 Hz), 4.17 (dd, 1H, 3’-H, J = 3.1, 4.8 Hz), 4.00 - 
3.94 (m, 1H, 4’-H), 3.68 (dd, 1H, 5’-Ha, J = 3.7, 12.1 Hz), 3.56 (dd, 1H, 5’-Hb, J = 3.7, 12.1 Hz). 
13C NMR (DMSO-d6) 2 154.38 (C-6), 152.29 (C-2), 148.52 (C-4), 139.94 (C-8), 139.03 (C-2’’, 
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chlorobenzyl), 131.12 (C-5’’, chlorobenzyl), 128.95 (C-4’’ + C-6’’, chlorobenzyl), 128.11 (C-3’’ 
+ C-7’’, chlorobenzyl), 119.73 (C-5), 87.90 (C-1’), 85.85 (C-4’), 73.50 (C-2’), 70.60 (C-3’), 
61.60 (C-5’), 42.30 (C-1’’, chlorobenzyl).
N6-4-methoxybenzyl-adenosine (15). To a suspension of 6-chloropurine riboside (57 mg, 0.20 
mmol) in 10 mL of MeOH, 3 eq of 4-methoxybenzylamine (78 µL, 0.6 mmol) and 3.6 eq of dry 
triethylamine (100 µL, 0.71 mmol) were added and stirred overnight at  60 oC. Reaction was 
separated by  normal phase chromatography (4 g silica RediSep Column, 0-20% MeOH in DCM, 
over 55 cv) to yield 46.3 mg of product as a white powder (0.12 mmol, 60%). Rf 0.64 
(MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2  8.37 (bs, 2H, 8-H + N6-H), 8.21 (bs, 1H, 2-H), 
7.28 (d, 2H, 3’’-H + 7’’-H, methoxybenzyl, J = 8.65 Hz), 6.88 - 6.83 (m, 2H, 4’’-H + 6’’-H, 
methoxybenzyl), 5.90 (d, 1H, 1’-H, J = 6.12 Hz), 5.44 (d, 1H, 2’-OH, J = 4.24 Hz), 5.39 (bs, 1H, 
5’-OH), 5.18 (bs, 1H, 3’-OH), 4.63 (bs, 3H, 2’-H + 1’’-H2, methylbenzyl), 4.16 (bs, 1H, 3’-H), 
3.97 (dd, 1H, 4’-H, J = 3.44, 6.64 Hz), 3.71 (s, 3H, 8’’-H3, methoxy), 3.68 - 3.64 (m, 1H, 5’-Ha), 
3.60 - 3.52 (m, 1H, 5’-Hb). 13C NMR (DMSO-d6) 2 158.09 (C-5’’, methoxybenzyl), 154.43 
(C-6), 152.29 (C-2), 148.41 (C-4), 139.80 (C-8), 131.91 (C-2’’, methoxybenzyl), 128.47 (C-3’’ + 
C-7’’, methoxybenzyl), 119.75 (C-5), 113.59 (C-4’’ + C-6’’, methoxybenzyl), 87.92 (C-1’), 85.86 
(C-4’), 73.45 (C-2’), 70.61 (C-3’), 61.63 (C-5’), 54.98 (C-8”, methoxy), 42.29 (C-1’’, 
methoxybenzyl).
N6-4-pyridinemethyl-adenosine (16). To a suspension of 6-chloropurine riboside (57 mg, 0.20 
mmol) in 10 mL of MeOH, 3 eq of 4-(aminomethyl)pyridine (77 µL, 0.6 mmol) and 3.6 eq of dry 
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triethylamine (100 µL, 0.71 mmol) were added and stirred overnight at  60 oC. Reaction was 
separated by  normal phase chromatography (4 g silica RediSep Column, 0-60% MeOH in DCM, 
over 120 cv) to yield 69.2 mg of product as an orange powder (0.19 mmol, 97%, crude, ~20% of 
weight may be 4-pyridinemethanamine based on NMR). Rf 0.81 (MeOH:DCM  = 1:5); 1H NMR 
(DMSO-d6) 2 8.53 (bs, 1H, N6-H), 8.47 (dd, 2H, 4’’-H + 6’’-H, pyridinemethyl, J = 1.60, 4.44 
Hz), 8.35 (s, 1H, 8-H), 8.20 (s, 1H, 2-H), 7.30 (d, 2H, 3’’-H + 7’’-H, pyridinemethyl, J = 5.80 
Hz), 5.91 (d, 1H, 1’-H, J = 6.12 Hz), 5.34 (bs, 3H, 2’-OH, 3’-OH + 5’-OH), 4.73 (bs, 2H, 1’’-H2, 
pyridinemethyl), 4.62 (dd, 1H, 2’-H, J = 5.5, 10.8 Hz), 4.16 (dd, 1H, 3’-H, J = 3.1, 4.8 Hz), 4.00 
- 3.95 (m, 1H, 4’-H), 3.68 (dd, 1H, 5’-Ha, J = 3.68, 12.13 Hz), 3.56 (dd, 1H, 5’-Hb, J = 3.68, 
12.09 Hz); 13C NMR (DMSO-d6) 2 154.48 (C-6), 152.27 (C-2), 149.41 (C-4’’ + C-6’’, 
pyridinemethyl), 149.02 (C-4), 140.08 (C-8), 122.00 (C-3’’ + C-7’’, pyridinemethyl), 119.89 
(C-5), 87.87 (C-1’), 85.84 (C-4’), 73.50 (C-2’), 70.58 (C-3’), 61.58 (C-5’), 41.94 (C-1’’, 
pyridinemethyl); MS m/z 359.034, expected 359.1468 (M + H)+.
N6-tetrazole-adenosine (17). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 
10 mL of MeOH, 9 eq of 5-aminotetrazole (151 mg, 1.8 mmol) and 7.2 eq of dry triethylamine 
(200 µL, 1.42 mmol) were combined in a sealed tube and stirred for 72 hours at 80 oC.  Reaction 
was separated by normal phase chromatography  (4 g silica RediSep Column, 0-50% MeOH in 
DCM, over 55 cv) to yield 23 mg of product as an orange powder (0.07 mmol, 34%, crude, 
~10% of weight may be Et3N based on NMR). Rf 0.11 (MeOH:DCM = 1:4); 1H NMR (DMSO-
d6) 2 8.58 (s, 1H, 8-H), 8.42 (s, 1H, 2-H), 6.47 (bs, 1H, N6-H), 5.98 (d, 1H, 1’-H, J = 5.88 Hz), 
5.70 - 4.85 (bs, 3H, 2’-OH, 3’-OH & 5’-OH), 4.63 (dd, 1H, 2’-H, J = 5.56, 11.84 Hz), 4.19 (dd, 
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1H, 3’-H, J = 3.52, 4.80 Hz), 4.00 - 3.95 (m, 1H, 4’-H), 3.71 (dd, 1H, 5’-Ha, J = 3.84, 12.04 Hz), 
3.56 (dd, 1H, 5’-Hb, J = 3.84, 12.04 Hz). 13C NMR (DMSO-d6) 2 153.72 (C-6), 151.67 (C-2), 
151.27 (C-1’’, tetrazole) 150.02 (C-4), 141.31 (C-8), 120.23 (C-5), 87.78 (C-1’), 85.76 (C-4’), 
73.67 (C-2’), 70.42 (C-3’), 61.42 (C-5’).
N6-cyclohexyl-adenosine (18). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) 
in 5 mL of MeOH, 3 eq of cyclohexylamine (69 µL, 0.6 mmol) and 3 eq of dry  triethylamine (84 
µL, 0.6 mmol) were added then stirred overnight at 60 oC. Based on TLC, a substantial amount 
of product was formed but did not separate adequately from the small amount of starting material 
even after two attempts of normal phase chromatography (4 g silica RediSep Column, 0-20% & 
0-10% MeOH in DCM). Separation was improved slightly using amine-functionalized silica (4.7 
g Amine RediSep Column, 0-10% DCM  in MeOH over 60 column volumes) to yield 22 mg 
(0.06 mmol, 31%) as clear glassy solid. Rf 0.67 (MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 
8.34 (s, 1H, 8-H), 8.19 (bs, 1H, 2-H), 7.85 (bd, 1H, N6-H, J = 7.88 Hz), 5.88 (d, 1H, 1’-H, J = 
6.20 Hz), 5.50 - 5.35 (m, 2H, 2’-OH & 5’-OH), 5.16 (d, 1H, 3’-OH, J = 4.64 Hz), 4.61 (dd, 1H, 
2’-H, J = 6.04, 11.28 Hz), 4.15 (td?, 1H, 3’-H, J = 3.16, 4.72, 7.76 Hz), 4.09?-? (m, 1H, 1’’-H, 
cyclohexyl), 3.97 (dd, 1H, 4’-H, J= 3.4, 6.5 Hz), 3.72 - 3.64 (m, 1H, 5’-Ha), 3.60 - 3.51 (m, 1H, 
5’-Hb), 1.88 (bd, 2H, 2’’-H(equatorial) + 6’’-H(equatorial), cyclohexyl, J = 7.96 Hz), 1.75 (bd, 2H, 3’’-H
(equatorial) + 5’’-H(equatorial), cyclohexyl, J = 12.28 Hz), 1.62 (bd, 1H, 4’’-H(equatorial), cyclohexyl, J = 
12.72 Hz), 1.52 - 1.22 (m, 4H, 2’’-H(axial), 3’’-H(axial), 5’’-H(axial) & 6’’-H(axial), cyclohexyl), 1.21 - 
1.03 (m, 1H, 4’’-H(axial), cyclohexyl).13C NMR (DMSO-d6) 2 153.91 (C-6), 152.29 (C-2), 148.31 
(C-4), 139.53 (C-8), 119.64 (C-5), 87.96 (C-1’), 85.88 (C-4’), 73.43 (C-2’), 70.64 (C-3’), 61.66 
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(C-5’), 48.76 (C-1’’, cyclohexyl), 32.25 (C-2’’ & C-6’’, cyclohexyl), 25.19 (C-4’’, cyclohexyl), 
24.95 (C-3’’ & C-5’’, cyclohexyl). 
N6-tetrahydropyran-adenosine (19). To a suspension of 6-chloropurine riboside (57 mg, 0.20 
mmol) in 5 mL of MeOH, 3 eq of 4-aminotetrahydropyran (60.7 mg, 0.6 mmol) and 3 eq of dry 
triethylamine (84 µL, 0.6 mmol) were added then stirred overnight at 60 oC.  Reaction was 
separated by  normal phase chromatography (4 g silica RediSep Column, 0-10% MeOH in DCM, 
over 40 cv) to yield 28.6 mg (0.08 mmol, 41%) as a clear glassy solid. Rf 0.46 (MeOH:DCM = 
1:9); 1H NMR (DMSO-d6) 2 8.37 (s, 1H, 8-H), 8.21 (bs, 1H, 2-H), 7.80 (bs, 1H, N6-H), 5.89 (d, 
1H, 1’-H, J = 6.16 Hz), 5.46 - 5.36 (m, 2H, 2’-OH & 5’-OH), 5.17 (d, 1H, 3’-OH, J = 4.64 Hz), 
4.61 (dd, 1H, 2’-H, J = 6.1, 11.3 Hz), 4.34 (bs, 1H, 1’’-H, tetrahydropyran), 4.17 - 4.13 (m, 1H, 
3’-H), 3.97 (dd, 1H, 4’-H, J= 3.40, 6.60 Hz), 3.90 (dd, 2H, 3’’-H(equatorial) + 4’’-H(equatorial), 
tetrahydropyran, J = 2, 12 Hz), 3.72 - 3.64 (m, 1H, 5’-Ha), 3.60 - 3.52 (m, 1H, 5’-Hb), 3.41 (dt, 
2H, 3’’-H(axial) + 4’’-H(axial), cyclohexyl, J = 12, 2 Hz), 1.81 (bd, 2H, 2’’-H(equatorial) + 5’’-H
(equatorial), tetrahydropyran, J = 10.8 Hz), 1.81 (bd, 2H, 2’’-H(axial) + 5’’-H(axial), tetrahydropyran, J 
= 9.52 Hz). 13C NMR (DMSO-d6) 2 153.90 (C-6), 152.26 (C-2), 148.56 (C-4), 139.69 (C-8), 
119.75 (C-5), 87.92 (C-1’), 85.86 (C-4’), 73.47 (C-2’), 70.61 (C-3’), 66.24 (C-3’’ & C-4’’, 
tetrahydropyran), 61.66 (C-5’), 46.17 (C-1’’, tetrahydropyran), 32.40 (C-2’’ & C-5’’, 
tetrahydropyran). 
N6-piperidine-adenosine (20). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) 
in 5 mL of MeOH, 3 eq of 4-Aminopiperidine (64 µL, 0.6 mmol) and 3 eq of dry triethylamine 
91
(84 µL, 0.6 mmol) were added then stirred overnight at 60 oC.  Reaction was separated by 
normal phase chromatography (4 g silica RediSep  Column, 0-25% MeOH in DCM, over 70 cv) 
to yield 52.3 mg (0.15 mmol, 75%) as light yellow crystals. Rf 0.08 (MeOH:DCM = 1:9); 1H 
NMR (DMSO-d6) 2 8.44 (s, 1H, 8-H), 8.26 (s, 1H, 2-H), 5.93 (d, 1H, 1’-H, J = 5.93 Hz), 5.32 
(bs, 2H, 3’’-H(equatorial) + 5’’-H(equatorial), piperidine), 4.58 (dd, 1H, 2’-H, J = 5.62, 5.34 Hz), 4.17 
(dd, 1H, 3’-H, J= 3.46, 4.83 Hz), 3.97 (dd, 1H, 4’-H, J= 3.5, 7.0 Hz), 3.68 (dd, 1H, 5’-Ha, J = 
3.66, 12.07 Hz), 3.56 (dd, 1H, 5’-Hb, J = 3.73, 12.07 Hz), 3.36 - 3.26 (m, 1H, 1’’-H, cyclohexyl), 
3.26 - 3.17 (m, 2H, 3’’-H(axial) + 5’’-H(axial), piperidine), 2.02 (bd, 2H, 2’’-H(equatorial) + 6’’-H
(equatorial), piperidine, J = 12.47 Hz), 1.58 - 1.42 (m, 2H, 2’’-H(axial) + 6’’-H(axial), piperidine). 13C 
NMR (DMSO-d6) 2 153.10 (C-6), 151.78 (C-2), 150.32 (C-4), 138.89 (C-8), 119.60 (C-5), 87.75 
(C-1’), 85.72 (C-4’), 73.52 (C-2’), 70.44 (C-3’), 61.44 (C-5’), 47.59 (C-1’’, piperidine), 42.96 
(C-3’’ & C-5’’, piperidine), 30.43 (C-2’’ & C-6’’, piperidine); MS m/z 350.932, expected 351.178 
(M + H)+.
N6-methylcyclopropyl-adenosine (21). To a suspension of 6-chloropurine riboside (57 mg, 0.20 
mmol) in 5 mL of MeOH, 3 eq of aminomethylcyclopropane (52 µL, 0.6 mmol) and 3 eq of dry 
triethylamine (84 µL, 0.6 mmol) were added then stirred overnight at 60 oC.  Reaction was 
separated by  normal phase chromatography (4 g silica RediSep Column, 0-10% MeOH in DCM, 
over 40 cv) to yield 52.7 mg (0.16 mmol, 82%) as fluffy crystals/powder. Rf 0.81 (MeOH:DCM 
= 3:17); 1H NMR (DMSO-d6) 2 8.35 (s, 1H, 8-H), 8.20 (bs, 1H, 2-H), 7.93 (bs, 1H, N6-H), 5.89 
(d, 1H, 1’-H, J = 6.24 Hz), 5.46 - 5.38 (m, 2H, 2’-OH & 5’-OH), 5.17 (d, 1H, 3’-OH, J = 4.60 
Hz), 4.62 (dd, 1H, 2’-H, J = 6.1, 11.3 Hz), 4.18 - 4.13 (m, 1H, 3’-H), 3.98 (dd, 1H, 4’-H, J= 3.5, 
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6.5 Hz), 3.73 - 3.64 (m, 1H, 5’-Ha), 3.61 - 3.52 (m, 1H, 5’-Hb), 3.37 (bs, 2H, 1’’-H2, 
methylcyclopropyl), 1.21 - 1.09 (m, 1H, 2’’-H, methylcyclopropyl), 0.45 - 0.38 (m, 2H, 3’’-Ha + 
4’’-Ha, methylcyclopropyl), 0.31 - 0.24 (m, 2H, 3’’-Hb + 4’’-Hb, methylcyclopropyl). 13C NMR 
(DMSO-d6) 2 154.61 (C-6), 152.29 (C-2), 148.31 (C-4), 139.31 (C-8), 119.65 (C-5), 87.94 
(C-1’), 85.88 (C-4’), 73.45 (C-2’), 70.63 (C-3’), 61.65 (C-5’), 43.95 (C-1’’, methylcyclopropyl), 
11.11 (C-2’’, methylcyclopropyl), 3.21 (C-3’’ & C-4’’, methylcyclopropyl).
N6-propargyl-adenosine (22). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) 
in 10 mL of MeOH, 3 eq of propargylamine (38 µL, 0.6 mmol) and 3.6 eq of dry triethylamine 
(100 µL, 0.71 mmol) were added and stirred overnight at 60 oC. Reaction was separated by 
normal phase chromatography (4 g silica RediSep Column, 0-15% MeOH in DCM, over 38 cv), 
a yellowish residue on a dried fraction was rinsed off 3x with ~1 mL MeOH to yield 27 mg (0.09 
mmol, 44%) as a spongy white powder. Rf 0.30 (MeOH:DCM  = 1:9); 1H NMR (DMSO-d6) 2 
8.41 (s, 1H, 8-H), 8.29 (bs, 1H, 2-H), 8.26 (bs, 1H, N6-H), 5.92 (d, 1H, 1’-H, J = 6.08 Hz), 5.46 
(d, 1H, 2’-OH, J = 6.21 Hz), 5.35 (dd, 1H, 5’-OH, J = 6.97, 4.68 Hz), 5.20 (d, 1H, 3’-OH, J = 
4.72 Hz), 4.65 - 4.58  (m, 1H, 2’-H), 4.27 (bs, 2H, 1’’-H2, propargyl), 4.19 - 4.14 (m, 1H, 3’-H), 
4.01 - 3.95(m, 1H, 4’-H), 3.74 - 3.65 (m, 1H, 5’-Ha), 3.61 - 3.53 (m, 1H, 5’-Hb), 3.04 (bs, 1H, 
3’’-H, propargyl). 13C NMR (DMSO-d6) 2 153.91 (C-6), 152.19 (C-2),  148.80 (C-4), 140.14 
(C-8), 119.83 (C-5), 87.85 (C-1’), 85.81 (C-4’), 81.79 (C-2’’, propargyl), 73.50 (C-2’), 72.34 
(C-3’’, propargyl), 70.55 (C-3’), 61.57 (C-5’), 29.18 (C-1’’, propargyl).
93
N6-allyl-adenosine (23). To a suspension of 6-chloropurine riboside (57 mg, 0.20 mmol) in 10 
mL of MeOH, 3 eq of allylamine (45 µL, 0.6 mmol) and 3.6 eq of dry  triethylamine (100 µL, 
0.71 mmol) were added and stirred overnight at 60 oC. Reaction was separated by  normal phase 
chromatography  (4 g silica RediSep Column, 0-12% MeOH in DCM, over 34 cv) to yield 26 mg 
(0.08 mmol, 42%) as a white powder. Rf 0.40 (MeOH:DCM = 1:9); 1H NMR (DMSO-d6) 2 8.37 
(s, 1H, 8-H), 8.21 (s, 1H, 2-H), 8.06 (bs, 1H, N6-H), 6.02 - 5.92 (m, 1H, 2’’-H, allyl), 5.90 (d, 
1H, 1’-H, J = 6.21 Hz), 5.16 5.45 (d, 1H, 2’-OH, J = 6.2 Hz), 5.40 (dd, 1H, 5’-OH, J = 4.56, 
7.12 Hz), 5.19 (d, 1H, 3’-OH, J = 6.2 Hz), 5.18 - 5.11 (m, 1H, 3’’-Hcis, allyl), 5.06 (ddd, 1H, 3’’-
Htrans, allyl, J = 1.48, 3.20, 10.28 Hz),  4.68 - 4.56 (m, 1H, 2’-H), 4.23 - 4.05 (m, 3H, 3’-H, + 1’’-
H2, allyl), 4.02 - 3.94 (m, 1H, 4’-H), 3.73 - 3.63 (m, 1H, 5’-Ha), 3.60 - 3.52 (m, 1H, 5’-Hb). 13C 
NMR (DMSO-d6) 2 154.43 (C-6), 152.28 (C-2),  148.35 (C-4), 139.78 (C-8), 135.58 (C-2’’, 
allyl), 119.72 (C-5), 114.97 (C-3’’, allyl), 87.88 (C-1’), 85.86 (C-4’), 73.43 (C-2’), 70.62 (C-3’), 
61.63 (C-5’), 41.91 (C-1’’, allyl).
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CHAPTER 4: Synthesis of Second-Generation Compounds
Rationale 
 The original goal for synthesizing first-generation compounds was to design inhibitors 
that targeted the more selective, substrate-binding pocket  of ErmC’ or KsgA. We had expected 
these adenosine analogs (1-23) to orient  in a similar manner as the putative target adenosine, and 
for the N6-substituents to branch into the adjacent SAM-binding pocket.  However, X-ray  data of 
ErmC’ in complex with 7 and 12 revealed that the SAM pocket was the preferred binding site for 
at least these two inhibitors, and that the N6-substituents were directed away  from the substrate-
binding pocket. Furthermore, these co-crystals of ErmC’ showed the 5’-C of 7 and 12 were 
pointed directly at the originally targeted substrate pocket of ErmC’ (Figure 31). 
Tyr-104
6.0 Å
Figure 31.  First-generation compounds 7 (pink) and 12 (cyan) bound in SAM pocket of 
ErmC’ (wheat) with 5’-C pointed towards the adenosine pocket. Shown in gray are the target 
adenine and the “flipped” tyrosine 104, (Tyr-108) in M.TaqI + DNA (PDB 1G38),41 which were 
superimposed over ErmC’ same as in Figure 7 (Chapter 1).  
95
 This unanticipated binding mode presented us with the opportunity to design a new 
library of compounds which could bridge into the substrate pocket through a second substituent. 
Our new goal was to add a phenyl substituent to the 5’-carbon on one of the first-generation 
inhibitors in order to improve potency and/or selectivity.  We hypothesized that an aromatic 
group extending off the 5’-C of an adenosine analog could form #-# stacking with the essential 
tyrosine (Tyr-104 in ErmC’, or Tyr-116 in KsgA), similar to the interactions that have been 
predicted for the target adenosine and the “flipped” tyrosine. 
 To test this principle, we synthesized four derivatives of N6-cyclopentyl adenosine (1). 
For each of these analogues, the 5’-carbon was attached with an aromatic amine, which replaced 
the 5’-OH of 1 with a 5’-N.  For these second-generation compounds, the linker between the 5’-
N and the phenyl ring varied from 1 to 4 carbons (Figure 32). Additionally, the replacement of 
5’-OH with a secondary amine could have acted as a bioisostere for the sulfur atom in SAM. We 
selected 1 to use as the scaffold in this limited series of compounds because this inhibitor: i) had 
been referenced by  other relevant publications; ii) showed inhibition for both KsgA and ErmC’; 
and iii) did not have a potentially reactive N6-substituent (ex: the octylamine on 7).  
30 31 32 33
Figure 32. Chemical structures of second-generation compounds (30-33)
96
Synthesis
 Several different strategies were explored for synthesizing second-generation compounds. 
The follow section first describes the many synthetic routes that were attempted, but  were 
ultimately  unsuccessful at producing the desired final product (Figures 33-39). After a successful 
reaction scheme was found to yield 31, the remaining second-generation compounds (30, 32 and 
33) were synthesized using this same strategy (Table 5).
Mitsunobu Reactions
  The simplest and most direct route that we conceived for adding the 5’-substituent was 
tried first, the Mitsunobu reaction. This reaction is often used to couple an alcohol with another 
group containing a nucleophilic function (ex. carboxylic acids, phenols, or imides).93  Typically, 
reagents such as diisopropyl azodicarboxylate (DIAD) and triphenylphosphine (TPP) are used to 
form a reactive intermediate (Morrison–Brunn–Huisgen betaine), which acts to both deprotonate 
the nucleophile and bind the alcohol.94  The deprotonated nucleophile then substitutes the alcohol 
resulting in the loss of an H2O, thereby reducing DIAD to diisopropyl hydrazinedicarboxylate 
and oxidizing TPP to triphenylphosphine oxide. 
 For our reaction, we expected the amine on phenethylamine to act  as the nucleophilic 
component and substitute the 5’-OH on 6-chloropurine riboside (Figure 33). If successful, we 
could have made 31 by later adding the N6-cyclopentyl (as reacted in Chapter 3). In the first 
attempt, 60 mg of starting material (6-chloropurine riboside) was used to yield ~5 mg of a 
product that resembled 31 by NMR (albeit, at a low purity and poor yield).  However, mass 
analysis of this compound reported 372.140 m/z and not the expected 390.126 m/z (M  + H)+. 
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Therefore, we repeated this reaction on a larger scale (1 g of starting material) and purified the 
product more extensively. However, the NMR spectra from the latter reaction clearly matched 
the spectra of the similar but distinct product 12 (previously generated in Chapter 3). 
Furthermore, the mass analysis from the former reaction also indicated that the product was 12 
(expected 372.1666 m/z) (M  + H)+. It was concluded that the 6-Cl group  on the starting material 
was more readily substituted than the 5’-OH group during this Mitsunobu reaction.
unintended product 
(12)
Figure 33.  Mitsunobu reaction with 6-chloropurine riboside and phenethylamine. This reaction 
made the N6-substitution product (12) rather than the desired C5’-substitution. The dotted arrow 
shows the subsequent reaction that would have been used to obtain the final product 31.
 The Mitsunobu reaction was performed again on adenosine, without the reactive 6-Cl 
group (Figure 34).  If successful, we could have later added the N6-substituent by reductive 
amination or by converting the N6 to the more familiar 6-Cl group (based on a previous report).95 
The first attempt used adenosine that had been protected with isopropylidene on the 2’-OH and 
3’-OH groups, but  no products were generated (top, Figure 34).  Similarly, when this reaction 
was repeated using the unprotected adenosine (plus 1 eq. of HCl), no products were formed 
(bottom, Figure 34).  
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Figure 34.  Mitsunobu reaction with adenosine and phenethylamine. Neither attempts with the 
protected adenosine (top) or the unprotected adenosine + 1 eq. of HCl (bottom) yielded any 
products, as seen by TLC.  
 As a new strategy, we tried performing substitution reactions on the ribose alone, which 
could later be joined to the adenine portion via a glycosylation reaction (based on a previous 
report).96 After all secondary alcohols of the ribose were protected with isopropylidene, as 
previously  described97 (1st step, Figure 35), we tried the Mitsunobu reaction to substitute the 5-
OH group with phenethylamine (2nd step, Figure 35), but no products were formed.
†
Figure 35. Mitsunobu reaction with protected ribose and phenethylamine. After protecting the 
ribose with isopropylidene (left), the Mitsunobu reaction was attempted to add phenethylamine 
(right), but TLC showed only starting material.
† Product matched NMR from previous work by Gyepes et al.97
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 It’s unclear why the Mitsunobu reaction failed to substitute the primary alcohol with 
phenethylamine in any of the aforementioned reactions. It was suggested in the literature that the 
order in which reagents are added may make the difference in whether this reaction is successful 
or not.98  [Note: For the reactions in Figures 34 and 35, the alcohol (i.e., the 5-OH on ribose or 
the 5’-OH on adenosine) and phenethylamine were first dissolved in tetrahydrofuran (THF). 
Then, TPP was added and the reaction vial was cooled to -20 oC before adding DIAD.]  Perhaps 
the reaction would have worked if DIAD and TPP were first  mixed, then added to 
phenethylamine or the alcohol.  Nonetheless, the Mitsunobu reaction was abandoned for the 
remainder of this report, though the product from the first step in Figure 35 (the protected ribose) 
was carried forward to subsequent reactions with slightly better success.
Substitution of 5-OH on ribose
 Continuing with our strategy of reacting ribose before the adenine portion is attached, we 
replaced the 5-OH of ribose with a leaving group, which could then be substituted with 
phenethylamine (Figure 36). This first  reaction successfully  added the mesylate group to ribose, 
following a previous method97 (top left, Figure 36). We then attempted to replace the mesylate 
with phenethylamine (1.5 eq.) in the presence of potassium carbonate (1.25 eq.) via an Sn2 
reaction (top right, Figure 36).  However, no products were formed despite raising the 
temperature to 80 oC and extending the reaction overnight  (monitored by TLC stained with 
Ninhydrin and Hanessian’s stain).  Likewise, when this reaction was repeated using a stronger 
base (1 eq. of sodium hydride) no products were formed (middle right, Figure 36).
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†‡
Figure 36. Leaving groups added to 5-OH of ribose. Mesylate added (top left), but was not 
substituted in our basic conditions (top right and middle right). Tosylate added (bottom left), and 
was substituted by phenethylamine (bottom right). 
† or ‡  Products matched NMR’s by Gyepes et al. (†),97 and Abdel-Rahman et al. (‡).99
 
 Taking a slightly different route, we added a more labile leaving group, tosylate, to the 5-
OH of our protected ribose (bottom left, Figure 36), in accordance with a previously published 
procedure.99  Next, the tosylated ribose was dissolved into phenethylamine (10 eq.) for a neat 
reaction at 85 oC (bottom right, Figure 36). After being purified by normal phase 
chromatography, the desired product was confirmed by NMR. 
Attempts to deprotect ribose
 After substituting the 5-OH of ribose with phenethylamine, the remaining hydroxyls 
needed to be deprotected before we could attempt to join the adenine portion of 31 by 
101
glycosylation. Our first attempt followed a procedure previously used to deprotect an adenosine 
analog, which also had an amine substituent at the 5’ position.100 In a similar manner, our 
protected 5-phenethylamine ribose (400 mg) was treated with 8.5 mL of 70% trifluoroacetic acid 
(TFA) for 30 min at RT (1st reaction, Figure 37).  Afterwards, a TLC of this reaction reported 
several products in addition to unreacted starting material. [Note: TLC was stained with 
Ninhydrin & Hanessian’s stain. The more prominent spot was also the most polar (Rf = 0.25, 
DCM:MeOH 4:1), and was indicative of the deprotected ribose.]  However, after purifying the 
reaction contents by normal phase chromatography, NMR analysis did not show the desired 
product or anything resembling a ribose. 
2 hr reflux at 100 °C, co-evaporated w/MeOH + H2O
Figure 37.   Four deprotection reactions attempted on 5-phenethylamine ribose. Only a partially 
deprotected product was recovered (3rd step). 
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 The second attempt followed a procedure used to deprotect a ribose, which had an ethyl 
group attached to the 5-O atom.101 Likewise, we refluxed our protected ribose (389 mg) in 4.2 
mL of 40 mM HCl at 100 oC for 2 hours (2nd reaction, Figure 37).  However, the TLC of this 
reaction showed only  starting material.  It was also noticed that starting material remained in an 
insoluble layer at  the bottom of the reaction vial.  Therefore, after recovering this starting 
material (346 mg) with DCM extractions, we added 2 mL of dioxanes to improve solubility 
during our next attempt at deprotection (3rd reaction, Figure 37).  [Note: This reaction originally 
had 40 mM HCl, but the pH was ~7, so HCl was raised to 200 mM, and the pH was 1-2. 
Strangely, at the end of the reaction the pH read ~7.]  After extracting products with EtOAc (3 x 
15 mL), the TLC of this reaction reported two polar compounds (Rf = 0.64 & 0.27 with 
DCM:MeOH at  4:1, or Rf = 0.23 & 0.12 with DCM:MeOH at 9:1), and only traces of starting 
material (Rf = 0.99 with DCM:MeOH at 4:1, or Rf = 0.95 with DCM:MeOH at 9:1), suggesting 
that this reaction may have produced both the fully  deprotected ribose (as seen by  the most polar 
spot on TLC) and a partially deprotected ribose (indicated by 2nd most polar spot on TLC). 
However, after separating these compounds by normal phase chromatography, NMR analysis 
showed only  the partially  deprotected ribose, which still contained the C1-methoxy group (3rd 
reaction, Figure 37).
 The last attempt at deprotecting our ribose used methanolic HCl (0.33 mL of 3 N, 1.1 eq.) 
and 2 mL of 50% dioxanes in DI H2O (v/v) to dissolve 0.28 g of starting material (4th reaction, 
Figure 37).  [Note: Additional HCl (40 µL of 12.1 M) was added to this reaction to lower the pH 
from ~7 to a pH of ~ 1.]  Unfortunately, NMR analysis showed no products that were indicative 
of a deprotected ribose after this reaction was separated by normal phase and reverse phase 
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chromatography.  No further attempts were made to synthesis second-generation compounds 
using this strategy of reacting ribose independently.
Addition of azide to adenosine
  As a new strategy  for making 31, we sought to replace the 5’-OH of 6-chloropurine 
riboside with an azide (N3), which could later be reacted by  reductive amination102 to introduce 
the 5’-phenethylamine substituent (Figure 38).  First, the 2’-OH and 3’-OH groups on 6-
chloropurine riboside were protected with isopropylidene, following an earlier method103 (1st 
step, Figure 38).  Next, the 5’-OH was replaced with tosylate (Ts) by  reacting the purified 
product with Ts-Cl (1 eq.) in dry  pyridine under N2 (2nd step, Figure 38).  NMR analysis 
confirmed that the 5’-OH was successfully replaced with the tosylate group. [Note: TLC showed 
product, starting material, and unreacted Ts-Cl, respectively at Rf = 0.51, 0.79 & 0.89 in 
DCM:MeOH of 19:1. This reaction was then co-evaporated with toluene and washed with 10% 
Cu(OAc)2 to remove residual pyridine. Product was extracted with DCM, concentrated in vacuo, 
and purified by normal phase and then reverse phase chromatography.]
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desired product
“double-azide” 
byproduct
†
Figure 38.  Addition of azide.  6-chloropurine riboside was protected with isopropylidene (1st 
step), and tosylated at 5’-position (2nd step). The azide did substitute the 5’-Ts to give the desired 
product, but additionally substituted 6-Cl to also give the “double-azide” byproduct (3rd step). 
Dotted arrows indicate the proposed reductive amination reaction for adding the 5’-substituent, 
based on previous work by Townsend et al.102
† Product matched NMR by Kappler et al.103
 We then tried substituting the 5’-tosylate group with an azide group by adding 1.2 eq of 
NaN3 and refluxing in sealed tube with an aprotic solvent, dry DMSO (3rd step, Figure 38).  After 
20 min, no product was seen by TLC, therefore, excess NaN3 (4.1 eq.) was added and heated 20 
more min. However, the TLC again reported no product that was distinguishable from the 
starting material.  Irrespective of the TLC, the reaction was quenched (2x vol. H2O) and 
extracted (3x vol. CHCl3) for NMR analysis.  Interestingly, this spectra showed “twinned peaks” 
from two species resembling adenosine analogues with attached azide(s). Further analysis by 
mass spectrometry indicated one species was the desired product (reported 352.4 m/z, expected 
352.1 m/z), and a second species was the “double-azide” byproduct (3rd step, Figure 38) 
(reported 359.4 m/z, expected 359.1 m/z)(M+H). Ultimately, this strategy for making 31 was 
abandoned when we were unable to separate either species by  normal phase or reverse phase 
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chromatography. Regrettably, this reaction may have succeeded if the second addition of NaN3 
was avoided.
Substitution of 5’-OH on lead compound 1
 We reasoned from previous attempts at substituting the 5’-OH on 6-chloropurine riboside 
that it may  be necessary  to first add the N6-cyclopentyl (as to make 1) to avoid unwanted 
substitutions with the 6-Cl group as had occurred with reactions in Figures 33 & 38. 
Additionally, we saw how the tosylate group at the 5-position of ribose was successfully replaced 
by phenethylamine when reacted neat (shown in Figure 36). Therefore, our final strategy was to 
similarly  add a leaving group at the 5’-position of 1, then react neat with phenethylamine (or 
other aromatic amines) to produce the 5’ N-substituents on second-generation compounds.
  After protecting the starting material with isopropylidene (top left, Figure 39) as 
previously  done,97 the N6-cyclopentyl was added (as in Chapter 3) to give compound 24 with an 
overall yield of 50% (top  middle, Figure 39).  As an aside, when the order of these last two steps 
was reversed (i.e., N6-cyclopentyl added before isopropylidene), we saw a better overall yield of 
66% for 24 (middle left, Figure 39), thus subsequent reactions followed this more productive 
route.
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(1)
(24)
(25)
(24)
Figure 39. Leaving groups added to 5’-OH of 1. Tosylation of 24 gave both product and cyclized 
byproduct (top right). Mesylation of 24 successfully produced 25 (middle right). 
 The first leaving group we attempted to add to 24 was the tosylate (top right, Figure 39), 
using the same conditions from the similar tosylation reaction in Figure 36. However, in this 
reaction NMR analysis indicated a “cyclized byproduct” had formed in addition to the desired 
5’-tosylate product (top right, Figure 39). We were unable to separate these two species by 
reversed phase chromatography. Cyclization of adenosine analogs during similar tosylation 
reactions has also been reported in earlier literature.104-107 [Note: Evidence of our cyclized 
byproduct came from the NMR spectra, which showed only one of the two purine protons in the 
aromatic region at 7.14 ppm (likely  the C2-H), in addition, the other purine proton (C8-H) was 
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suspected of being the singlet found in the non-aromatic region at  5.64 ppm, which did not 
coordinate with a neighboring proton during a COSY NMR experiment.]
 The second attempt to add a leaving group to 24 used the less labile mesylate, which was 
reported to not  cause cyclization of the adenosine analog during a similar reaction.104  Similarly 
in our reaction, the mesylate was successfully  added to the 5’-OH of 24 without cyclizing, to 
give 25 in a good yield (middle right, Figure 39). This same mesylation reaction was attempted 
on the unprotected 1 to test if the protecting step could be eliminated from the overall reaction 
scheme (bottom left, Figure 39). However, the TLC of this reaction reported multiple 
byproducts, thus validating the need to protect 1 before the mesylation reaction. [Note: 25 
appeared unstable, and was thus used in the subsequent reactions immediately after purification.]  
2nd Generation Final Products; 5’-Substitution and Deprotection
 The addition of a 5’-substituent to our adenosine analog was finally realized by reacting 
neat the mesylated precursor (25) with the substituted amine (1st step, Table 5).  In short, 25 was 
dissolved into 10 eq. of amine (benzylamine, phenethylamine, propylphenylamine or 
butylphenylamine) and heated for ~9 hr at 60 oC to give the protected intermediate 26 - 29, 
respectively.  Generally, the TLC analysis suggested that these reactions had gone to near 
completion, reporting only trace amounts of starting material (25) with a small amount of 
byproduct or impurity (possibly a degradant  of 25).  The lower than expected yields for 26 - 29 
were likely the results of purification steps used to remove the excess aromatic amines, which 
often eluted closely with the desired product during normal phase chromatography. 
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Table 5. Addition of 5’-substitution and deprotection of 2nd generation products. 
 Lastly, 26 - 29 were deprotected with trifluoroacetic acid (TFA) according to an earlier 
method102 (2nd step, Table 5). [Note: Initially, we attempted to deprotect 27 using TFA anhydride 
(not TFA) without success. Other attempts with 50% formic acid108 or 0.5 M HCl were also 
unsuccessful at deprotecting 27.] Further details of reaction conditions and results for products 
24 - 33 are provided in the experimental section.  Structural identity for compounds 24 - 33 was 
confirmed by proton and carbon NMR, assisted by COSY and HSQC (see Appendix B). 
Additionally, high resolution mass spectrometry (HRMS) of 24 - 33 agreed with the expected 
masses (see experimental section).
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Conclusion
 The goal of adding substituents to both N6 and 5’-C of adenosine was realized through a 
five-step synthesis to give compounds 30 - 33 (Figure 40), which were previously  unreported in 
the literature.   While this reaction scheme used only cyclopentyl as the N6-substituent, our 
process may still be acceptable with other substituents at this position.  However, a substituent 
such as N6-8-octylamine in 7 may need to be first protected (ex. with BOC) to prevent 
polymerization or other by-products from forming in the subsequent reaction steps.
 Likewise, this process may be suitable for adding a wide variety of other substituted 
amines to the 5’-position of 25 besides the 4 aromatic amines used on 30-31. One example that 
we plan to try is to use the primary amine on N6-ethylamine-adenosine (6) to substitute the 5’-
tosylate of 25 in order to make a bi-substrate analog containing two adenosine components. 
30 31 32 33
5% overall yield 17% overall yield 23% overall yield 15% overall yield
Figure 40. Overall yields for second-generation compounds 30-33. 
 Overall, we have successfully developed a strategy to generate a library  of adenosine- 
based compounds that can be elaborated at two positions (N6 and 5’). The motivation for 
generating these compounds was to make ErmC’/KsgA inhibitors that function by  targeting both 
active site pockets.  These compounds were then tested for their ability to inhibit the 
methyltransferase activity of ErmC’ and KsgA, as discussed next in Chapter 5. 
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Experimental Section
Chemicals and Solvents. Triethylamine, p-toluenesulfonic acid monohydrate (TsOH), 
methanesulfonyl chloride (Ms-Cl), 3-phenyl-1-propylamine, 4-phenylbutylamine, 2,2-
dimethoxypropane, trifluoroacetic acid (TFA), and deuterated chloroform (CDCl3) were 
purchased from Sigma-Aldrich (USA). Benzylamine was purchased from Acr1s Organics 
(Belgium). 2-Phenethylamine was bought from Alfa Aesar (England). Methanol (MeOH), 
dichlromethane (DCM), isopropanol (IPA), hexanes, triethylamine (Et3N), and tetrahydrofuran 
(THF) were purchased through Fisher Scientific (USA).
Chromatography. Thin-layer chromatography (TLC) was performed on silica plates purchased 
from Analtech (USA). Preparative chromatography was done with RediSep®Rf  columns 
containing silica or C18, and a Combiflash®Rf  instrument, all purchased through Teledyne Isco, 
Inc. (USA). 
Instruments and Analyses.  1H and 13C NMR spectra were obtained using 400 MHz Bruker 
spectrometer with a Bruker Topspin 2.1 software. Chemical shifts are reported as ppm (2) using 
solvent peaks or tetramethylsilane (TMS) as the internal standard. High-resolution mass 
spectrometry  (HRMS) were outsourced to the Chemistry Department of Virginia Commonwealth 
University.
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Synthesis
 2', 3'-O-Isopropylidene-N6-cyclopentyl adenosine (24).  To a solution of compound 1 (0.64 g, 
1.92 mmol) in 3.3 mL dry acetone, 5 eq. of 2,2-Dimethoxypropane (1.18 mL, 9.63 mmol) and 
1.1 eq. of p-toluensulfonic acid monohydrate (0.41 g, 2.16 mmol) were added under N2 and 
stirred for 2.5 hours at room temp. Reaction was quenched with saturated solution of NaHCO3 
(3.2 mL) until pH of reaction was 7-8. Neutralized reaction was concentrated in vacuo then 
separated by  normal phase chromatography  (12 g Silica RediSep Column, 5:95 MeOH:DCM for 
8 min with flow rate of 30 mL/min). Product was further purified by crystallization in hexanes to 
give 0.64 g of white crystalline foam (1.7 mmol, 88.4%). Rf 0.48 (MeOH:DCM = 1:19); 1H 
NMR (CDCl3) 2 8.26 (bs, 1H, 2-H), 7.71 (bs, 1H, 8-H), 6.74 (bs, 1H, 5’-OH), 5.81 (bs, 1H, N6-
H), 5.77 (d, 1H, 1’-H, J = 4.80 Hz), 5.13 (dd, 1H, 2’-H, J = 5.55, 5.16 Hz),  5.04 (dd, 1H, 3’-H, 
J = 0.8, 5.8 Hz), 4.52 (bs, 1H, 1”-H, cyclopentyl), 4.47 (d, 1H, 4’-H, J = 0.92 Hz), 3.91 (dd, 1H, 
5’-Ha, J = 1.4, 12.8 Hz), 3.72 (d, 1H, 5’-Hb, J = 12.61 Hz), 2.13 - 1.99 (m, 2H, 2’’-Ha + 5’’-Ha, 
cyclopentyl), 1.77 - 1.59 (m, 4H, 3’’-H2 + 4’’-H2, cyclopentyl), 1.58 (s, 3H, 2’’’-H3, 
isopropylidene), 1.56 - 1.41 (m, 2H, 2’’-Hb + 5’’-Hb, cyclopentyl), 1.31 (s, 3H, 3’’’-H3, 
isopropylidene); 13C NMR (CDCl3) 2 154.92 (C-6), 152.68 (C-2), 147.14 (C-4), 139.43 (C-8), 
120.44 (C-5), 113.97 (C-1’’’, isopropylidene), 94.44 (C-1’), 86.09 (C-4’), 83.04 (C-2’), 81.74 
(C-3’), 63.46 (C-5’), 52.36 (C-1’’, cyclopentyl), 33.43 (C-2’’+ C-5’’, cyclopentyl), 27.68 (C-2’’’, 
isopropylidene), 25.25 (C-3’’’, isopropylidene), 23.70 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 
376.1998, expected 376.1985 (M + H)+. 
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2', 3'-Isopropylidene-5'-mesyl-N6-cyclopentyl adenosine (25).* 
*Note: the following describes the synthesis of the batch used to make 26 and 29. 
To a vial of 24 (0.21 g, 0.57 mmol) purged with N2, dry DCM (6 mL) and 2.5 eq. triethylamine 
(0.2 mL, 1.44 mmol) were added. In a separate vial purged with N2, 0.1 mL methanesulfonyl 
chloride (Ms-Cl) was added to 0.9 mL dry DCM, then 663 µL of this 1:10 diluted solution of 
Ms-Cl (0.85 mmol, 1.5 eq.) was added to the vial with 24 and stirred at RT for 45 min. The 
reaction was loaded directly  to 40 g silica and separated by normal phase chromatography (12 g 
Silica RediSep Column, 0 to 15% MeOH in DCM over 16 cv) to yield 255.77 mg of white 
crystalline solid (0.564 mmol, 98.7%, crude). Rf 0.63 (MeOH:DCM = 1:19); 1H NMR (CDCl3) 2 
8.29 (bs, 1H, 2-H), 7.75 (s, 1H, 8-H), 6.03 (d, 1H, 1’-H, J = 2.00 Hz), 5.65 (bs, 1H, N6-H), 5.41 
(dd, 1H, 2’-H, J = 2.00, 6.32 Hz), 5.10 (dd, 1H, 3’-H, J = 3.08, 6.28 Hz), 4.62 - 4.48 (m, 1H, 1’’-
H, cyclopentyl), 4.48 - 4.43 (m, 1H, 4’-H),  4.42 - 4.31 (m, 2H, 5’-H2),  2.83 (s, 3H, 1’’’’-H3, 
mesylate), 2.15 - 2.02 (m, 2H, 2’’-Ha + 5’’-Ha, cyclopentyl), 1.76 - 1.58 (m, 4H, 3’’-H2 + 4’’-H2, 
cyclopentyl), 1.54 (s, 3H, 2’’’-H3, isopropylidene), 1.53 - 1.41 (m, 2H, 2’’-Hb + 5’’-Hb, 
cyclopentyl), 1.33 (s, 3H, 3’’’-H3, isopropylidene); 13C NMR (CDCl3) 2 154.69 (C-6), 153.41 
(C-2), 148.23 (C-4), 139.04 (C-8), 120.40 (C-5), 114.70 (C-1’’’, isopropylidene), 90.94 (C-1’), 
84.87 (C-4’), 84.06 (C-2’), 81.51 (C-3’), 68.56 (C-5’), 52.51 (C-1’’, cyclopentyl), 37.52 (C-1’’’’, 
mesylate), 33.43 (C-2’’+ C-5’’, cyclopentyl), 27.08 (C-2’’’, isopropylidene), 25.30 (C-3’’’, 
isopropylidene), 23.70 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 454.1762, expected 454.1760 (M 
+ H)+.
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2', 3'-Isopropylidene-5'-mesyl-N6-cyclopentyl adenosine (25).**
**Note: The following describes the synthesis for a batch used to make 25 and 27. 
To a vial of 24 (0.25 g, 0.68 mmol, from 5/10/10) purged with N2, dry DCM (8.5 mL) and 2.5 eq. 
triethylamine (236 µL, 1.69 mmol) were added. In a separate vial purged with N2, 78.66 µL Ms-
Cl was added to 1 mL dry  DCM, then 1079 µL of this diluted Ms-Cl (1.02 mmol, 1.5 eq.) was 
added to vial with 24 and stirred at RT for 45 min. The reaction was loaded directly  to 40 g silica 
and separated by normal phase chromatography to yield 298.78 mg of white crystalline solid 
(0.659 mmol, 97.2 %, crude).   
2', 3'-Isopropylidene-5'-mesyl-N6-cyclopentyl adenosine (25).***
***Note: the following describes the synthesis of a batch that was used to make 28. 
To a vial of 24 (0.22 g, 0.59 mmol) purged with N2, dry DCM (6 mL) and 2.5 eq. triethylamine 
(0.2 mL, 1.48 mmol) were added. In a separate vial purged with N2, 0.1 mL Ms-Cl was added to 
0.9 mL dry DCM, then 690 µL of this diluted solution Ms-Cl (0.89 mmol, 1.5 eq.) was added to 
vial with 24 and stirred at RT for 45 min. The reaction was loaded directly to 40 g silica and 
separated by normal phase chromatography to yield 270.56 mg of white crystalline solid (0.597 
mmol, 100%, crude).
2’, 3’-O-Isopropylidene-5’-deoxy-5’-benzylamino-N6-cyclopentyl adenosine (26).  To a vial 
of 25 (144.1 mg, 0.32 mmol),  10 eq. of benzylamine (0.35 mL, 3.2 mmol) was added, dissolving 
the starting material. This “neat” reaction was carried out under N2 for 12 hr at  60 oC then loaded 
directly  onto 4 g silica and separated twice by normal phase chromatography (12 g Silica 
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RediSep  Column, 0 to 100% MeOH in DCM over 30 cv) to yield 43.51 mg (0.09 mmol, 29.5%, 
crude). Rf 0.32 (MeOH:DCM = 1:19); 1H NMR (CDCl3) 2 8.12 (bs, 1H, 2-H), 7.70 (s, 1H, 8-H), 
7.32 - 7.09 (m, 5H, 3’’’’-H, 4’’’’-H, 5’’’’-H, 6’’’’-H + 7’’’’-H, benzyl), 5.88 (d, 1H, 1’-H, J = 3.24 
Hz), 5.66 (d, 1H, N6-H, J = 4.76 Hz), 5.39 (dd, 1H, 2’-H, J = 3.3, 6.4 Hz), 4.97 (dd, 1H, 3’-H, J 
= 3.1, 6.4 Hz), 4.61 - 4.43 (m, 1H, 1’’-H, cyclopentyl), 4.35 - 4.26 (m, 1H, 4’-H), 3.70 (s, 2H, 
1’’’’-H2, benzyl), 2.88 - 2.73 (m, 2H, 5’-H2), 2.10 - 1.99 (m, 2H, 2’’-Ha + 5’’-Ha, cyclopentyl), 
1.75 - 1.55 (m, 4H, 3’’-H2 + 4’’-H2, cyclopentyl), 1.53 (s, 3H, 2’’’-H3, isopropylidene), 1.52 - 
1.42 (m, 2H, 2’’-Hb + 5’’-Hb, cyclopentyl), 1.30 (s, 3H, 3’’’-H3, isopropylidene); 13C NMR 
(CDCl3) 2 154.63 (C-6), 153.27 (C-2), 148.41 (C-4), 140.06 (C-2’’’’, benzyl), 139.03 (C-8), 
128.35 (C-3’’’’+ C-7’’’’, benzyl), 127.97 (C-4’’’’ + C-6’’’’, benzyl), 126.95 (C-5’’’’, benzyl), 
120.49 (C-5), 114.43 (C-1’’’, isopropylidene), 91.04 (C-1’), 85.61 (C-4’), 83.36 (C-2’), 82.38 
(C-3’), 53.79 (C-1’’’’, benzyl), 52.43 (C-1’’, cyclopentyl), 50.73 (C-5’), 33.43 (C-2’’+ C-5’’, 
cyclopentyl), 27.33 (C-2’’’, isopropylidene), 25.44 (C-3’’’, isopropylidene), 23.70 (C-3’’+ C-4’’, 
cyclopentyl); HRMS m/z 465.2617, expected 465.2614 (M + H)+.
2’, 3’-O-Isopropylidene-5’-deoxy-5’-phenethylamino-N6-cyclopentyl adenosine (27). To a 
vial of 25 (298.78 mg, 0.659 mmol,),  10 eq. of 2-phenethylamine (0.82 mL, 6.52 mmol) was 
added, dissolving the starting material. This “neat” reaction was carried out under N2 for 9 hr at 
60 oC then loaded directly onto 4 g silica and separated once by normal phase chromatography 
(12 g Silica RediSep Column,  0-100% MeOH in DCM for over 36 cv) then separated by reverse 
phase chromatography (13 g C18 RediSep Column,  5-100% THF in DI H2O over 24 cv) to yield 
98.39 mg of clear yellowish gel (0.206 mmol, 31.2%). Rf 0.57 (MeOH:DCM = 1:9); 1H NMR 
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(CDCl3) 2 8.29 (bs, 1H, 2-H), 7.73 (s, 1H, 8-H), 7.19 - 7.13 (m, 2H, 5’’’’-H + 7’’’’-H, phenethyl), 
7.12 - 7.04 (m, 3H, 4’’’’-H, 6’’’’-H + 7’’’’-H, phenethyl), 5.91 (d, 1H, 1’-H, J = 3.04 Hz), 5.63 
(bd, 1H, N6-H, J = 6.68 Hz), 5.37 (dd, 1H, 2’-H, J = 3.04, 6.44 Hz), 4.94 (dd, 1H, 3’-H, J = 3.2, 
6.4 Hz), 4.54 (bs, 1H, 1’’-H, cyclopentyl), 4.31 - 4.24 (m, 1H, 4’-H), 2.92 - 2.73 (m, 4H, 5’-H2 + 
1’’’’-H2, phenethyl), 2.73 - 2.63 (m, 2H, 2’’’’-H2), 2.13 - 2.00 (m, 2H, 2’’-Ha + 5’’-Ha, 
cyclopentyl), 1.74 - 1.56 (m, 4H, 3’’-H2 + 4’’-H2, cyclopentyl), 1.53 (s, 3H, 2’’’-H3, 
isopropylidene), 1.52 - 1.42 (m, 2H, 2’’-Hb + 5’’-Hb, cyclopentyl), 1.30 (s, 3H, 3’’’-H3, 
isopropylidene); 13C NMR (CDCl3) 2 154.62 (C-6), 153.29 (C-2), 148.? (C-4), 139.78 (C-3’’’’, 
phenethyl), 138.94 (C-8), 128.64 (C-4’’’’+ C-8’’’’, phenethyl), 128.38 (C-5’’’’+ C-7’’’’, 
phenethyl), 126.11 (C-6’’’’, phenethyl), 120.44 (C-5), 114.48 (C-1’’’, isopropylidene), 90.87 
(C-1’), 85.60 (C-4’), 83.53 (C-2’), 82.35 (C-3’), 52.45 (C-1’’, cyclopentyl), 51.21 (C-1’’’’, 
phenethyl), 51.18 (C-5’), 36.16 (C-2’’’’, phenethyl), 33.42 (C-2’’+ C-5’’, cyclopentyl), 27.28, 
25.42 (C-2’’’+ C-3’’’, isopropylidene), 23.70 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 479.2776, 
expected 479.2771 (M + H)+.
2’, 3’-O-Isopropylidene-5’-deoxy-5’-propylphenylamino-N6-cyclopentyl adenosine (28). To a 
vial of 25 (270.56 mg, 0.597 mmol), 10 eq. of 3-phenyl-1-propylamine (0.848 mL, 5.967 mmol) 
was added, dissolving the starting material. This “neat” reaction was carried out under N2 for 12 
hr at 60 oC.  Reaction contents dissolved in 5 mL DCM  were treated with CuSO4 (5 mL, 1% in 
water) to extract amine, but no amine was seen in aqueous layer by  TLC, so the green-colored 
organic layer was loaded onto 4 g silica and separated once by normal phase chromatography (12 
g Silica RediSep  Column,  0 to 5% MeOH in DCM  over 13 cv) to yield 106 mg (0.215 mmol, 
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36%). Rf 0.30 (MeOH:DCM = 1:19); 1H NMR (CDCl3) 2 8.26 (bs, 1H, 2-H), 7.74 (bs, 1H, 8-H), 
7.23 - 7.14 (m, 2H, 6’’’’-H + 8’’’’-H, propylphenyl), 7.13 - 7.02 (m, 3H, 5’’’-H, 7’’’’-H + 9’’’’-H, 
propylphenyl), 5.89 (d, 1H, 1’-H, J = 3.24 Hz), 5.66 (bd, 1H, N6-H, J = 6.08 Hz), 5.33 (dd, 1H, 
2’-H, J = 6.3, 3.3 Hz), 5.16 - 5.07 (m, 1H, 3’-H), 4.54 (bs, 1H, 1’’-H, cyclopentyl), 4.38 - 4.30 
(m, 1H, 4’-H),  3.03 - 2.93 (m, 1H, 5’-Ha), 2.92 - 2.83 (m, 1H, 5’-Hb), 2.64 (t, 2H, 1’’’’-H2, J = 
7.3 Hz, propylphenyl), 2.56 (t, 2H, 3’’’’-H2, J = 7.52 Hz, propylphenyl), 2.12 - 1.98 (m, 2H, 2’’-
Ha + 5’’-Ha, cyclopentyl), 1.88 - 1.74 (m, 2H, 2’’’’-H2), 1.74 - 1.56 (m, 4H, 3’’-H2 + 4’’-H2, 
cyclopentyl), 1.53 (s, 3H, 2’’’-H3, isopropylidene), 1.52 - 1.41 (m, 2H, 2’’-Hb + 5’’-Hb, 
cyclopentyl), 1.31 (s, 3H, 3’’’-H3, isopropylidene); 13C NMR (CDCl3) 2 154.72 (C-6), 153.20 
(C-2), 148.23 (C-4), 141.44 (C-4’’’’, propylphenyl), 139.00 (C-8), 128.39 (C-6’’’’+ C-8’’’’, 
propylphenyl), 128.33 (C-5’’’’+ C-9’’’’, propylphenyl), 125.92 (C-7’’’’, propylphenyl ), 120.65 
(C-5), 114.64 (C-1’’’, isopropylidene), 91.31 (C-1’), 84.55 (C-4’), 83.35 (C-2’), 82.10 (C-3’), 
52.47 (C-1’’, cyclopentyl), 50.83 (C-5’), 49.12 (C-1’’’’, propylphenyl), 33.43 (C-2’’+ C-5’’, 
cyclopentyl), 33.36 (C-3’’’’, propylphenyl), 30.44 (C-2’’’’, propylphenyl), 27.27 (C-2’’’, 
isopropylidene), 25.42 (C-3’’’, isopropylidene), 23.70 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 
493.2942, expected 493.2927 (M + H)+. 
2’, 3’-O-Isopropylidene-5’-deoxy-5’-butylphenylamino-N6-cyclopentyl adenosine (29).  To a 
vial of 25 (139 mg, 0.31 mmol), 10 eq. of 4-phenylbutylamine (0.48 mL, 3.1 mmol) was added, 
dissolving the starting material. This “neat” reaction was carried out under N2 for 12 hr at 60 oC 
then loaded directly onto 4 g silica and separated twice by normal phase chromatography (12 g 
Silica RediSep Column,  0-100% MeOH in DCM over 27.2 cv) to yield 36.5 mg (0.07 mmol, 
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23.5%). Rf 0.39 (MeOH:DCM  = 1:19); 1H NMR (CDCl3) 2 8.28 (bs, 1H, 2-H), 7.75 (s, 1H, 8-H), 
7.22 - 7.14 (m, 2H, 7’’’’-H + 9’’’’-H, butylphenyl), 7.12 - 7.03 (m, 3H, 6’’’’-H, 8’’’’-H + 10’’’’-H, 
butylphenyl), 5.91 (d, 1H, 1’-H, J = 3.04 Hz), 5.63 (bd, 1H, N6-H, J = 6.92 Hz), 5.40 (dd, 1H, 
2’-H, J = 6.44, 3.04 Hz), 4.94 (dd, 1H, 3’-H, J = 6.44, 3.36 Hz), 4.55 (bs, 1H, 1’’-H, 
cyclopentyl), 4.31 - 4.23 (m, 1H, 4’-H),  2.86 - 2.73 (m, 2H, 5’-H2), 2.60 - 2.45 (m, 4H, 2’’-H2, 
5’’-H2, butylphenyl), 2.12 - 2.00 (m, 2H, 2’’-Ha + 5’’-Ha, cyclopentyl), 1.75 - 1.57 (m, 4H, 3’’-H2 
+ 4’’-H2, cyclopentyl), 1.57 - 1.36 (m, 6H, 2’’-Hb + 5’’-Hb, cyclopentyl, 2’’’’-H2 + 3’’’’-H2, 
butylphenyl), 1.53 (s, 3H, 2’’’-H3, isopropylidene), 1.31 (s, 3H, 3’’’-H3, isopropylidene); 13C 
NMR (CDCl3) 2 154.65 (C-6), 153.30 (C-2), 148.50 (C-4), 142.41 (C-5’’’’, butylphenyl), 139.00 
(C-8), 128.36 (C-6’’’’+ C-10’’’’, butylphenyl), 128.25 (C-7’’’’+ C-9’’’’, butylphenyl), 120.52 
(C-5), 114.47 (C-1’’’, isopropylidene) 90.91 (C-1’), 85.63 (C-4’), 83.53 (C-2’), 82.38 (C-3’), 
52.49 (C-1’’, cyclopentyl), 51.47 (C-5’), 49.81 (C-1’’’’, butylphenyl), 35.76 (C-4’’’’, 
butylphenyl), 33.45 (C-2’’+ C-5’’, cyclopentyl), 29.56 (C-2’’’’, butylphenyl), 29.06 (C-3’’’’, 
butylphenyl), 27.29 (C-2’’’, isopropylidene), 25.45 (C-3’’’, isopropylidene), 23.70 (C-3’’+ C-4’’, 
cyclopentyl); HRMS m/z 507.3092, expected 507.3084 (M + H)+.
5’-deoxy-5’-benzylamino-N6-cyclopentyl adenosine (30). To a vial of 41 mg (0.09 mmol) of 26 
on ice, an ice cold solution of TFA:H2O 10:1 (317 µL, 3.57 mL/mmol) was added stirred on ice 
for 1 hr, then warmed to RT over 2 hr. The reaction was neutralized with saturated solution of 
NaHCO3 (3.5 mL), then extracted with CHCl3 (4x 5 mL).  An unknown impurity, which NMR 
suggests was also present in 25, was crystallized out by dissolving the dried extract in hot 
hexanes (~20 mL, at 60 oC) then concentrated to ~1 mL forming a white fuzz of fine needle 
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crystals at room temperature. After centrifuging down the precipitate, the liquid portion was 
purified further by normal phase chromatography (12 g Silica RediSep Column, 0 to 37% MeOH 
in DCM  over 18 cv) to yield 9.53 mg of a light tan powder (0.02 mmol, 25.4%). Rf 0.38 
(MeOH:DCM = 1:9); 1H NMR (CDCl3) 2 7.99 (bs, 1H, 2-H), 7.76 (s, 1H, 8-H), 7.30 - 7.14 (m, 
5H, 3’’’-H, 4’’’-H, 5’’’-H, 6’’’-H + 7’’’-H, benzyl), 5.92 - 5.73 (m, 2H, N6-H + 1’-H), 4.63 - 4.44 
(m, 2H, 2’-H + 1’’-H, cyclopentyl) 4.37 (dd, 1H, 3’-H, J = 3.72, 5.12 Hz), 4.31 - 4.22 (m, 1H, 
4’-H),  3.85 - 3.72 (m, 2H, 1’’’-H2, benzyl), 2.97 - 2.84 (m, 2H, 5’-H2), 2.11 - 1.98 (m, 2H, 2’’-Ha 
+ 5’’-Ha, cyclopentyl), 1.76 - 1.54 (m, 4H, 3’’-H2 + 4’’-H2, cyclopentyl), 1.53 - 1.40 (m, 2H, 2’’-
Hb + 5’’-Hb, cyclopentyl); 13C NMR (CDCl3) 2 154.62 (C-6), 152.71 (C-2), 147.83 (C-4), 138.32 
(C-8 + C-2’’’, benzyl), 128.60 (C-4’’’+ C-6’’’, benzyl), 128.28 (C-3’’’+ C-7’’’, benzyl), 127.52 
(C-5’’’, benzyl), 120.23 (C-5), 90.40 (C-1’), 84.64 (C-4’), 74.94 (C-2’), 72.13 (C-3’), 53.74 
(C-1’’’, benzyl), 52.41 (C-1’’, cyclopentyl), 50.23 (C-5’), 33.40 (C-2’’+ C-5’’, cyclopentyl), 
27.08, 23.70 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 425.2300, expected 425.2301 (M + H)+.
5’-deoxy-5’-phenethylamino-N6-cyclopentyl adenosine (31). To a vial of 59 mg (0.12 mmol) 
of 27 on ice, an ice cold solution of TFA:H2O 10:1 (400 µL, 3.57 mL/mmol) was added stirred 
on ice for 1 hr, then warmed to RT over 2 hr. Reaction was neutralized with saturated solution of 
NaHCO3 (3.5 mL), then extracted with CHCl3 (4x 5 mL). The organic layer was concentrated in 
vacuo then purified further by  normal phase chromatography (4 g Silica RediSep Column, 0 to 
20% MeOH in DCM over 80 cv).  An impurity, which NMR suggests was “grease”, was 
precipitated out as a white solid/film when dried product was dissolved in MeOH.  After 
centrifuging down the greasy precipitate at 0 oC, the MeOH supernatant was concentrated in 
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vacuo and co-evaporated with hexanes to yield 43 mg of a light  pink powder (0.10 mmol, 87%). 
Rf 0.37 (MeOH:DCM = 1:9); 1H NMR (CDCl3) 2 8.08 (bs, 1H, 2-H), 7.75 (s, 1H, 8-H), 7.14 - 
7.08 (m, 2H, 5’’’-H + 7’’’-H, phenethyl), 7.07 - 6.98 (m, 3H, 4’’’-H, 6’’’-H + 8’’’-H, phenethyl), 
6.34 - 5.60 (m, 4H, 2’-OH, 3’-OH, N6-H + 1’-H), 4.61 - 4.37 (m, 3H, 2’-H, 3’-H + 1’’-H), 4.31 
(bd, 1H, 4’-H, J = 3.88 Hz),  3.28 - 3.17 (m, 1H, 5’-Ha), 3.14 - 3.06 (m, 1H, 5’-Hb), 3.05 - 2.94 
(m, 2H, 1’’’-H2, phenethyl), 2.88 - 2.73 (m, 2H, 2’’’-H2, phenethyl), 2.10 - 1.94 (m, 2H, 2’’-Ha + 
5’’-Ha, cyclopentyl), 1.74 - 1.52 (m, 4H, 3’’-H2 + 4’’-H2, cyclopentyl), 1.52 - 1.37 (m, 2H, 2’’-Hb 
+ 5’’-Hb, cyclopentyl); 13C NMR (CDCl3) 2 154.69 (C-6), 152.56 (C-2), 147.37 (C-4), 138.86 
(C-8), 137.13 (C-3’’’, phenethyl), 128.65 (C-5’’’+ C-7’’’, phenethyl), 128.53 (C-4’’’+ C-8’’’, 
phenethyl), 126.81 (C-6’’’, phenethyl), 120.95 (C-5), 90.67 (C-1’), 81.96 (C-4’), 74.69 (C-2’), 
71.22 (C-3’), 52.42 (C-1’’, cyclopentyl), 50.22 (C-1’’’, phenethyl),  49.27 (C-5’), 33.62 (C-2’’’, 
phenethyl), 33.33 (C-2’’+ C-5’’, cyclopentyl), 23.69 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 
439.2498, expected 439.2458 (M + H)+.
5’-deoxy-5’-propylphenylamino-N6-cyclopentyl adenosine (32). To a vial of 104.87 mg (0.21 
mmol) of 28 on ice, an ice cold solution of TFA:H2O 10:1 (760 µL, 3.57 mL/mmol) was added 
stirred on ice for 1 hr, then warmed to RT over 2 hr. Reaction was neutralized with saturated 
solution of NaHCO3 (8.5 mL), then extracted with CHCl3 (4x 10 mL). The organic layer was 
concentrated in vacuo and co-evaporated with hexanes to yield 95.3 mg of a light amber powder 
(0.21 mmol, 99%). Rf 0.38 (MeOH:DCM = 1:9); 1H NMR (CDCl3) 2 8.13 (bs, 1H, 2-H), 7.76 
(bs, 1H, 8-H), 7.25 - 7.15 (m, 2H, 6’’’ + 8’’’-H, propylphenyl), 7.13 - 7.07 (m, 1H, 7’’’-H, 
propylphenyl), 7.06 - 7.0 (m, 2H, 5’’’ + 9’’’-H, propylphenyl), 6.04 - 5.32 (m, 4H, N6-H, 1’-H, 
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2’-OH + 3’-OH), 4.74 - 4.36 (m, 3H, 1’’-H, cyclopentyl, 3’-H + 2’-H), 4.25 (bs, 1H, 4’-H), 3.17 
(d, 1H, 5’-Ha, J = 10.24 Hz), 2.96 (d, 1H, 5’-Hb, J = 10.64 Hz), 2.74 (t, 2H, 1’’’-H2, J = 7.4 Hz, 
propylphenyl), 2.56 (t, 2H, 3’’’-H2, J = 7.4 Hz, propylphenyl), 2.12 - 1.96 (m, 2H, 2’’-Ha + 5’’-
Ha, cyclopentyl), 1.93 - 1.76 (m, 2H, 2’’’-H2, propylphenyl), 1.75 - 1.55 (m, 4H, 3’’-H2 + 4’’-H2, 
cyclopentyl), 1.54 - 1.39 (m, 2H, 2’’-Hb + 5’’-Hb, cyclopentyl); 13C NMR (CDCl3) 2 154.79 
(C-6), 152.56 (C-2), 147.61 (C-4), 140.51 (C-4’’’, propylphenyl), 138.74 (C-8), 128.55 (C-6’’’+ 
C-8’’’, propylphenyl), 128.25 (C-5’’’+ C-9’’’, propylphenyl), 126.23 (C-7’’’, propylphenyl), 
120.58 (C-5), 90.89 (C-1’), 82.51 (C-4’), 74.97 (C-2’), 70.99 (C-3’), 52.42 (C-1’’, cyclopentyl), 
49.67 (C-5’), 48.83 (C-1’’’, propylphenyl), 33.37 (C-2’’+ C-5’’, cyclopentyl), 33.01 (C-3’’’, 
propylphenyl), 29.16 (C-2’’’, propylphenyl), 23.71 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 
453.2608, expected 453.2614 (M + H)+. 
5’-deoxy-5’-butylphenylamino-N6-cyclopentyl adenosine (33). To a vial of 31 mg (0.06 mmol) 
of 29 on ice, an ice cold solution of TFA:H2O 10:1 (217 µL, 3.57 mL/mmol) was added stirred 
on ice for 1 hr, then warmed to RT over 2 hr. Reaction was neutralized with saturated solution of 
NaHCO3 (3.5 mL), then extracted with CHCl3 (4x 5 mL).  An impurity, which NMR suggests 
was “grease”, precipitated out as a white solid/film when dried product was dissolved in MeOH. 
After centrifuging down the greasy precipitate at 0 oC, the MeOH supernatant was concentrated 
in vacuo and co-evaporated with hexanes to yield 33 mg of a light orangish brown powder (0.07 
mmol, 98%). Rf 0.26 (MeOH:DCM = 1:9); 1H NMR (CDCl3) 2 8.10 (bs, 1H, 2-H), 7.76 (s, 1H, 
8-H), 7.21 - 7.14 (m, 2H, 7’’’-H + 9’’’-H, butylphenyl), 7.11 - 7.05 (m, 1H, 8’’’’-H, butylphenyl), 
7.05 - 7.00 (m, 2H, 6’’’-H + 10’’’-H, butylphenyl), 618 (bs, 2H, 2’-OH + 3’-OH), 5.90 (bd, 1H, 
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N6-H, J = 3.04 Hz), 5.83 (d, 1H, 1’-H, J = 3.88 Hz), 4.61 - 4.53 (m, 1H, 3’-H), 4.53 - 4.44 (m, 
1H, 1’’-H, cyclopentyl), 4.44 - 4.37 (m, 1H, 2’-H), 4.28 (d, 1H, 4’-H, J = 3.76 Hz), 3.36 (dd, 1H, 
5’-Ha, J = 3.9, 13.18 Hz), 3.06 (dd, 1H, 5’-Hb, J = 3.00, 13.00 Hz), 2.92 - 2.73 (m, 2H, 1’’’-H2, 
butylphenyl), 2.56 - 2.45 (m, 2H, 4’’’-H2, butylphenyl), 2.08 - 1.98 (m, 2H, 2’’-Ha + 5’’-Ha, 
cyclopentyl),  1.75 - 1.51 (m, 8H, 3’’-H2 + 4’’-H2, cyclopentyl, 2’’’-H2 + 3’’’-H2, butylphenyl), 
1.51 - 1.39 (m, 2H, 2’’-Hb + 5’’-Hb, cyclopentyl); 13C NMR (CDCl3) 2 154.84 (C-6), 152.49 
(C-2), 147.27 (C-4), 141.25 (C-5’’’, butylphenyl), 139.03 (C-8), 128.43 (C-7’’’+ C-9’’’, 
butylphenyl), 128.25 (C-6’’’+ C-10’’’, butylphenyl), 126.02 (C-8’’’, butylphenyl), 120.75 (C-5), 
91.17 (C-1’), 81.19 (C-4’), 74.88 (C-2’), 70.46 (C-3’), 52.41 (C-1’’, cyclopentyl), 48.89 (C-1’’’, 
phenethyl),  48.81 (C-5’), 35.17 (C-4’’’, butylphenyl), 33.31 (C-2’’+ C-5’’, cyclopentyl), 28.37 
(C-3’’’, butylphenyl), 26.28 (C-2’’’, butylphenyl), 23.71 (C-3’’+ C-4’’, cyclopentyl); HRMS m/z 
467.2772, expected 467.2771 (M + H)+.
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CHAPTER 5: Inhibition Assays for Second-Generation 
Compounds
 
 After synthesizing the second library of potential inhibitors (Figure 41), these compounds 
were prepared for in vitro screening against  ErmC’ and KsgA by dissolving them into DMSO to 
final concentrations of 1 mM  and 10% DMSO. In addition to second-generation compounds 
(30-33), the protected intermediates (24-29) were also included. The lead compound (1), which 
provided the scaffold for these new compounds, was used as a reference to gauge how the 5’-
substitution on 30-33 affected inhibition. Similarly, sinefungin was used as a positive control. 
       Sinefungin   Reference analog (1)          24            25
 26   29    28  27
  30   31    32  33
Figure 41. Chemical structures of second-generation compounds (30-33), protected intermediates 
(24-29) and controls (sinefungin & reference analog 1) tested at 1 mM against ErmC’& KsgA.
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Screening ErmC’ and KsgA against second-generation compounds at 1 mM 
 Compounds shown in Figure 41 were tested for inhibition using the same enzymatic 
reactions to screen first-generation compounds in Chapter 3. The one difference, however, was 
the use of a filter binding assay to measure methyltransferase activity rather than the previously 
used method of SPA. [Note: Initial attempts to screen second-generation compounds used SPA, 
but unexplainably  produced excessive background counts, so this method was temporarily 
suspended.]  Results from the preliminary screening with ErmC’ (Figure 42) showed second-
generation compounds (30-33) were significantly more inhibitory than 1, suggesting that the 
addition of the phenyl substituent at the 5’-position improved binding interactions as 
hypothesized. Surprisingly, compounds 26-29, which had their 2’-OH and 3’-OH protected with 
isopropylidene, also showed significant inhibition against ErmC’. This was unexpected since all 
ErmC’ co-structures show that the 2’-OH and 3’-OH on adenosine-based ligands formed 
hydrogen bonds with Glu-59 (as in Figure 5, Chapter 1). The protecting group  on 26-29 should 
preclude this interaction with ErmC’, and should even cause steric hindrance for ligands binding 
to the SAM pocket in the classical mode. Therefore, these early data indicated that 26-29 were 
not binding in a like manner to first-generation compounds. 
 The activity of KsgA was similarly  tested in the presence of compounds 1, 24-33 and 
sinefungin at 1 mM  (Figure 43). Unlike ErmC’, KsgA showed virtually no inhibition from 
second-generation compounds (30-33). One of the protected intermediates (28), however, did 
significantly inhibit KsgA.  Although the reasons for this outlier are uncertain, 28 may have 
acted through a mechanism similar to that of 26-29 inhibiting ErmC’ (i.e., 28 may have bound 
outside the SAM site of KsgA as well).
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(b)
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Figure 42. Screening second-generation compounds for ErmC’ inhibition. Reaction were 
completed in 50 µL with 1 mM test-compound dissolved in 10% DMSO, 0.2 µM ErmC’, 0.2 µM 
23S (from B. subtilis), buffer K, 20 µM SAM  (780 cpm/pmol), and incubated at 37 °C for 32 
min.  Activity was measured by filter binding assay  (a), which was used to calculate the percent 
inhibition (b). Reactions were done in triplicate, and the average was graphed with error bars of 
+/- 1 Std Dev.
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Figure 43.  Screening second-generation compounds for KsgA inhibition. Reactions were in 50 
µL with 1 mM test-compound dissolved in 10% DMSO, 0.2 µM KsgA, 0.2 µM 30S (from ksgR 
E. coli), buffer K, 20 µM  SAM (780 cpm/pmol), 37 °C for 5 min.  Activity  was measured by 
filter binding assay (a), which was used to calculate the percent inhibition (b). Reactions were 
done in triplicate, and the average was graphed with error bars of +/- 1 Std Dev. 
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 The results of screening ErmC’ and KsgA are summarized in Table 6.  Despite the 
structural similarities between these two MTases, experiments with 30-33 indicated that the 
addition of 5’-phenyl substituents to the scaffold of 1 improved selectivity towards ErmC’ over 
KsgA. While the lack of KsgA inhibition by 30-33 may have been a setback for our goal of 
developing a novel class of antibiotics that target ribosomal assembly, this was seen as a 
breakthrough for our other goal of developing selective ErmC’ inhibitors to restore the 
effectiveness of MLSB antibiotics. Therefore, the remainder of experiments in this dissertation 
focused on ErmC’, while KsgA awaits future study. 
Table 6. Summary of ErmC’ and KsgA inhibition from 1, 24-33 and sinefungin at 1 mM.
Test Compound ErmC’ Inhibition KsgA Inhibition
# substituent at 5’ 2’ & 3’ Average Std Dev Average Std Dev
1 OH OH, OH 16% 9.1 6.3% 10
24 OH isopropylidene -6.8% 8.5 0.8% 5.8
25 Mesylate isopropylidene -8.8% 20 1.6% 9.7
26 Benzylamine isopropylidene 28% 6.8 4.5% 14
27 Phenethylamine isopropylidene 40% 14 6.0% 12
28 Propylphenylamine isopropylidene 53% 16 41% 11
29 Butylphenylamine isopropylidene 59% 32 15% 5.9
30 Benzylamine OH, OH 64% 21 5.7% 2.5
31 Phenethylamine OH, OH 55% 26 7.0% 4.5
32 Propylphenylamine OH, OH 71% 21 9.0% 3.4
33 Butylphenylamine OH, OH 81% 12 7.4% 0.6
C- “Sinefungin” OH, OH 87% 8.4 95% 0.8
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Co-crystallization of Second-Generation Compounds on ErmC’
 After observing an improvement in potency and selectivity with 30-33 towards 
ErmC’ (relative to 1), we were eager to investigate the binding interactions of these new 
inhibitors. The following questions were asked regarding the effects of second-generation 
compounds on ErmC’: (i) are these ligands binding to the SAM site in the classical mode for 
adenosine analogs; (ii) is the 5’-substituent bridging into the target adenosine pocket; (iii) does 
this phenyl substituent form #-stacking with a flipped-out Tyr-104; and (iv) does the length of the 
linker on the 5’-substituent influence these potential interactions?
 We attempted to answer these questions by X-ray crystallography  on ErmC’ complexed 
with one or more of the second-generation compounds. Using the same conditions and 
techniques to co-crystallize ErmC’ with 7 and 12 (described in Chapter 3), dozens of quality 
crystals were formed over several crystallization attempts with ErmC’ in the presence of 26-33. 
While in nearly all cases crystals were formed, diffraction data could only be collected from a 
few of these crystals, of which none showed a ligand bound to ErmC’.  Most of these crystals 
were lost as a result of happenstance (ex. instrument failures, challenges in looping and mounting 
crystals to the instrument).  Even so, the successful diffraction of ErmC’ crystallized with 30, 
showed only  the apo form of ErmC’. The same result was observed when X-ray data was 
collected on an apo crystal of ErmC’ that had been previously soaked with 31.  The absence of 
second-generation ligands from these crystals would later be seen as possible evidence for a 
binding mechanism that  was unlike the binding mode observed for first-generation compounds 7 
and 12 in complex with ErmC’.
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IC50 Studies 
 Although the previous co-crystallization attempts did not provide a clear picture of the 
binding mode for second-generation compounds, additional enzymatic experimentation could 
offer us some insight into how these inhibitors were acting (or not acting) on ErmC’. Extensive 
inhibition assays were performed with ErmC’ to calculate IC50 values (the concentration of a test 
compound that results in 50% inhibition) for compounds 1 and 30-33. Here, the objective was to 
more precisely compare the inhibitory  effects of second-generation compounds with that of our 
original lead inhibitor (1).   
Effects of DMSO on ErmC’
 Before starting the IC50 studies, we looked more closely at the effects of DMSO on 
ErmC’ to determine an appropriate amount of this solvent for introducing test-compounds into 
IC50 reactions.  The results of testing ErmC’ with different volumes of DMSO showed that 10% 
DMSO, which had typically been the amount used, contributed to a 26.6% loss of activity 
relative to the same experiments without DMSO (Figure 44). Therefore, it was decided that 
subsequent inhibition assays should have 5% DMSO, which resulted in only a 4.4% loss of 
ErmC’ activity (Figure 44).  In addition, we decided that  reactions used in the IC50 studies would 
have an end-point time of 8 min instead of 32 min used previously.
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Figure 44. Effects of DMSO concentration on the activity of ErmC’.  Varying amounts of DMSO 
(0, 2.5, 5, 7.5, 10, 15, 20 or 25 µL) were incorporated into 50 µL reactions with 0.2 µM ErmC’, 
0.2 µM 23S (from B. subtilis), buffer K, 20 µM SAM (780 cpm/pmol), incubated at  37 °C for 8 
min, and quenched with 10 µL of 100 mM cold SAM.  Reactions were done in triplicate, activity 
was measured by filter binding, and the averages were graphed with error bars of +/- 1 Std Dev.
First attempt of IC50 studies using 20 µM SAM
 Initially, IC50 reactions followed the same conditions described in Figure 42, except 
inhibitor concentrations were varied (1 µM  to 1 mM in 5% DMSO) and reactions were quenched 
at 8 min. However, when ErmC’ activity was plotted against inhibitor concentration (Figure 45), 
data did not  produce a well defined lower plateau (i.e., the maximum inhibitory  effect was not 
seen).  Therefore, we sought to alter these conditions in order to potentiate a greater effect from 
these test-compounds. Traditionally, our reactions used SAM at an excess of 100x the ErmC’ and 
23S concentrations (i.e., 20 µM SAM). This may not have been appropriate in IC50 assays for 
inhibitors that were expected to compete for the SAM-binding site.  Instead, we decided that the 
SAM concentration should be lowered to near or below its KM, previously reported at 3 µM.36
130
 Propylphenyl (32)
Butylphenyl (33)
Phenethyl (31)
Benzyl (30)
Sinefungin
SAH
Figure 45. Initial IC50 assays for ErmC’ with 30-33, sinefungin and SAH, using 20 µM SAM. 
Compounds were tested at 0, 1, 5, 10, 25, 50, 100, 250, 500, and 1000 µM. Reactions were 
completed as described in Figure 42, except reactions had 5% DMSO and were quenched at  8 
min.  Reactions were done in triplicate, measuring their activity by  filter binding assays, and 
graphing averages with error bars of +/- 1 SEM.
Optimizing SAM concentration for IC50 studies
 Since an objective of this study was to compare IC50 values of 1 and second-generation 
compounds, we sought to peg our SAM  concentration to the same level that was used previously 
by Clancy et al to report an IC50 value of 63 µM for 1.85  Unfortunately, the SAM  concentration 
used in this study was not clearly defined.  To estimate this amount, we tested ErmC’ activity 
with [1] fixed at 63 µM, and varied the SAM concentration until we saw 50% inhibition (Figure 
46). Based on this experiment, we concluded that 0.5 µM SAM would be an appropriate 
concentration for repeating IC50 experiments.  Note: In order to increase the signal measured, we 
raised the ratio of Hot:Cold SAM to 1:18 (5% 3H-SAM) from the typical 1:97 (1% 3H-SAM). 
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  (1)
  (1)
Figure 46. The effects of SAM concentration on ErmC’ inhibition with 1 fixed at 63 µM. 
Reactions were completed as before except 5% DMSO was used and reactions were quenched at 
120 min (as described by Clancy et al.).85 [SAM] was tested at 0.05, 0.1, 0.5 and 1.0 µM  (5% 3H-
SAM), and activity was measured by filter binding assay. 
 These same optimization tests (Figure 46) also demonstrated that 1 acted competitively 
with SAM. Although we had already suspected 1 was binding to the SAM pocket (based on 
crystallographic data of ErmC’ bound to similar adenosine analogs), this experiment provided 
supporting enzymatic evidence for such a binding mode.  These results contradicted the earlier 
reports by Clancy  et al., which claimed that changing the SAM  concentration did not affect 
ErmC’ inhibition by 185, as well as Feder et al.’s in silico model, which showed 1 docking into 
the adenosine pocket of ErmC’ 40 (previously discussed in Chapter 3, Figure 22).
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New time course assay with 0.5 µM SAM
 Before repeating IC50 experiments with this new concentration of SAM, a time-course 
assay of ErmC’ (Figure 47) was completed using 0.5 µM SAM (5% 3H-SAM). Under these 
conditions, the 8-minute time-point still appeared to be within the linear region of ErmC’ activity 
(i.e., maximum velocity), and was thus retained as the selected endpoint for new IC50 assays. 
However, we decided to again raise the proportion of 3H-SAM used in subsequent IC50 reactions 
to 10% of the relative SAM concentration in order to further improve the measurable signal. 
 It should also be noted that while performing these time-course experiments we were able 
to resolve the earlier dilemma of SPA beads producing excessive background counts. This 
problem appeared to be corrected by using a newer batch of 3H-SAM and/or by  lowering the 
absolute amount of 3H-SAM  in each reaction.  In either case, SPA was returned to as the more 
convenient assay for measuring ErmC’ activity.
Figure 47.  Time course assay of ErmC’ with 0.5 µM SAM. Reaction were performed as before 
except 0.5 µM SAM  (5% 3H-SAM) was used and the volume was scaled up to 0.5 mL. Activity 
was measured by  SPA at the time points of 1, 15, 30, 60, 120, 180 and 240 min.  Assays were 
done in triplicate, plotting the average with error bars of +/- 1 Std Dev.
133
IC50 assays repeated at 0.5 µM SAM
 We repeated IC50 experiments with the SAM concentration of 0.5 µM (10%  3H-SAM) to 
be in agreement with the previous report  by  Clancy et al. Under these new conditions we 
expected ErmC’ to demonstrate a greater sensitivity  to inhibitors that bind to the SAM site, 
thereby allowing IC50 values to be more accurately measured.  In addition to test-compounds 1 
and 30-33, three known inhibitors of ErmC’ (sinefungin, SAH  32 and adenosine 109) were also 
tested as positive controls. After subtracting background counts, ErmC’ activity  was plotted 
against the concentrations of each of these 8 inhibitors (Figure 48).
  Propylphenyl (32)
 Butylphenyl (33)
Phenethyl (31)
Benzyl (30)
Sinefungin
SAH
Cyclopentyl (1)
Adenosine 
Figure 48. ErmC’ activity vs. inhibitor concentration. Reactions were done as before except 5% 
DMSO and 0.5 µM SAM  (10% 3H-SAM) were used, and reactions were quenched at 8 min. 
Reactions were done in triplicate, measuring their activity by SPA, and graphing averages with 
error bars of +/- 1 SEM. Legend lists compounds in order of least inhibitory (top) to most 
inhibitory (bottom). 
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 These new experiments showed that  lowering the SAM concentration produced a greater 
inhibitory effect by 1, which was expected from a compound shown to compete for the SAM-
binding site. However, when 30-33 were also tested at  this lower SAM  concentration, there was 
little or no increase of ErmC’ inhibition. In fact, second-generation compounds, which had 
previously  shown greater ErmC’ inhibition than 1 during tests with 20 µM SAM (Figure 42), 
were now less inhibitive than their parent compound 1 in these new tests using 0.5 µM SAM 
(Figure 48). To illustrate the different effects from these inhibitors at high and low SAM 
concentrations, Figure 49 was created by extrapolating the percent inhibitions from tests with 1 
mM sinefungin, 1 and 30-33 in Figure 48 (0.5 µM SAM), and plotted next to the percent 
inhibitions by these compounds in similar tests using 20 µM SAM from Figure 42.
sinefungin 1 30 31 32 33
Figure 49. Comparing ErmC’ inhibition from tests at two different concentrations of SAM. 
Yellow bars are results of tests with 1 mM sinefungin, 1 and 30-33 from Figure 48 (0.5 µM 
SAM), and blue bars are results of the similar tests from Figure 42 (20 µM SAM).
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 These surprising results suggest at least two of our second-generation compounds (32 and 
33) were not acting at  the SAM-pocket as the parent compound (1) had done, but were possibly 
binding to an alternate site. This claim may be less obvious for 30 and 31, since their activity did 
increase slightly at the lower SAM concentration, nonetheless, the inhibition from 1 had still 
increased to a greater extent than for any of the second-generation compounds (Figure 49). 
 Ultimately, these experiments at 0.5 µM SAM  (Figure 48) were used to calculate IC50 
values for these eight inhibitors (Table 7). The two compounds that had IC50 values previously 
reported by Clancy et al. (sinefungin at 5.0 µM, and 1 at 63 µM)85 were in close agreement with 
our calculated values of 6.251 and 60.79 µM, respectively.  While we had initially  expected IC50 
values for second-generation compounds to be much lower than that of our lead inhibitor (based 
on screening results from Figure 44), these values calculated for 30-33 (146.0, 92.35, 825.3 and 
455.7 µM, respectively) were actually higher than that of 1.  In fact, even the IC50 value for 
adenosine (31.80 µM) was lower than those of 30-33, and for that matter, 1 as well. 
Table 7. ErmC’ IC50 values for 1, 30-33, sinefungin, SAH and adenosine, with 0.5 µM SAM. 
IC50 (µM)
95% 
Confidence Intervals R2
# of points
 Analyzed
Sinefungin 6.251  (5.0)† 5.265 to 7.423 0.9881 24
SAH 16.35 14.23 to 18.78 0.9927 24
Adenosine 31.80 27.58 to 36.67 0.9910 24
Cyclopentyl (1) 60.79  (63)† 40.85 to 90.48 0.9289 24
Benzyl (30) 146.0 117.1 to 182.0 0.9747 21
Phenethyl (31) 92.35 57.69 to 147.8 0.8879 21
Propylphenyl (32) 825.3 635.8 to 1071 0.9134 21
Butylphenyl (33) 455.7 326.8 to 635.5 0.9053 21
Values calculated from data in Figure 48 using Prism 5.0a software with a nonlinear regression 
(curve fit) of log(inhibitor) vs. response(background subtracted) and the bottom constrained to 0.
†  IC50 values previously published by Clancy et al.8
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Discussion
Proposed binding mode of second-generation compounds
 We had originally asked several questions regarding the interactions of second-generation 
compounds with ErmC’ based on our assumption that  these compounds would bind in the likely 
SAM pocket, however, the outcome of the previous experiments has since suggested otherwise. 
This presented a new question - if 30-33 were not binding to the SAM pocket, then how were 
these compounds acting to inhibit ErmC’?
 One mechanism currently being investigated is that of second-generation compounds 
binding within the substrate pocket of ErmC’. A model illustrating how these inhibitors might 
bind to the substrate pocket  is depicted below (Figure 50). 
SAM pocket
Target adenosine 
pocket
Glu-128
!-helix E
!
!-helix D
30
Figure 50. Proposed binding mechanism of second-generation inhibitors into the target adenosine 
pocket of ErmC’. Represented by  30, the adenosine moiety  would orient like the putative 
substrate, and the 5’-phenyl substituent would be sandwiched between the hydrophobic cleft of "-
helices D & E, and the protonated 5’-N+ would form an ionic bond with Glu-128.
137
 We propose that the adenosine moiety of second-generation inhibitors orients within 
ErmC’ in a similar fashion as the putative adenosine substrate.  As a result, the 5’-C of our ligand 
would be pointed between the "-helices D and E, where the phenyl substituent could lie 
favorably within this hydrophobic cleft.  Further stability could be achieved through an ionic 
bond between the protonated 5’-N+ of our inhibitor and the Glu-128 on ErmC’ (Figure 50).
 This orientation would also offer an explanation for why protected intermediates 26-29 
unexpectedly  inhibited ErmC’ (described in Figure 42). By binding to the target adenosine site in 
this manner, the 2’-O and 3’-O of inhibitors 26-29 would be pointed away  from the binding 
pocket and into the surrounding solvent, thus precluding the potential interference from an 
isopropylidene that is attached at these positions.  Additionally, this binding mechanism in Figure 
50 may  explain why attempts to crystallize ErmC’ with second-generation compounds failed to 
show a bound ligand, despite the successes of co-crystallizing ErmC’ with 7 and 12 (Chapter 3). 
Crystallizing ErmC’ may cause motifs around the target adenosine site (in particular, "-helices D 
and E) to pack so tightly that an inhibitor at this binding site is displaced.  [Note: On-going 
experiments with molecular dynamic simulations of ErmC’ show that the "-helices D and E are 
very dynamic in solution, supporting the idea that crystallized ErmC’ could impede binding of 
second-generation compounds into the target adenosine site (unpublished results, John Hackett, 
VCU).]
 This proposed binding mode was recently tested using increasing concentrations of 23S 
to see if this effected a change in ErmC’ inhibition by second-generation compounds (Figure 51). 
Results from this preliminary competition assay showed that raising the concentration of 23S 
caused a drop of inhibition from 32 and 33, while inhibition by  1, 30 and 31 remained constant 
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or increased slightly (Figure 51).  Although these tests will need to be investigated further, these 
early data have provided partial support for the idea that at least  32 and 33 are binding within the 
target adenosine pocket.
“DMSO” 
Propylphenyl (32)
Butylphenyl (33)
Phenethyl (31)
Benzyl (30)
Cyclopentyl (1)
Benzyl (30)
Propylphenyl (32)
Butylphenyl (33)
Phenethyl (31)
Cyclopentyl (1)
Figure 51.  Competition assays with increasing concentrations of 23S. Compounds were added at 
a final concentration of 1 mM to reaction like those described in Figure 42, except 23S was 
varied (3.5, 10, 20 and 85). Activity was measured by filter binding assay after 32 min. 
Future work
 One future objective will be to elucidate the interactions of second-generation 
compounds with ErmC’.  This might simply be accomplished by further attempts at co-
crystallization, since only  two of our crystals were previously tried by X-ray diffraction. We will 
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also try  new crystallization conditions that include SAM (at 20 µM, for example) in case cofactor 
facilitates the binding of 30-33 into the adenosine pocket of ErmC’. [Note: Allosteric binding 
sites for SAM  have been observed in certain DNA methyltransferases,111-115 but have never been 
investigated with ErmC’.]  Alternatively, NMR spectroscopy of ErmC’ in solution with one of 
the second-generation compounds could provide knowledge about the binding site of these 
inhibitors. One obstacle to this approach will be the limited solubility of ErmC’ in the absence of 
glycerol, though this may be ameliorated by adding a minimal amount of DMSO.
 If the proposed binding mode for 30-33 is confirmed, it would signify that we have come 
full circle from our original goal of docking adenosine analogs into the substrate pocket with N6-
substituents probing for interactions within the SAM pocket of ErmC’.  Our model (Figure 50) 
shows the N6-cyclopentyl of 30 branching into the SAM pocket  in agreement with the in silico 
docking of 1 performed by Feder et al.40 (Figure 22). Therefore, a third library of test-
compounds may  be synthesized that uses the scaffold from one of our second-generation 
compounds and replaces the N6-cyclopentyl with other exploratory groups.  For example, we 
could borrow from the same library of substituents placed on the N6-position of first-generation 
compounds (1-23), since these groups were originally picked for the purpose of probing the 
SAM pocket. 
Conclusions
 In response to the growing threat of antibiotic resistance, two closely related 
methyltransferases were targeted - ErmC’ to restore MLSB antibiotics, and KsgA to form a novel 
class of antibiotics that stalls ribosomal assembly. One of the biggest challenges we faced with 
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designing inhibitors suitable for drug development was to selectively block ErmC’ or KsgA 
without also affecting methyltransferases important in human physiology. The common approach 
to this challenge has been to aim for the more specific substrate binding pocket of the intended 
methyltransferase rather than the more ubiquitous SAM binding pocket. Success with this 
strategy appeared to have been realized when Clancy et al. presented N6-cyclopentyl adenosine 
(1) as a potent and selective ErmC’ inhibitor that was not competitive with SAM  binding. This 
was followed up by the study from Feder et al., which showed 1 docking into the substrate 
pocket of ErmC’ and the N6-cyclopentyl substituent branching into the neighboring SAM pocket, 
in silico.  
 Based largely on these findings, we synthesized the first library  of compounds 1-23, 
which included N6-cyclopentyl adenosine (as the lead inhibitor and as a benchmark) along with 
22 other analogues that varied by the substitution on the N6-position.!Our objective was for these 
new adenosine analogs to similarly dock into the substrate pocket of ErmC’ (as the target-
adenosine putatively orients) and to use the substituents in this library to probe for more 
favorable interactions within the adjacent SAM pocket.  Additionally, these compounds would be 
tested for inhibition against KsgA, a paralog of ErmC’. 
" After developing a scintillation proximity assay  (SPA) that efficiently measured rRNA 
methylation using commercially available yttrium silicate (YSi) scintillant beads, compounds 
1-23 were screened at 1 mM (with 20 µM  SAM). For ErmC’, several of our compounds were 
either more potent (7) or nearly as potent (4, 12, 18 & 19) as the lead compound 1.  We also saw 
for the first time that 1 was inhibitory towards KsgA, and that other compounds (5, 7 & 18) were 
more potent.  However, when two of these inhibitors (7 & 12) were co-crystallized with ErmC’ 
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we saw that these compounds docked into the SAM  pocket with an orientation similar to other 
adenosine-based ligands (SAM, SAH and sinefungin) and the 5’-C of 7 and 12 was pointed at 
the substrate pocket. A similar binding mode was also indicated for 1 after we saw that raising 
SAM concentrations resulted in a loss of inhibition (contrary to the previous report by Clancy  et 
al.). 
 Therefore, the second library of compounds was designed to exploit this orientation by 
adding substituents off the 5’-C of our lead inhibitor. Through a five step synthesis, the 5’-OH of 
1 was replaced with an amine linked to either a benzyl, phenethyl, propylphenyl or butylphenyl 
to give 30 - 33, respectively. Our new objective was for second-generation compounds to dock 
into the SAM pocket of ErmC’ or KsgA, and for the 5’-phenyl substituent to probe for potential 
interactions within the neighboring substrate pocket. 
" Initially we saw these second-generation compounds to be more inhibitory than the lead 
compound against ErmC’, but they were not active against KsgA, suggesting that the addition of 
the 5’-phenyl substituent had improved potency and selectivity towards ErmC’. However, during 
IC50 assays with ErmC’ the SAM  concentration was lowered from 20 µM  to 0.5 µM, and we saw 
that the inhibition by  30 - 33 was nearly unchanged. Inhibition by 1 was as expected higher at 
these lower [SAM] conditions, but was now unexpectedly more potent than 30 - 33.  These 
results and other preliminary  data lead us to believe that second-generation inhibitors were not 
acting primarily at the SAM  pocket (as 1, 7 & 12 had done), but were possibly binding within the 
substrate pocket of ErmC’ as was originally intended for first-generation compounds.    
 Clearly much further research is needed before inhibitors of ErmC’ or KsgA may be 
developed into appropriate therapies for antibiotic resistant infections. The screening, 
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synthesizing and co-crystallization work that have been presented herein should provide a 
substantial basis for any future work in this area. 
 
Experimental Section
Inhibition Assays
Screening 1, 24-33 and sinefungin at 1 mM (Figures 42 and 43)
 Test compounds were added by 5 µL from 10 mM stock dissolved in DMSO to a typical 
enzyme reaction with either ErmC’ or KsgA, as described in Chapter 3 except filter binding 
assays were used to measure activity. In short, reactions were completed in 50 µL containing 
buffer K, 1 mM test-compound, 10% DMSO, 0.2 µM  of rRNA substrate (23S from B. subtilis for 
ErmC’ or 30S from ksgR E. coli for KsgA), 0.2 µM of enzyme (ErmC’ or KsgA), 20 µM SAM 
(780 cpm/pmol) (Hot:Cold SAM at 1:97), incubated at  37 °C for 32 min for ErmC’ or 5 min for 
KsgA, and quenched with 10 µL of 100 mM cold SAM. Each reaction was done in triplicate, and 
the average was graphed with error bars of +/- 1 Std Dev.
Testing the effects of DMSO concentrations on ErmC’ activity (Figure 44)
 Varying amounts of DMSO (0, 2.5, 5, 7.5, 10, 15, 20 or 25 µL) were incorporated into 
typical ErmC’ reactions, as described above except the incubation time was 8 min and no test 
compound was added with DMSO.  These reactions were done in triplicate, measuring their 
activity by  filter binding assay and graphing the averages with error bars of +/- 1 Std Dev using 
excel software. Background counts were not considered for these reactions .
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First attempt at IC50 assays using 20 µM SAM (Figure 45)
 Test compounds (30-33, sinefungin & SAH) were added (2.5 µL of 20x stock dissolved 
in DMSO) to final concentrations of 0, 1, 5, 10, 25, 50, 100, 250, 500, and 1000 µM  in typical 
ErmC’ reactions as described for Figure 42, except reactions had 5% DMSO and were quenched 
at 8 min.  Reactions were done in triplicate, except for SAH (only two replicas completed for 1 
µM) and 32 (only two replicas completed for 1, 5 and 10 µM).  Methylation activity  was 
measured by  filter binding assay and averages were graphed with error bars of +/- 1 SEM  using 
Prism 5.0a software and nonlinear regression(curve fit) of log(inhibitor) vs. response with the 
bottom constrained to 0.  Background counts were not subtracted from signals.
Testing the effects of SAM concentration on ErmC’ inhibition with 1 fixed at 63 µM (Figure 46)
 Compound 1 was added at  a final concentration of 63 µM  to typical ErmC’ reactions, 
except the SAM concentration was varied (0.05, 0.1, 0.5 and 1.0 µM), the ratio of Hot:Cold 
SAM was raised to 1:18 (5% 3H-SAM), reactions had 5% DMSO and were quenched at 120 min 
(reaction time same as reactions performed by Clancy et al.85).   Activity was measured by filter 
binding assay.
Time course assay of ErmC’ with 0.5 µM SAM (Figure 47)
 Reactions were performed as before except 0.5 µM  SAM  (5% 3H-SAM) was used and the 
volume was scaled up  to 0.5 mL. Activity  was measured by SPA at the time points of 1, 15, 30, 
60, 120, 180 and 240 min. Assays were done in triplicate, plotting the average with error bars of 
+/- 1 Std Dev. 
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IC50 assays repeated using 0.5 µM SAM  (Figure 48 and Table 7)
 
 Compounds (1, 30-33, sinefungin, SAH and adenosine) were tested between 0.1 µM and 
1.0 mM in typical ErmC’ reactions (as described for Figure 42), except reactions had 5% DMSO, 
were quenched at 8 min and activity was measured by SPA. Reactions were done in triplicate, 
the background counts from reactions without enzyme were subtracted from signals and averages 
were graphed with error bars of +/- 1 SEM using Prism 5.0a software with  nonlinear regression
(curve fit) of log(inhibitor) vs. response(background subtracted) and the bottom constrained to 0. 
Concentrations of test-compounds were determined by UV absorbance
using extinction coefficients of 16.68 mM-1cm-1 for 1, 30-33 (measuring the OD271) and 15.5 
mM-1cm-1 for sinefungin, SAH and adenosine (measuring the OD260). 
Testing the effects of 23S concentrations on inhibition of ErmC’ by 1 and 30-33 (Figure 51)
 Compounds (1 and 30-33) were tested at 1 mM in the same ErmC’ reaction used for 
Figure 42, except the concentration of 23S was varied (3.5, 10, 20 & 85 pmol) and each reaction 
was performed once.  
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270
13C NMR of 5’-deoxy-5’-benzylamino-N6-cyclopentyl adenosine (30).
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